<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="ph1" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">ph1</book-part-id>
      <title-group>
        <title>Primary Hyperoxaluria Type 1</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Coulter-Mackie</surname>
            <given-names>Marion B</given-names>
          </name>
          <degrees>PhD</degrees>
          <aff>Pediatrics (Biochemical Diseases)<break/>BC Children's Hospital and BC Women's Hospital &#x00026; Health Centre<break/>Vancouver, Canada</aff>
          <email>marioncm@mail.ubc.ca</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>White</surname>
            <given-names>Colin T</given-names>
          </name>
          <degrees>MD</degrees>
          <aff>Pediatrics (Nephrology)<break/>BC Children's Hospital and BC Women's Hospital &#x00026; Health Centre<break/>Vancouver, Canada</aff>
          <email>cwhite@cw.bc.ca</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lange</surname>
            <given-names>Dirk</given-names>
          </name>
          <degrees>PhD</degrees>
          <aff>Department of Urologic Sciences<break/>University of British Columbia<break/>Vancouver, Canada</aff>
          <email>dirk.lange@ubc.ca</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Chew</surname>
            <given-names>Ben H</given-names>
          </name>
          <degrees>MD, MSc, FRCSC</degrees>
          <aff>Department of Urologic Sciences<break/>University of British Columbia<break/>Vancouver, Canada</aff>
          <email>ben.chew@ubc.ca</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date iso-8601-date="2002-06-19" date-type="created">
          <day>19</day>
          <month>6</month>
          <year>2002</year>
        </date>
        <date iso-8601-date="2014-07-17" date-type="updated">
          <day>17</day>
          <month>7</month>
          <year>2014</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="bgc" document-type="chapter">Primary Familial Brain Calcification</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="ph2" document-type="chapter">Primary Hyperoxaluria Type 2</related-object>
      <abstract id="ph1.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Primary hyperoxaluria type 1 (PH1) is caused by a deficiency of the liver peroxisomal enzyme alanine:glyoxylate-aminotransferase (AGT), which catalyzes the conversion of glyoxylate to glycine. When AGT activity is absent, glyoxylate is converted to oxalate, which forms insoluble calcium salts that accumulate in the kidney and other organs. Individuals with PH1 are at risk for recurrent nephrolithiasis (deposition of calcium oxalate in the renal pelvis/urinary tract), nephrocalcinosis (deposition of calcium oxalate in the renal parenchyma), or end-stage renal disease (ESRD) with a history of renal stones or calcinosis. Age at onset of symptoms typically ranges from one to 25 years. Approximately 19% of affected individuals present before age four to six months with severe disease, often associated with failure to thrive, nephrocalcinosis, anemia, and metabolic acidosis. Approximately 54% of affected individuals present in late childhood or early adolescence, usually with symptomatic nephrolithiasis. The remainder of affected individuals present in adulthood with recurrent renal stones. The natural history of untreated PH1 is one of inexorable decline in renal function as a result of progressive nephrolithiasis/nephrocalcinosis, with eventual progression to oxalosis (widespread tissue deposition of calcium oxalate) and death from ESRD.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of PH1 is suspected in an individual with an elevated oxalate to creatinine ratio in urine and an elevated plasma oxalate concentration. The diagnosis can be confirmed by detection of biallelic pathogenic variants in <italic toggle="yes">AGXT</italic> on molecular genetic testing. Failure to detect at least one common, known, or otherwise proven <italic toggle="yes">AGXT</italic> pathogenic variant requires consideration of liver biopsy to assay the activity of the enzyme alanine:glyoxylate-aminotransferase (AGT).</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Reduction of calcium oxalate supersaturation and oxalate biosynthesis; organ transplantation as either preemptive liver transplantation or combined liver/kidney transplantation. For kidney stones: consider shockwave lithotripsy, percutaneous nephrolithotomy, or ureteroscopy.</p>
          <p><italic toggle="yes">Prevention of primary manifestations:</italic> Maintenance of high fluid intake; pyridoxine supplements for those who are pyridoxine responsive; use of potassium or sodium citrate, pyrophosphate-containing solutions, or thiazides to minimize stone formation.</p>
          <p><italic toggle="yes">Surveillance:</italic> Regular renal ultrasound and fundoscopic eye examinations; ongoing urinalysis; regular measurement of glomerular filtration rate (GFR). Additionally:</p>
          <list list-type="bullet">
            <list-item>
              <p>In those with reduced GFR: regular measurement of plasma oxalate.</p>
            </list-item>
            <list-item>
              <p>In patients with greatly reduced GFR or rapid deterioration in function: multi-system testing prior to initiation of dialysis</p>
            </list-item>
          </list>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Dehydration; foods high in oxalate (e.g., chocolate, rhubarb, and starfruit); megadoses of vitamins C and D; loop diuretics.</p>
          <p><italic toggle="yes">Evaluation of relatives at risk:</italic> Early diagnosis of at-risk relatives enables early institution of treatment and preventive measures.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>PH1 is inherited in an autosomal recessive manner. At conception, each sib of a proband with PH1 has a 25% risk of being affected, a 50% risk of being an asymptomatic carrier, and a 25% risk of being unaffected and not a carrier. Carrier testing for at-risk relatives and prenatal diagnosis for pregnancies at increased risk are possible if both pathogenic variants have been identified in a family. Assay of AGT enzymatic activity prenatally is not generally offered because it requires a fetal liver biopsy.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="ph1.Diagnosis">
        <title>Diagnosis</title>
        <sec id="ph1.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p>Primary hyperoxaluria type 1 (PH1) is suspected in a proband with any of the following [<xref ref-type="bibr" rid="ph1.REF.milliner.2005.154">Milliner 2005</xref>, <xref ref-type="bibr" rid="ph1.REF.bobrowski.2008.152">Bobrowski &#x00026; Langman 2008</xref>, <xref ref-type="bibr" rid="ph1.REF.cochat.2012.1729">Cochat et al 2012</xref>]:</p>
          <list list-type="bullet">
            <list-item>
              <p>Frequent recurrent nephrolithiasis (deposition of calcium oxalate stones in the renal pelvis/urinary tract). Renal ultrasound examination often reveals bilateral and multiple radiopaque calculi [<xref ref-type="bibr" rid="ph1.REF.jamieson.2000.b32">Jamieson et al 2000</xref>, <xref ref-type="bibr" rid="ph1.REF.hoppe.2009.1264">Hoppe et al 2009</xref>].Note: (1) Computed tomography (CT) and kidney ureter bladder (KUB) x-ray may demonstrate similar findings. (2) CT scan is more sensitive than KUB in the detection of stones [<xref ref-type="bibr" rid="ph1.REF.barrett.1999">Barrett &#x00026; Danpure 1999</xref>]; however, one must consider the radiation risk associated with CT.</p>
            </list-item>
            <list-item>
              <p>Stone composition of pure calcium oxalate monohydrate (whewellite). PH1 calculi also demonstrate peculiar morphologic characteristics including a whitish or pale yellow surface and a distinct crystalline structure, not found in stones formed as a result of other hyperoxaluric states [<xref ref-type="bibr" rid="ph1.REF.daudon.2008.100">Daudon et al 2008</xref>].</p>
            </list-item>
            <list-item>
              <p>Nephrocalcinosis (deposition of calcium oxalate in the renal parenchyma), in particular if associated with decreased glomerular filtration rate (GFR). In older children or adults, the strongest echoes are from the corticomedullary regions, whereas in infants the pattern is more likely to be that of diffuse nephrocalcinosis with few if any observable discrete stones.Note: Computed tomography (CT) and kidney ureter bladder (KUB) x-ray may demonstrate similar findings.</p>
            </list-item>
            <list-item>
              <p>The finding of oxalate crystals in any biologic fluid or tissue [<xref ref-type="bibr" rid="ph1.REF.cochat.2012.1729">Cochat et al 2012</xref>].</p>
            </list-item>
            <list-item>
              <p>A child with a first kidney stone [<xref ref-type="bibr" rid="ph1.REF.cochat.2012.1729">Cochat et al 2012</xref>].</p>
            </list-item>
            <list-item>
              <p>A child younger than age six to 12 months with failure to thrive [<xref ref-type="bibr" rid="ph1.REF.cochat.2013.649">Cochat &#x00026; Rumsby 2013</xref>].</p>
            </list-item>
            <list-item>
              <p>End-stage renal disease (ESRD) with a history of renal stones or calcinosis</p>
            </list-item>
          </list>
          <p>Note: PH1 is often associated with nephrocalcinosis, anemia, and metabolic acidosis [<xref ref-type="bibr" rid="ph1.REF.cochat.1999.746">Cochat et al 1999</xref>]. Most affected individuals are symptomatic before age ten years [<xref ref-type="bibr" rid="ph1.REF.sikora.2008.1181">Sikora et al 2008</xref>]. In rare cases, diagnosis may be complicated by co-occurrence of more common unrelated kidney disorders [<xref ref-type="bibr" rid="ph1.REF.devriendt.2011.107">Devriendt et al 2011</xref>]. See <xref ref-type="sec" rid="ph1.Testing_Strategy">Testing Strategy</xref> for algorithms to aid in diagnosis and treatment.</p>
          <sec id="ph1.Preliminary_Testing">
            <title>Preliminary Testing</title>
            <p><bold>Urinary oxalate-to-creatinine molar ratio.</bold> Wherever possible, preliminary testing should include a 24-hour urine collection for oxalate and creatinine. Note: In the absence of a 24-hour sample, random urine samples are acceptable.</p>
            <p>At any age urinary oxalate excretion persistently above 0.7 mmol/1.73 m<sup>2</sup> per day or above the age-related reference range(s) (<xref ref-type="table" rid="ph1.T.normal_values_for_urinary_oxalate">Table 1</xref>) warrants further diagnostic evaluation [<xref ref-type="bibr" rid="ph1.REF.milliner.2005.154">Milliner 2005</xref>].</p>
            <p>Note: (1) Those individuals who present in adulthood often have urinary oxalate excretion at the lower range of hyperoxaluria values [<xref ref-type="bibr" rid="ph1.REF.watts.1998.4">Watts 1998</xref>]. (2) Urinary excretion of creatinine on a per-kg basis differs between males and females and does not stabilize until ages 14 to 18 years [<xref ref-type="bibr" rid="ph1.REF.remer.2002.561">Remer et al 2002</xref>].</p>
            <p><bold>Concentration of glycolic acid (glycolate).</bold> Wherever possible, preliminary testing should include a 24-hour urine collection for glycolate. Measurement of glycolate in urine depends on either reversed phase high-pressure liquid chromatography or ion chromatography.</p>
            <p>Normal ranges (<xref ref-type="table" rid="ph1.T.normal_values_for_urinary_oxalate">Table 1</xref>) are defined for each separate assay [<xref ref-type="bibr" rid="ph1.REF.petrarulo.1998.23">Petrarulo et al 1998</xref>]:</p>
            <list list-type="bullet">
              <list-item>
                <p>Approximately 66% of individuals with PH1 have hyperoxaluria and high concentration of glycolic acids in the urine (hyperglycolic aciduria) [<xref ref-type="bibr" rid="ph1.REF.milliner.2005.154">Milliner 2005</xref>], as do some with <related-object link-type="booklink" source-id="gene" document-id="ph3" document-type="chapter">primary hyperoxaluria type 3</related-object> (PH3) (see <xref ref-type="sec" rid="ph1.Differential_Diagnosis">Differential Diagnosis</xref>) [<xref ref-type="bibr" rid="ph1.REF.harambat.2010.443">Harambat et al 2010</xref>].</p>
              </list-item>
              <list-item>
                <p>Approximately 25% of individuals with PH1 do not have hyperglycolic aciduria [<xref ref-type="bibr" rid="ph1.REF.danpure.2001">Danpure 2001</xref>].</p>
              </list-item>
            </list>
            <p>Thus, hyperglycolic aciduria suggests but does not confirm the diagnosis of PH1 in an individual with hyperoxaluria.</p>
            <table-wrap id="ph1.T.normal_values_for_urinary_oxalate" position="anchor" orientation="portrait">
              <label>Table 1. </label>
              <caption>
                <p>Normal Values for Urinary Oxalate, Glycolate, and L-Glycerate Excretion in 24-Hour Urine and Spot Urine Samples</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Parameter</th>
                    <th id="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Age</th>
                    <th id="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Normal Values&#x000a0;<sup>1</sup></th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_1 hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_2" valign="middle" colspan="2" align="left" scope="row" rowspan="1"/>
                    <td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                      <bold>In 24-hour urine samples</bold>
                    </td>
                  </tr>
                  <tr>
                    <td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Urinary oxalate excretion&#x000a0;<sup>2</sup></td>
                    <td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_2" rowspan="3" valign="middle" align="left" colspan="1">All ages</td>
                    <td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">&#x0003c;0.50 mmol (&#x0003c;45 mg)/1.73 m<sup>2</sup>/day</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Urinary glycolate excretion</td>
                    <td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_3" valign="middle" colspan="1" align="left" rowspan="1">&#x0003c;0.50 mmol (&#x0003c;45 mg)/1.73 m<sup>2</sup>/day</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Urinary l-glyceric acid excretion</td>
                    <td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_3" valign="middle" colspan="1" align="left" rowspan="1">&#x0003c;5 &#x003bc;mol/L</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_1 hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_2" valign="middle" colspan="2" align="left" scope="row" rowspan="1"/>
                    <td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                      <bold>In spot urine samples</bold>
                    </td>
                  </tr>
                  <tr>
                    <td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_1" rowspan="5" valign="middle" align="left" scope="row" colspan="1">Spot urinary oxalate-to-creatinine molar ratio&#x000a0;<sup>2</sup></td>
                    <td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">0-6 mos&#x000a0;<sup>3</sup></td>
                    <td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">&#x0003c;325-360 mmol/mol</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">7-24 mos&#x000a0;<sup>3</sup></td>
                    <td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">&#x0003c;132-174 mmol/mol</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">2-5 yrs</td>
                    <td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">&#x0003c;98-101 mmol/mol</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">5-14 yrs</td>
                    <td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">&#x0003c;70-82 mmol/mol</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">&#x0003e;16 yrs</td>
                    <td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">&#x0003c;40 mmol/mol</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_1" rowspan="5" valign="middle" align="left" scope="row" colspan="1">Spot urinary glycolate-to-creatinine molar ratio</td>
                    <td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">0-6 mos&#x000a0;<sup>3</sup></td>
                    <td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">&#x0003c;363-425 mmol/mol</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">7-24 mos&#x000a0;<sup>3</sup></td>
                    <td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">&#x0003c;245-293 mmol/mol</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">2-5 yrs</td>
                    <td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">&#x0003c;191-229 mmol/mol</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">5-14 yrs</td>
                    <td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">&#x0003c;166-186 mmol/mol</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">&#x0003e;16 yrs</td>
                    <td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">&#x0003c;99-125 mmol/mol</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_1" rowspan="5" valign="middle" align="left" scope="row" colspan="1">Spot urinary l-glycerate-to-creatinine molar ratio</td>
                    <td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">0-6 mos&#x000a0;<sup>3</sup></td>
                    <td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">14-205 mmol/mol</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">7-24 mos&#x000a0;<sup>3</sup></td>
                    <td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">14-205 mmol/mol</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">2-5 yrs</td>
                    <td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">14-205 mmol/mol</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">5-14 yrs</td>
                    <td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">23-138 mmol/mol</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">&#x0003e;16 yrs</td>
                    <td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">&#x0003c;138 mmol/mol</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn>
                  <p>Adapted from <xref ref-type="bibr" rid="ph1.REF.hoppe.2012.467">Hoppe [2012]</xref></p>
                </fn>
                <fn id="ph1.TF.1.1">
                  <label>1. </label>
                  <p>Values are laboratory and method dependent.</p>
                </fn>
                <fn id="ph1.TF.1.2">
                  <label>2. </label>
                  <p>To prevent alkaline conversion of ascorbate to oxalate in urine, the sample must be strongly acidified to stabilize ascorbate and minimize formation of calcium crystals [<xref ref-type="bibr" rid="ph1.REF.marangella.1995">Marangella &#x00026; Petrarulo 1995</xref>].</p>
                </fn>
                <fn id="ph1.TF.1.3">
                  <label>3. </label>
                  <p>In children younger than age 1.5-2.0 years, rapidly changing glomerular filtration rates make the interpretation of oxalate to creatinine ratio of little practical value [Applegarth, personal communication]. Normal newborns and young infants/children can excrete &#x02265;3-5 times the amount of oxalate excreted by adults; this amount slowly decreases into the normal adult range in the older child [<xref ref-type="bibr" rid="ph1.REF.leumann.1990.493">Leumann et al 1990</xref>, <xref ref-type="bibr" rid="ph1.REF.von_schnakenburg.1994.27">von Schnakenburg et al 1994</xref>, <xref ref-type="bibr" rid="ph1.REF.marangella.1995">Marangella &#x00026; Petrarulo 1995</xref>].</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <p><bold>Concentration of L-glycerate.</bold> Elevation of this urinary metabolite is often seen, but not pathognomonic for either PH1 [<xref ref-type="bibr" rid="ph1.REF.cochat.2013.649">Cochat &#x00026; Rumsby 2013</xref>] or primary hyperoxaluria type 2 (PH2) (see <xref ref-type="sec" rid="ph1.Differential_Diagnosis">Differential Diagnosis</xref>) [<xref ref-type="bibr" rid="ph1.REF.rumsby.2001.1697">Rumsby et al 2001</xref>].</p>
            <p><bold>Concentration of HOG (4-hydroxy-2-oxoglutarate).</bold> Increased levels of this urinary metabolite have been seen in conjunction with the presumed diagnosis of PH3 [<xref ref-type="bibr" rid="ph1.REF.belostotsky.2012.1497">Belostotsky et al 2012</xref>].</p>
            <p><bold>Urinary calcium.</bold> Individuals with PH1 and <xref ref-type="sec" rid="ph1.Differential_Diagnosis">PH2</xref> often have hypocalciuria; though those with <xref ref-type="sec" rid="ph1.Differential_Diagnosis">PH3</xref> often demonstrate significant hypercalciuria [<xref ref-type="bibr" rid="ph1.REF.williams.2012.3191">Williams et al 2012</xref>].</p>
            <p><bold>Plasma concentration of oxalate.</bold> Plasma oxalate concentration exceeding the upper limit of the normal range when corrected for renal function is consistent with but not diagnostic of primary hyperoxaluria. Individuals with primary hyperoxaluria type 1 usually have plasma oxalate levels two to five times the upper limit of normal. Of note, in their recent review <xref ref-type="bibr" rid="ph1.REF.cochat.2013.649">Cochat &#x00026; Rumsby [2013]</xref> contend that plasma oxalate concentrations higher than 50 &#x000b5;mol/L regardless of renal function would be very suggestive of PH1.</p>
            <p>When the GFR is known to be reduced (&#x0003c;60 mL/min/1.73 m<sup>2</sup>), plasma oxalate concentration should be measured and monitored regularly (at least annually).</p>
            <p>Note: (1) Pediatric normal ranges are defined for the specific assay used [<xref ref-type="bibr" rid="ph1.REF.petrarulo.1998.23">Petrarulo et al 1998</xref>] and are affected by the degree of renal dysfunction and/or need for dialysis (see <xref ref-type="table" rid="ph1.T.plasma_oxalate_concentrations_in_i">Table 2</xref>). (2) Interpretation of results warrants caution: in affected individuals with adequate renal function, elevation of plasma oxalate concentration may be modest; in individuals with end-stage renal disease, absolute excretion of oxalate and glycolic acid is lower even with a very high plasma oxalate concentration [<xref ref-type="bibr" rid="ph1.REF.danpure.2001">Danpure 2001</xref>, <xref ref-type="bibr" rid="ph1.REF.hoppe.2009.1264">Hoppe et al 2009</xref>]. (3) In plasma, the spontaneous occurrence of oxalogenesis requires stringent handling of the sample, including handling in a cold environment, immediate deproteinization, and freezing until assayed.</p>
            <table-wrap id="ph1.T.plasma_oxalate_concentrations_in_i" position="anchor" orientation="portrait">
              <label>Table 2. </label>
              <caption>
                <p>Plasma Oxalate Concentrations in Individuals with PH1 by Renal Function</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_ph1.T.plasma_oxalate_concentrations_in_i_1_1_1_1" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_ph1.T.plasma_oxalate_concentrations_in_i_1_1_1_1"/>
                    <th id="hd_h_ph1.T.plasma_oxalate_concentrations_in_i_1_1_1_2" valign="middle" colspan="3" align="left" scope="colgroup" rowspan="1">Individual with PH1 Stratified by Renal Function</th>
                    <th id="hd_h_ph1.T.plasma_oxalate_concentrations_in_i_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Individual w/out PH1</th>
                  </tr>
                  <tr>
                    <th headers="hd_h_ph1.T.plasma_oxalate_concentrations_in_i_1_1_1_2" id="hd_h_ph1.T.plasma_oxalate_concentrations_in_i_1_1_2_1" valign="middle" colspan="1" align="left" scope="colgroup" rowspan="1">GFR 20-30 mL/min/1.73 m<sup>2</sup></th>
                    <th headers="hd_h_ph1.T.plasma_oxalate_concentrations_in_i_1_1_1_2" id="hd_h_ph1.T.plasma_oxalate_concentrations_in_i_1_1_2_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">GFR &#x0003c;20 mL/min/1.73 m<sup>2</sup> or ESRD&#x000a0;<sup>1</sup></th>
                    <th headers="hd_h_ph1.T.plasma_oxalate_concentrations_in_i_1_1_1_2" id="hd_h_ph1.T.plasma_oxalate_concentrations_in_i_1_1_2_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Maintenance HD&#x000a0;<sup>2</sup></th>
                    <th headers="hd_h_ph1.T.plasma_oxalate_concentrations_in_i_1_1_1_3" id="hd_h_ph1.T.plasma_oxalate_concentrations_in_i_1_1_2_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Maintenance HD&#x000a0;<sup>2</sup></th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_ph1.T.plasma_oxalate_concentrations_in_i_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                      <bold>Plasma oxalate concentration&#x000a0;<sup>3</sup></bold>
                    </td>
                    <td headers="hd_h_ph1.T.plasma_oxalate_concentrations_in_i_1_1_1_2 hd_h_ph1.T.plasma_oxalate_concentrations_in_i_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">&#x0003e;2 &#x000b5;mol/L</td>
                    <td headers="hd_h_ph1.T.plasma_oxalate_concentrations_in_i_1_1_1_2 hd_h_ph1.T.plasma_oxalate_concentrations_in_i_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">&#x0003e;20 &#x000b5;mol/L</td>
                    <td headers="hd_h_ph1.T.plasma_oxalate_concentrations_in_i_1_1_1_2 hd_h_ph1.T.plasma_oxalate_concentrations_in_i_1_1_2_3" valign="middle" align="left" rowspan="1" colspan="1">50 - &#x0003e;100 &#x000b5;mol/L</td>
                    <td headers="hd_h_ph1.T.plasma_oxalate_concentrations_in_i_1_1_1_3 hd_h_ph1.T.plasma_oxalate_concentrations_in_i_1_1_2_4" valign="middle" align="left" rowspan="1" colspan="1">10-40 &#x000b5;mol/L</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn>
                  <p>m<sup>2</sup> = meters squared</p>
                </fn>
                <fn>
                  <p>GFR = glomerular filtration rate</p>
                </fn>
                <fn>
                  <p>HD = hemodialysis</p>
                </fn>
                <fn id="ph1.TF.2.1">
                  <label>1. </label>
                  <p>End-stage renal disease but not on dialysis</p>
                </fn>
                <fn id="ph1.TF.2.2">
                  <label>2. </label>
                  <p>Sample drawn pre-dialysis</p>
                </fn>
                <fn id="ph1.TF.2.3">
                  <label>3. </label>
                  <p>Individual without PH1 normal value &#x0003c;2.5 &#x000b5;mol/L based on oxalate oxidase assay</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </sec>
        </sec>
        <sec id="ph1.Confirming_the_Diagnosis">
          <title>Confirming the Diagnosis</title>
          <p>The diagnosis of PH1 can be confirmed by detection of biallelic pathogenic variants in <italic toggle="yes">AGXT</italic> on molecular genetic testing (<xref ref-type="table" rid="ph1.T.summary_of_molecular_genetic_testi">Table 3</xref>)<italic toggle="yes">.</italic> Of note, molecular genetic testing is indicated in all patients as genotype information helps predict treatment responses (see <xref ref-type="sec" rid="ph1.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</xref>) [<xref ref-type="bibr" rid="ph1.REF.harambat.2010.443">Harambat et al 2010</xref>].</p>
          <p>If molecular genetic testing fails to detect at least one common, known, or otherwise proven <italic toggle="yes">AGXT</italic> pathogenic variant, liver biopsy for the purpose of assaying alanine:glyoxylate-aminotransferase (AGT) enzyme activity (see <bold>Assay of AGT catalytic activity</bold> below) needs to be considered.</p>
          <sec id="ph1.Molecular_Genetic_Testing">
            <title>Molecular Genetic Testing</title>
            <p><bold>One genetic testing strategy</bold> is testing of <italic toggle="yes">AGXT</italic> that may begin with EITHER sequence analysis [<xref ref-type="bibr" rid="ph1.REF.monico.2007.1905">Monico et al 2007</xref>] OR targeted analysis for pathogenic variants or sequencing of selected exons.</p>
            <p>If only one pathogenic variant is identified, follow with sequence analysis of exons and flanking intronic regions [<xref ref-type="bibr" rid="ph1.REF.williams.2007.1216">Williams &#x00026; Rumsby 2007</xref>, <xref ref-type="bibr" rid="ph1.REF.coultermackie.2008.598">Coulter-Mackie et al 2008</xref>].</p>
            <p>Deletion/duplication analysis may be useful if only one pathogenic variant has been identified or if hemizygosity is suspected. However, so far, only six of more than 170 known pathogenic variants are of the type that would be detectable by this approach.Note: Typically, testing is included for the two common <italic toggle="yes">AGXT</italic> polymorphic variants defined most importantly by the presence of a proline or a leucine at amino acid residue. Although the p.Pro11Leu variant, referred to as the &#x0201c;minor allele,&#x0201d; does not cause PH1 by itself, it is known to exacerbate the deleterious effects of other pathogenic variants in <italic toggle="yes">cis</italic> configuration. See <xref ref-type="sec" rid="ph1.Molecular_Genetics">Molecular Genetics</xref>. The most common pathogenic variant <xref ref-type="table" rid="ph1.T.agxt_allelic_variants_discussed_in">c.508G&#x0003e;A</xref> (p.Gly170Arg) occurs in <italic toggle="yes">cis</italic> configuration with the &#x0201c;minor allele,&#x0201d; while the second most common pathogenic variant <xref ref-type="table" rid="ph1.T.agxt_allelic_variants_discussed_in">c.33dupC</xref> (p.Lys12GlnfsTer156) occurs in <italic toggle="yes">cis</italic> configuration with the &#x0201c;major allele&#x0201d; (see <xref ref-type="table" rid="ph1.T.summary_of_molecular_genetic_testi">Table 3</xref>, footnote 2 and <xref ref-type="sec" rid="ph1.Molecular_Genetic_Pathogenesis">Molecular Genetics</xref>, <bold>&#x0201c;Major&#x0201d; and &#x0201c;minor&#x0201d; <italic toggle="yes">AGXT</italic> alleles</bold>).</p>
            <p><bold>An alternative genetic testing strategy</bold> is use of a multi-gene panel that includes <italic toggle="yes">AGXT</italic> (mutation of which causes PH1), <italic toggle="yes">GRHPR</italic> (mutation of which causes PH2) and <italic toggle="yes">HOGA1</italic> (mutation of which causes PH3) (see <xref ref-type="sec" rid="ph1.Differential_Diagnosis">Differential Diagnosis</xref>). Note: The genes included and the methods used in multi-gene panels vary by laboratory and over time.</p>
            <table-wrap id="ph1.T.summary_of_molecular_genetic_testi" position="anchor" orientation="portrait">
              <label>Table 3. </label>
              <caption>
                <p>Summary of Molecular Genetic Testing Used in Primary Hyperoxaluria Type 1</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_ph1.T.summary_of_molecular_genetic_testi_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                    <th id="hd_h_ph1.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                    <th id="hd_h_ph1.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Proportion of Probands with a Pathogenic Variant Detectable by This Method</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_ph1.T.summary_of_molecular_genetic_testi_1_1_1_1" rowspan="3" valign="middle" align="left" scope="row" colspan="1">
                      <italic toggle="yes">AGXT</italic>
                    </td>
                    <td headers="hd_h_ph1.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Targeted analysis for pathogenic variants&#x000a0;<sup>2,&#x000a0;3</sup></td>
                    <td headers="hd_h_ph1.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">50%-70%&#x000a0;<sup>4</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_ph1.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Sequence analysis&#x000a0;<sup>3,&#x000a0;5,&#x000a0;6</sup></td>
                    <td headers="hd_h_ph1.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">100%&#x000a0;<sup>7</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_ph1.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Deletion/duplication analysis&#x000a0;<sup>8</sup></td>
                    <td headers="hd_h_ph1.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">&#x0003c;3%&#x000a0;<sup>9</sup></td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="ph1.TF.3.1">
                  <label>1. </label>
                  <p>See <related-object source-id="gene" document-id="ph1" object-id="ph1.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein. See <xref ref-type="sec" rid="ph1.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants.</p>
                </fn>
                <fn id="ph1.TF.3.2">
                  <label>2. </label>
                  <p>Targeted analysis for pathogenic variants refers to testing for specific common <italic toggle="yes">AGXT</italic> pathogenic variant(s). Pathogenic variants included in a panel may vary by laboratory but generally include the two most common pathogenic variants, <xref ref-type="table" rid="ph1.T.agxt_allelic_variants_discussed_in">c.508G&#x0003e;A</xref> (p.Gly170Arg) and <xref ref-type="table" rid="ph1.T.suggested_transplantation_options">c.33dupC</xref> (p.Lys12GlnfsTer156). At least 50% of uncharacterized European and North American individuals with PH1 have at least one p.Gly170Arg pathogenic allele [<xref ref-type="bibr" rid="ph1.REF.rumsby.2004.959">Rumsby et al 2004</xref>], which is specifically associated with mistargeting of AGT to the mitochondria. The c.33dupC pathogenic allele is the second most common variant [<xref ref-type="bibr" rid="ph1.REF.pirulli.1999.523">Pirulli et al 1999</xref>, <xref ref-type="bibr" rid="ph1.REF.coultermackie.2004.64">Coulter-Mackie et al 2004</xref>]. The choice of less common pathogenic variants for targeted analysis for pathogenic variants may be influenced by the ethnic background of the affected individual [<xref ref-type="bibr" rid="ph1.REF.coultermackie.2005.264">Coulter-Mackie 2005</xref>].</p>
                </fn>
                <fn id="ph1.TF.3.3">
                  <label>3. </label>
                  <p>Generally, analysis includes testing for the <italic toggle="yes">AGXT</italic> &#x0201c;minor&#x0201d; or &#x0201c;major allele&#x0201d; status. See <xref ref-type="sec" rid="ph1.Molecular_Genetics">Molecular Genetics</xref>, <bold>&#x0201c;Major&#x0201d; and &#x0201c;minor&#x0201d; <italic toggle="yes">AGXT</italic> alleles</bold>.</p>
                </fn>
                <fn id="ph1.TF.3.4">
                  <label>4. </label>
                  <p>Molecular genetic testing for the four most common pathogenic variants identifies both alleles in approximately 34% of individuals with PH1 and one allele in approximately 28% [<xref ref-type="bibr" rid="ph1.REF.rumsby.2004.959">Rumsby et al 2004</xref>]. A panel including the four common pathogenic variants plus an additional group of recurrent pathogenic variants detected at least one pathogenic variant in 83% of individuals with PH1 and both pathogenic variants in 51% [<xref ref-type="bibr" rid="ph1.REF.coultermackie.2008.598">Coulter-Mackie et al 2008</xref>]. Sequencing of selected exons (1,4, and 7) detected at least one pathogenic variant in 70% and both in 50% [<xref ref-type="bibr" rid="ph1.REF.williams.2007.1216">Williams &#x00026; Rumsby 2007</xref>, <xref ref-type="bibr" rid="ph1.REF.williams.2009.910">Williams et al 2009</xref>].</p>
                </fn>
                <fn id="ph1.TF.3.5">
                  <label>5. </label>
                  <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
                </fn>
                <fn id="ph1.TF.3.6">
                  <label>6. </label>
                  <p>Sequence analysis can detect the common and rare <italic toggle="yes">AGXT</italic> pathogenic variants included in the targeted analysis panels.</p>
                </fn>
                <fn id="ph1.TF.3.7">
                  <label>7. </label>
                  <p>In individuals with enzymatically confirmed PH1 or one common <italic toggle="yes">AGXT</italic> pathogenic variant already identified [<xref ref-type="bibr" rid="ph1.REF.coultermackie.2008.598">Coulter-Mackie et al 2008</xref>]</p>
                </fn>
                <fn id="ph1.TF.3.8">
                  <label>8. </label>
                  <p>Testing that identifies exon or whole-gene deletions/duplications not detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA. Included in the variety of methods that may be used are: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and chromosomal microarray (CMA) that includes this gene/chromosome segment.</p>
                </fn>
                <fn id="ph1.TF.3.9">
                  <label>9. </label>
                  <p>Out of more than 170 known <italic toggle="yes">AGXT</italic> pathogenic variants, six large deletions have been reported [<xref ref-type="bibr" rid="ph1.REF.nogueira.2000.384">Nogueira et al 2000</xref>, <xref ref-type="bibr" rid="ph1.REF.coultermackie.2001.314">Coulter-Mackie et al 2001</xref>, <xref ref-type="bibr" rid="ph1.REF.coultermackie.2005.172">Coulter-Mackie et al 2005</xref>, <xref ref-type="bibr" rid="ph1.REF.monico.2007.1905">Monico et al 2007</xref>, <xref ref-type="bibr" rid="ph1.REF.williams.2009.910">Williams et al 2009</xref>, <xref ref-type="bibr" rid="ph1.REF.tammachote.2012.2124">Tammachote et al 2012</xref>]. The sensitivity of this approach is expected to be low.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </sec>
          <sec id="ph1.Biochemical_Testing">
            <title>Biochemical Testing</title>
            <p><bold>Assay of alanine:glyoxylate-aminotransferase (AGT) enzyme (EC 2.6.1.44) catalytic activity</bold> requires at least 2 mg of liver taken by percutaneous needle biopsy or at autopsy. Several methods in use:</p>
            <list list-type="bullet">
              <list-item>
                <p><bold>AGT enzyme assay.</bold> A radiochemical method using <sup>14</sup>C-alanine with and without aminooxyacetic acid to inhibit AGT specifically in the presence of other enzymatic activities</p>
              </list-item>
              <list-item>
                <p><bold>Automated assay of AGT enzyme activity</bold> [<xref ref-type="bibr" rid="ph1.REF.horv_th.1994.336">Horv&#x000e1;th &#x00026; Wanders 1994</xref>, <xref ref-type="bibr" rid="ph1.REF.andy.1995.105">Andy et al 1995</xref>, <xref ref-type="bibr" rid="ph1.REF.rumsby.1997.400">Rumsby et al 1997</xref>]</p>
              </list-item>
            </list>
            <p>Note: (1) Approximately 50%-70% of affected individuals have undetectable levels of AGT catalytic activity, and approximately 30%-50% of affected individuals have substantial residual AGT catalytic activity (2%-48% of mean normal activity) [<xref ref-type="bibr" rid="ph1.REF.danpure.2001">Danpure 2001</xref>]. In many human metabolic disorders, this level of residual activity is sufficient for normal function. Most individuals with classic PH1 who have residual AGT enzymatic activity have a unique protein-targeting (or trafficking) defect in which functional AGT enzyme is synthesized in adequate amounts but approximately 90% of the enzyme produced is mislocalized to mitochondria and only approximately 10% is properly localized in the peroxisomes (where it catalyzes the glyoxylate substrate). Individuals with such a protein-trafficking defect have classic PH1 despite the presence of residual AGT activity. (2) The detection of a mistargeting pathogenic variant (See <xref ref-type="sec" rid="ph1.Molecular_Genetics">Molecular Genetics</xref>, &#x0201c;<bold>Major&#x0201d; and &#x0201c;minor&#x0201d; <italic toggle="yes">AGXT</italic> alleles</bold>) clarifies the significance of high residual AGT enzyme activity (when the diagnosis of PH1 has been established by liver biopsy and AGT enzyme assay), helping to distinguish between mislocalized AGT enzyme (i.e., classic PH1) and true partial AGT enzyme activity (no known associated phenotype).</p>
          </sec>
        </sec>
        <sec id="ph1.Testing_Strategy">
          <title>Testing Strategy</title>
          <p><bold>To confirm/establish the diagnosis in a proband.</bold> An evidence-based guideline for diagnosis that incorporates aspects of clinical and laboratory approaches to the diagnosis of primary hyperoxaluria has been developed [<xref ref-type="bibr" rid="ph1.REF.harambat.2011">Harambat et al 2011</xref>] (see <xref ref-type="fig" rid="ph1.F1">Figure 1</xref>). The intent of this algorithm is to facilitate recognition and diagnosis of affected individuals and to enable earlier treatment. The algorithm also assists the clinician in differentiating between PH types 1, 2, and 3 and provides guidance as to best-evidence conservative management of the conditions:</p>
          <list list-type="bullet">
            <list-item>
              <p>Measurement of urinary and plasma metabolites is a screening test (see <xref ref-type="sec" rid="ph1.Preliminary_Testing">Preliminary Testing</xref>). Restrict plasma oxalate measurements to GFR &#x0003c;30-45 mL/min/1.73 m<sup>2</sup> (chronic kidney disease [CKD] Category 3b or lower).</p>
            </list-item>
            <list-item>
              <p>Finding of known biallelic (homozygous or compound heterozygous) <italic toggle="yes">AGXT</italic> pathogenic variants confirms the diagnosis of PH1. Finding of one <italic toggle="yes">AGXT</italic> pathogenic variant in a symptomatic individual strongly supports the diagnosis.</p>
            </list-item>
          </list>
          <p><bold>Prognostic testing</bold>
<bold>for affected individuals.</bold> Testing for the presence of the specific pathogenic variants <xref ref-type="table" rid="ph1.T.agxt_allelic_variants_discussed_in">p.Gly170Arg</xref> and <xref ref-type="table" rid="ph1.T.agxt_allelic_variants_discussed_in">p.Phe152Ile</xref>, if not already determined through molecular genetic analysis, may have predictive value as these pathogenic variants are associated with a positive response to pyridoxine supplementation especially for homozygotes [<xref ref-type="bibr" rid="ph1.REF.van_woerden.2004.746">van Woerden et al 2004</xref>, <xref ref-type="bibr" rid="ph1.REF.monico.2005a.183">Monico et al 2005a</xref>, <xref ref-type="bibr" rid="ph1.REF.monico.2005b.1704">Monico et al 2005b</xref>]. Among the known pathogenic variants, p.Gly170Arg is associated with a better prognosis [<xref ref-type="bibr" rid="ph1.REF.hoppe.2010.383">Hoppe 2010</xref>]. See <xref ref-type="sec" rid="ph1.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</xref>.</p>
        </sec>
      </sec>
      <sec id="ph1.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="ph1.Clinical_Description">
          <title>Clinical Description</title>
          <p>In primary hyperoxaluria type 1 (PH1), supersaturation of the urine with oxalate leads to nephrolithiasis/nephrocalcinosis, renal tubular damage, and renal failure with eventual development of systemic manifestations (oxalosis) [<xref ref-type="bibr" rid="ph1.REF.marangella.2001">Marangella et al 2001</xref>]. The presentation of PH1 is variable. Age at onset of symptoms ranges from birth to the sixth decade (median age: 5-6 years) [<xref ref-type="bibr" rid="ph1.REF.lieske.2005b.290">Lieske et al 2005b</xref>]; exceptions occur.</p>
          <p>Approximately 19% of affected individuals present with a severe, very early-onset form of PH1 in the first few months of life. At the other end of the spectrum of clinical severity seen in PH1, some individuals remain apparently asymptomatic for more than 40-50 years [<xref ref-type="bibr" rid="ph1.REF.danpure.2001">Danpure 2001</xref>].</p>
          <p><bold>Renal manifestations.</bold> Overall the renal manifestations of PH1 can be quite variable, with individuals generally falling into one of five groups [<xref ref-type="bibr" rid="ph1.REF.cochat.2010.590">Cochat et al 2010</xref>]:</p>
          <list list-type="bullet">
            <list-item>
              <p>Early nephrocalcinosis and renal failure leading to a diagnosis in infancy or early childhood (infantile form)</p>
            </list-item>
            <list-item>
              <p>Recurrent urolithiasis and progressive renal failure with diagnosis in childhood or adolescence</p>
            </list-item>
            <list-item>
              <p>Late onset form with occasional stones diagnosed in adulthood</p>
            </list-item>
            <list-item>
              <p>Diagnosis secondary to recurrence following renal transplantation</p>
            </list-item>
            <list-item>
              <p>Diagnosis in a presymptomatic individual because of a positive family history</p>
            </list-item>
          </list>
          <p>While the median age for end-stage renal disease (ESRD) in PH1 is 24 years [<xref ref-type="bibr" rid="ph1.REF.bergstralh.2010.2493">Bergstralh et al 2010</xref>], ESRD can appear as early as age six months and is present in 50% of children at the time of diagnosis [<xref ref-type="bibr" rid="ph1.REF.cochat.1999.746">Cochat et al 1999</xref>]. In approximately 10%, the presentation/diagnosis of PH1 is made only following a renal transplant [<xref ref-type="bibr" rid="ph1.REF.cochat.2013.649">Cochat &#x00026; Rumsby 2013</xref>]; in 20%-50%, PH1 will be diagnosed at the time of their presentation in the late stages of chronic kidney disease (CKD) or even ESRD [<xref ref-type="bibr" rid="ph1.REF.harambat.2012.458">Harambat et al 2012</xref>, <xref ref-type="bibr" rid="ph1.REF.van_der_hoeven.2012.3855">van der Hoeven et al 2012</xref>].</p>
          <p>No validated tools are available to predict the renal course in PH1; however, <xref ref-type="bibr" rid="ph1.REF.diallo.2004.1767">Diallo et al [2004]</xref> described two patterns on renal ultrasound examination in individuals known to have PH1 and determined that all five individuals with cortical nephrocalcinosis developed ESRD, in contrast to 2/8 with medullary nephrocalcinosis.</p>
          <p>Also in evaluating the response of 12 individuals with PH1 to vitamin B<sub>6</sub>, <xref ref-type="bibr" rid="ph1.REF.hoyerkuhn.2014.468">Hoyer-Kuhn et al [2014]</xref> suggested that disease severity and long-term outcomes could depend on the presence of the <xref ref-type="table" rid="ph1.T.agxt_allelic_variants_discussed_in">c.508G&#x0003e;A</xref> (p.Gly170Arg) pathogenic variant, with worse outcomes expected in patients who did not have this pathogenic variant. See <xref ref-type="sec" rid="ph1.Reduction_of_Oxalate_Biosynthesis"><bold>Reduction of Oxalate Biosynthesis</bold></xref>.</p>
          <p>From the authors&#x02019; experience 19% of affected individuals present before age four to six months with severe <bold>early-onset (infantile)</bold> disease. In this group, presenting signs and symptoms include: nephrocalcinosis (91%) with or without nephrolithiasis (21%), failure to thrive (22%), urinary tract infection (21%), and uremia (14%). Early death is common; 50% have ESRD at diagnosis and 80% develop ESRD by age three years [<xref ref-type="bibr" rid="ph1.REF.cochat.1999.746">Cochat et al 1999</xref>, <xref ref-type="bibr" rid="ph1.REF.millan.2003.1458">Millan et al 2003</xref>]. The severity of infantile-onset PH1 is illustrated in case reports [<xref ref-type="bibr" rid="ph1.REF.mayordomocolunga.2011.173">Mayordomo-Colunga et al 2011</xref>].</p>
          <p>Some affected infants are pyridoxine sensitive and show improvement in renal function with high-dose vitamin B<sub>6</sub> therapy [<xref ref-type="bibr" rid="ph1.REF.van_woerden.2003.273">van Woerden et al 2003</xref>]. Case reports emphasize the importance of early diagnosis and prompt initiation of appropriate therapy [<xref ref-type="bibr" rid="ph1.REF.patwardhan.2005.173">Patwardhan &#x00026; Higgins 2005</xref>, <xref ref-type="bibr" rid="ph1.REF.khoo.2006.371">Khoo et al 2006</xref>, <xref ref-type="bibr" rid="ph1.REF.chand.2009.670">Chand &#x00026; Kaskel 2009</xref>, <xref ref-type="bibr" rid="ph1.REF.fargue.2009.767">Fargue et al 2009</xref>, <xref ref-type="bibr" rid="ph1.REF.orazi.2009.387">Orazi et al 2009</xref>].</p>
          <p>Approximately 54% of individuals present in <bold>late childhood or early adolescence</bold>. Although hematuria, dysuria, and urinary tract infections occur, nephrolithiasis is the most common presentation. In contrast, the presenting finding in the younger child is more likely to be recurrent urinary tract infections or enuresis [<xref ref-type="bibr" rid="ph1.REF.watts.1998.4">Watts 1998</xref>, <xref ref-type="bibr" rid="ph1.REF.milliner.2005.154">Milliner 2005</xref>].</p>
          <p>The remainder of affected individuals present in <bold>adulthood</bold> with recurrent renal stones [<xref ref-type="bibr" rid="ph1.REF.amoroso.2001.2072">Amoroso et al 2001</xref>]. For many of these adults, the diagnosis was either previously missed or delayed. Some individuals, mainly adults, may present with acute renal failure secondary to bilateral renal obstruction caused by oxalate stones. A higher prevalence of ESRD without a prior history of renal stones was observed in a national study from the Netherlands [<xref ref-type="bibr" rid="ph1.REF.van_woerden.2003.273">van Woerden et al 2003</xref>].</p>
          <p>The natural history of untreated PH1 is one of inexorable decline in renal function as a result of progressive nephrolithiasis/nephrocalcinosis, with eventual progression to oxalosis and certain death from ESRD and/or complications of oxalosis in the absence of treatment [<xref ref-type="bibr" rid="ph1.REF.watts.1998.4">Watts 1998</xref>, <xref ref-type="bibr" rid="ph1.REF.cochat.2003">Cochat &#x00026; Rolland 2003</xref>, <xref ref-type="bibr" rid="ph1.REF.bobrowski.2008.152">Bobrowski &#x00026; Langman 2008</xref>, <xref ref-type="bibr" rid="ph1.REF.hoppe.2009.1264">Hoppe et al 2009</xref>].</p>
          <p>In children with PH1, survival was only 76% following initiation of renal replacement therapy, the need for which occurred at a median age of only 1.5 years and carried an overall three times higher risk of death than ESRD due to any other cause [<xref ref-type="bibr" rid="ph1.REF.harambat.2012.458">Harambat et al 2012</xref>].</p>
          <p><bold>Oxalosis.</bold> When the glomerular filtration rate (GFR) is less than 25 mL/min/1.73 m<sup>2</sup>, the daily production of oxalate far outstrips renal oxalate clearance, resulting in a rapid decline in residual renal function with a concurrent increase in body oxalate stores (oxalosis) [<xref ref-type="bibr" rid="ph1.REF.watts.1998.4">Watts 1998</xref>, <xref ref-type="bibr" rid="ph1.REF.milliner.2005.154">Milliner 2005</xref>, <xref ref-type="bibr" rid="ph1.REF.cochat.2006.1075">Cochat et al 2006</xref>]. Oxalosis is the deposition of oxalate in a variety of tissues, including the kidneys, retina, myocardium, bone marrow, blood vessels, retina, heart, peripheral nerves, bone and bone marrow, subcutaneous tissue, and synovia [<xref ref-type="bibr" rid="ph1.REF.watts.1998.4">Watts 1998</xref>]. <xref ref-type="table" rid="ph1.T.organ_involvement_in_individuals_w">Table 4</xref> outlines both the organ involved and associated symptoms as well as suggested diagnostic imaging or testing.</p>
          <p>Bone is the largest repository for excess oxalate. Deposition of oxalate in bone, commonly identified as dense suprametaphyseal bands on x-ray, may lead to pain, erythropoietin-resistant anemia, and spontaneous fracture [<xref ref-type="bibr" rid="ph1.REF.cochat.2006.1075">Cochat et al 2006</xref>]. Bone mineral density measurements, as opposed to the gold standard of bone biopsy, allow for noninvasive assessment of oxalate burden [<xref ref-type="bibr" rid="ph1.REF.behnke.2001.2236">Behnke et al 2001</xref>].</p>
          <p><bold>Atherosclerotic oxalosis.</bold> A distinct form of cardiovascular involvement in oxalosis is the deposition of calcium oxalate crystals in atherosclerotic plaques of the coronary artery and other sites in the absence of renal insufficiency [<xref ref-type="bibr" rid="ph1.REF.fishbein.2008.117">Fishbein et al 2008</xref>].</p>
          <p><bold>Oral conditions associated with oxalosis.</bold> A number of oral or dental conditions have been described in PH1/oxalosis including dental pain due to oxalate deposition, root resorption, and rapidly appearing dental mobility [<xref ref-type="bibr" rid="ph1.REF.mitsimponas.2012.e301">Mitsimponas et al 2012</xref>].</p>
          <p><bold>Neurologic oxalosis.</bold> Although it is extremely uncommon for PH1 to present with stroke/infarct, two case reports describe stroke/infarct with evidence for calcium oxalate in the cerebral vessels or one possibly with microemboli consisting of circulating oxalate in supersaturated form [<xref ref-type="bibr" rid="ph1.REF.rao.2014.411">Rao et al 2014</xref>].</p>
          <table-wrap id="ph1.T.organ_involvement_in_individuals_w" position="anchor" orientation="portrait">
            <label>Table 4. </label>
            <caption>
              <p>Organ Involvement in Individuals with PH and Renal Failure</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_ph1.T.organ_involvement_in_individuals_w_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Involvment</th>
                  <th id="hd_h_ph1.T.organ_involvement_in_individuals_w_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Organ</th>
                  <th id="hd_h_ph1.T.organ_involvement_in_individuals_w_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Symptoms</th>
                  <th id="hd_h_ph1.T.organ_involvement_in_individuals_w_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Diagnosis</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_ph1.T.organ_involvement_in_individuals_w_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Always</td>
                  <td headers="hd_h_ph1.T.organ_involvement_in_individuals_w_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Kidney</td>
                  <td headers="hd_h_ph1.T.organ_involvement_in_individuals_w_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <list list-type="bullet">
                      <list-item>
                        <p>Stones</p>
                      </list-item>
                      <list-item>
                        <p>Medullary or diffuse nephrocalcinosis</p>
                      </list-item>
                      <list-item>
                        <p>Cortical nephrocalcinosis</p>
                      </list-item>
                    </list>
                  </td>
                  <td headers="hd_h_ph1.T.organ_involvement_in_individuals_w_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">US, CT (cortical nephrocalcinosis may be missed on US)</td>
                </tr>
                <tr>
                  <td headers="hd_h_ph1.T.organ_involvement_in_individuals_w_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">Frequent</td>
                  <td headers="hd_h_ph1.T.organ_involvement_in_individuals_w_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Bone</td>
                  <td headers="hd_h_ph1.T.organ_involvement_in_individuals_w_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <list list-type="bullet">
                      <list-item>
                        <p>Fractures</p>
                      </list-item>
                      <list-item>
                        <p>Bone pain</p>
                      </list-item>
                      <list-item>
                        <p>Growth retardation</p>
                      </list-item>
                    </list>
                  </td>
                  <td headers="hd_h_ph1.T.organ_involvement_in_individuals_w_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">X-ray</td>
                </tr>
                <tr>
                  <td headers="hd_h_ph1.T.organ_involvement_in_individuals_w_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Eye</td>
                  <td headers="hd_h_ph1.T.organ_involvement_in_individuals_w_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <list list-type="bullet">
                      <list-item>
                        <p>Disturbed vision</p>
                      </list-item>
                      <list-item>
                        <p>Specific brown colored retinal deposits</p>
                      </list-item>
                    </list>
                  </td>
                  <td headers="hd_h_ph1.T.organ_involvement_in_individuals_w_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Fundoscopy</td>
                </tr>
                <tr>
                  <td headers="hd_h_ph1.T.organ_involvement_in_individuals_w_1_1_1_1" rowspan="3" valign="middle" align="left" scope="row" colspan="1">Often</td>
                  <td headers="hd_h_ph1.T.organ_involvement_in_individuals_w_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Arteries</td>
                  <td headers="hd_h_ph1.T.organ_involvement_in_individuals_w_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <list list-type="bullet">
                      <list-item>
                        <p>Media calcifications</p>
                      </list-item>
                    </list>
                  </td>
                  <td headers="hd_h_ph1.T.organ_involvement_in_individuals_w_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">US, CT</td>
                </tr>
                <tr>
                  <td headers="hd_h_ph1.T.organ_involvement_in_individuals_w_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Myocardium</td>
                  <td headers="hd_h_ph1.T.organ_involvement_in_individuals_w_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <list list-type="bullet">
                      <list-item>
                        <p>Cardiac failure</p>
                      </list-item>
                      <list-item>
                        <p>Arrhythmia</p>
                      </list-item>
                      <list-item>
                        <p>Heart block</p>
                      </list-item>
                      <list-item>
                        <p>Left ventricular hypertrophy</p>
                      </list-item>
                      <list-item>
                        <p>Systolic and diastolic dysfunction</p>
                      </list-item>
                    </list>
                  </td>
                  <td headers="hd_h_ph1.T.organ_involvement_in_individuals_w_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">ECG, echocardiography, CT (calcifications)</td>
                </tr>
                <tr>
                  <td headers="hd_h_ph1.T.organ_involvement_in_individuals_w_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Thyroid</td>
                  <td headers="hd_h_ph1.T.organ_involvement_in_individuals_w_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <list list-type="bullet">
                      <list-item>
                        <p>Hypothyroidism</p>
                      </list-item>
                    </list>
                  </td>
                  <td headers="hd_h_ph1.T.organ_involvement_in_individuals_w_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">US, thyroid function tests</td>
                </tr>
                <tr>
                  <td headers="hd_h_ph1.T.organ_involvement_in_individuals_w_1_1_1_1" rowspan="5" valign="middle" align="left" scope="row" colspan="1">Less often</td>
                  <td headers="hd_h_ph1.T.organ_involvement_in_individuals_w_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Skin</td>
                  <td headers="hd_h_ph1.T.organ_involvement_in_individuals_w_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <list list-type="bullet">
                      <list-item>
                        <p>(Painful) skin nodules</p>
                      </list-item>
                      <list-item>
                        <p>Skin necrosis</p>
                      </list-item>
                      <list-item>
                        <p>Gangrene</p>
                      </list-item>
                      <list-item>
                        <p>Calciphylaxis-like skin lesions</p>
                      </list-item>
                      <list-item>
                        <p>Pruritus</p>
                      </list-item>
                    </list>
                  </td>
                  <td headers="hd_h_ph1.T.organ_involvement_in_individuals_w_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Skin biopsy</td>
                </tr>
                <tr>
                  <td headers="hd_h_ph1.T.organ_involvement_in_individuals_w_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Nerves</td>
                  <td headers="hd_h_ph1.T.organ_involvement_in_individuals_w_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <list list-type="bullet">
                      <list-item>
                        <p>Ischemic neuropathy</p>
                      </list-item>
                    </list>
                  </td>
                  <td headers="hd_h_ph1.T.organ_involvement_in_individuals_w_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Clinical assessment</td>
                </tr>
                <tr>
                  <td headers="hd_h_ph1.T.organ_involvement_in_individuals_w_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Muscle</td>
                  <td headers="hd_h_ph1.T.organ_involvement_in_individuals_w_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <list list-type="bullet">
                      <list-item>
                        <p>Myopathy by CaOx deposition</p>
                      </list-item>
                    </list>
                  </td>
                  <td headers="hd_h_ph1.T.organ_involvement_in_individuals_w_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Biopsy, CT</td>
                </tr>
                <tr>
                  <td headers="hd_h_ph1.T.organ_involvement_in_individuals_w_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Bowel</td>
                  <td headers="hd_h_ph1.T.organ_involvement_in_individuals_w_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <list list-type="bullet">
                      <list-item>
                        <p>Prolonged oxalosis (depositions of CaOx in the intestinal wall)</p>
                      </list-item>
                    </list>
                  </td>
                  <td headers="hd_h_ph1.T.organ_involvement_in_individuals_w_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">CT</td>
                </tr>
                <tr>
                  <td headers="hd_h_ph1.T.organ_involvement_in_individuals_w_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Joints</td>
                  <td headers="hd_h_ph1.T.organ_involvement_in_individuals_w_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <list list-type="bullet">
                      <list-item>
                        <p>Arthritis (late sign)</p>
                      </list-item>
                    </list>
                  </td>
                  <td headers="hd_h_ph1.T.organ_involvement_in_individuals_w_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">X-ray, CT</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>From <xref ref-type="bibr" rid="ph1.REF.cochat.2012.1729">Cochat et al [2012]</xref></p>
              </fn>
              <fn>
                <p>US = ultrasound</p>
              </fn>
              <fn>
                <p>CT= computed tomography</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Pregnancy.</bold> Pregnancy does not appear to be an important risk factor for the development of ESRD in the majority of women with PH1 [<xref ref-type="bibr" rid="ph1.REF.norby.2004.277">Norby &#x00026; Milliner 2004</xref>]; however, women in whom renal function deteriorated during the pregnancy and remained abnormal post-delivery have been reported [<xref ref-type="bibr" rid="ph1.REF.cimino.2005.341">Cimino et al 2005</xref>]. Following pregnancy women are at increased risk for stone formation.</p>
          <p>Women with PH1 have had successful pregnancies post-liver/kidney transplantation. In one woman liver function was apparently preserved, but renal graft function declined transiently after the birth of her first child and permanently after the birth of her second child [<xref ref-type="bibr" rid="ph1.REF.pruvot.1997.615">Pruvot et al 1997</xref>].</p>
          <p>Generally, the offspring of women with PH1 have done well [<xref ref-type="bibr" rid="ph1.REF.norby.2004.277">Norby &#x00026; Milliner 2004</xref>].</p>
        </sec>
        <sec id="ph1.Pathophysiology">
          <title>Pathophysiology</title>
          <p>The stone type that is most prevalent in individuals with PH1 is calcium oxalate monohydrate or whewellite [<xref ref-type="bibr" rid="ph1.REF.daudon.2008.100">Daudon et al 2008</xref>]. These authors noted that stones from patients with PH differ in morphologic characteristics from idiopathic calcium oxalate stone formers: they appear white or pale-yellow on the surface and form a loose, unorganized section whereas idiopathic oxalate stone formers appear as a dark-brown surface with a well-organized radiating inner structure. These differences in morphology suggest a different mechanism of stone formation from idiopathic oxalate stones.</p>
        </sec>
        <sec id="ph1.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>Although other genetic and environmental factors play a role in determining the course of PH1 [<xref ref-type="bibr" rid="ph1.REF.hoppe.2010.383">Hoppe 2010</xref>], pathogenic variants that result in mistargeting of AGT enzyme activity (see <xref ref-type="sec" rid="ph1.Molecular_Genetics">Molecular Genetics</xref>, <bold>Abnormal gene product</bold>) are the most likely to be associated with B<sub>6</sub> (pyridoxine) responsiveness [<xref ref-type="bibr" rid="ph1.REF.danpure.2001">Danpure 2001</xref>, <xref ref-type="bibr" rid="ph1.REF.monico.2005a.183">Monico et al 2005a</xref>] which is mediated by the effect of B<sub>6</sub> on catalytic activity, perixosomal import, and protein stability [<xref ref-type="bibr" rid="ph1.REF.fargue.2013a.1776">Fargue et al 2013a</xref>, <xref ref-type="bibr" rid="ph1.REF.fargue.2013b.2475">Fargue et al 2013b</xref>].</p>
          <list list-type="bullet">
            <list-item>
              <p>Homozygotes for either c.508G&#x0003e;A (p.Gly170Arg) or c.454T&#x0003e;A (p.Phe152Ile) show B<sub>6</sub> responsiveness and benefit from early treatement (see <xref ref-type="sec" rid="ph1.Management">Management</xref>).</p>
            </list-item>
            <list-item>
              <p>Response to B<sub>6</sub> therapy is relative to the number of copies of the p.Gly170Arg pathogenic variant present [<xref ref-type="bibr" rid="ph1.REF.monico.2005a.183">Monico et al 2005a</xref>, <xref ref-type="bibr" rid="ph1.REF.monico.2005b.1704">Monico et al 2005b</xref>].</p>
            </list-item>
            <list-item>
              <p>Results of in vitro studies suggest that additional pathogenic variants may respond to B<sub>6</sub>, reinforcing the recommendation of testing all patients for B<sub>6</sub> responsiveness [<xref ref-type="bibr" rid="ph1.REF.fargue.2013a.1776">Fargue et al 2013a</xref>].</p>
            </list-item>
          </list>
          <p>The presence of the p.Gly170Arg pathogenic variant could even predict disease severity and/or rate of progression [<xref ref-type="bibr" rid="ph1.REF.hoyerkuhn.2014.468">Hoyer-Kuhn et al 2014</xref>]. A large retrospective study of individuals with PH1 suggested that the p.Gly170Arg pathogenic variant is associated with longer preservation of renal function with conservative treatment compared to other pathogenic variants [<xref ref-type="bibr" rid="ph1.REF.harambat.2010.443">Harambat et al 2010</xref>].</p>
          <p>Although it may be possible to establish a relationship between the <italic toggle="yes">AGXT</italic> genotype and AGT enzyme activity in vitro, in most cases it is difficult to correlate enzyme activity with clinical severity [<xref ref-type="bibr" rid="ph1.REF.danpure.2001">Danpure 2001</xref>, <xref ref-type="bibr" rid="ph1.REF.pirulli.2003.297">Pirulli et al 2003</xref>, <xref ref-type="bibr" rid="ph1.REF.danpure.2004.1">Danpure &#x00026; Rumsby 2004</xref>, <xref ref-type="bibr" rid="ph1.REF.van_woerden.2004.746">van Woerden et al 2004</xref>].</p>
          <p>Although the clinical course of PH1 in affected sibs is usually similar, families in which affected relatives with identical pathogenic variants had different disease manifestations have been described [<xref ref-type="bibr" rid="ph1.REF.frishberg.2005.269">Frishberg et al 2005</xref>, <xref ref-type="bibr" rid="ph1.REF.beck.2006.984">Beck &#x00026; Hoppe 2006</xref>, <xref ref-type="bibr" rid="ph1.REF.lorenzo.2006.1115">Lorenzo et al 2006</xref>, <xref ref-type="bibr" rid="ph1.REF.mandrile.2008.309">Mandrile et al 2008</xref>, <xref ref-type="bibr" rid="ph1.REF.alfadhel.2012.373">Alfadhel et al 2012</xref>]. Possible causes of this intrafamilial variation include differences in activity level of other enzymes important in oxalate synthesis, modifier genes, the quantity of oxalate precursors in the diet, renal oxalate handling, absorption of dietary oxalate, hydration status, infections, and urinary crystallization factors [<xref ref-type="bibr" rid="ph1.REF.danpure.2001">Danpure 2001</xref>].</p>
          <p>Other than potential delay in diagnosis due to the rarity of PH1, the reason for a poorer outcome in infants with the same pathogenic variants as older individuals is not clear. Possibilities include:</p>
          <list list-type="bullet">
            <list-item>
              <p>The low glomerular filtration rate (GFR) (both absolute and corrected) in children under age six to 12 months, which predisposes to earlier oxalate deposition [<xref ref-type="bibr" rid="ph1.REF.quigley.2012.184">Quigley 2012</xref>]</p>
            </list-item>
            <list-item>
              <p>High oxalate excretion in infants (<xref ref-type="table" rid="ph1.T.normal_values_for_urinary_oxalate">Table 1</xref>)</p>
            </list-item>
            <list-item>
              <p>Reduced number of nephrons present at birth, which may be associated with low birth weight as well as environmental and genetic factors [<xref ref-type="bibr" rid="ph1.REF.luyckx.2005.s68">Luyckx &#x00026; Brenner 2005</xref>, <xref ref-type="bibr" rid="ph1.REF.puddu.2009.162">Puddu et al 2009</xref>, <xref ref-type="bibr" rid="ph1.REF.luyckx.2010.898">Luyckx &#x00026; Brenner 2010</xref>]</p>
            </list-item>
          </list>
        </sec>
        <sec id="ph1.Nomenclature">
          <title>Nomenclature</title>
          <p>With the identification of oxalate in human urine in the 1800s, hyperoxaluria fell into a category referred to as "oxalate diathesis" &#x02013; a catch-all term for a wide variety of ailments.</p>
          <p>PH1 can be considered a peroxisomal disorder, as it results from deficiency of a single peroxisomal enzyme. PH1, however, is distinct from disorders of peroxisomal biogenesis (see <related-object link-type="booklink" source-id="gene" document-id="pbd" document-type="chapter">Peroxisomal Biogenesis Disorders, Zellweger Type</related-object> and <related-object link-type="booklink" source-id="gene" document-id="rcdp" document-type="chapter">Rhizomelic Chondrodysplasia Punctata Type 1</related-object>) in that a normal number of relatively normal-looking peroxisomes are observed on liver biopsy.</p>
        </sec>
        <sec id="ph1.Prevalence">
          <title>Prevalence</title>
          <p>PH1 is estimated to account for 1%-2% of children with end-stage renal disease (ESRD) [<xref ref-type="bibr" rid="ph1.REF.harambat.2012.458">Harambat et al 2012</xref>].</p>
          <p>When considering the following statistics, it is important to remember that PH1 remains underdiagnosed because of the wide variability in its clinical presentation and age of onset.</p>
          <p>The prevalence of PH1 ranges from 1:1,000,000 to 3:1,000,000 depending on the population studied and the methods of ascertainment [<xref ref-type="bibr" rid="ph1.REF.danpure.2001">Danpure 2001</xref>, <xref ref-type="bibr" rid="ph1.REF.van_woerden.2003.273">van Woerden et al 2003</xref>, <xref ref-type="bibr" rid="ph1.REF.hoppe.2005.276">Hoppe et al 2005</xref>]; incidence ranges from 4:1,000,000 to 10:1,000,000 depending on the population [<xref ref-type="bibr" rid="ph1.REF.applegarth.2000.e10">Applegarth et al 2000</xref>, <xref ref-type="bibr" rid="ph1.REF.danpure.2001">Danpure 2001</xref>]. PH1 is estimated to occur in 1:120,000 live births in Europe [<xref ref-type="bibr" rid="ph1.REF.cochat.2006.1075">Cochat et al 2006</xref>].</p>
          <p>An increased frequency of PH1 (&#x02264;10%) has been reported in Tunisia and Kuwait [<xref ref-type="bibr" rid="ph1.REF.kamoun.1996.479">Kamoun &#x00026; Lakhoua 1996</xref>, <xref ref-type="bibr" rid="ph1.REF.aleisa.2004.1788">Al-Eisa et al 2004</xref>, <xref ref-type="bibr" rid="ph1.REF.cochat.2006.1075">Cochat et al 2006</xref>], in Arabs and Druze families of Israel [<xref ref-type="bibr" rid="ph1.REF.rinat.1999.2352">Rinat et al 1999</xref>], and in Iran [<xref ref-type="bibr" rid="ph1.REF.madani.2001.140">Madani et al 2001</xref>] as a result of the high rate of consanguinity in these populations. No single pathogenic variant is present in these populations [<xref ref-type="bibr" rid="ph1.REF.coultermackie.2005.264">Coulter-Mackie 2005</xref>] [<xref ref-type="bibr" rid="ph1.REF.rinat.1999.2352">Rinat et al 1999</xref>, <xref ref-type="bibr" rid="ph1.REF.frishberg.2005.269">Frishberg et al 2005</xref>]. Of note, in Tunisia an association was identified between specific pathogenic variants and geographic location within the country [<xref ref-type="bibr" rid="ph1.REF.nagara.2013.316">Nagara et al 2013</xref>].</p>
        </sec>
      </sec>
      <sec id="ph1.Genetically_Related_Allelic_Disorder">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>No other phenotypes are known to be associated with pathogenic variants in <italic toggle="yes">AGXT</italic>.</p>
      </sec>
      <sec id="ph1.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p><related-object link-type="booklink" source-id="gene" document-id="ph2" document-type="chapter"><bold>Primary hyperoxaluria type 2</bold></related-object>
<bold>(PH2)</bold> is caused by mutation of <italic toggle="yes">GRHPR,</italic> resulting in deficiency of the cytosolic enzyme glyoxylate reductase &#x02013; hydroxypyruvate reductase (GRHPR), which catalyzes the reduction of glyoxylate and hydroxypyruvate to D-glycerate. While found in many tissues, GRHPR is mainly found in hepatocytes with some expression in mitochondria [<xref ref-type="bibr" rid="ph1.REF.cregeen.2003.497">Cregeen et al 2003</xref>, <xref ref-type="bibr" rid="ph1.REF.belostotsky.2010.392">Belostotsky et al 2010</xref>]. In PH2, glyoxylate removal is impaired, resulting in the metabolism of glyoxylate by lactate dehydrogenase to oxalate and L-glycerate. The diagnosis of PH2 can be established by sequence analysis of <italic toggle="yes">GHPRH</italic> or assay of GRHPR enzymatic activity in liver. Inheritance is autosomal recessive.</p>
        <p>PH2 is rarer than PH1.</p>
        <p>From a small cohort of individuals with PH1 and PH2 from one center, PH1 as a group appears to differ from PH2 in the following respects:</p>
        <list list-type="bullet">
          <list-item>
            <p>PH2 is considered a less aggressive disease than PH1, even when onset is early.</p>
          </list-item>
          <list-item>
            <p>PH1 has statistically higher urine oxalate excretions and more stone-forming activity and thus requires more frequent stone removal.</p>
          </list-item>
          <list-item>
            <p>Individuals with PH1 have statistically lower urine osmolalities and lower urine concentration of calcium, citrate, and magnesium [<xref ref-type="bibr" rid="ph1.REF.milliner.2001.31">Milliner et al 2001</xref>]. (For a single individual with hyperoxaluria, the differences observed <bold>cannot</bold> reliably distinguish PH1 from PH2.)</p>
          </list-item>
          <list-item>
            <p>In PH1, urinary glycolate and oxalate are elevated.</p>
          </list-item>
          <list-item>
            <p>In PH2, urinary L-glycerate and oxalate are elevated [<xref ref-type="bibr" rid="ph1.REF.danpure.2001">Danpure 2001</xref>]; however, exceptions exist.</p>
          </list-item>
        </list>
        <p><related-object link-type="booklink" source-id="gene" document-id="ph3" document-type="chapter"><bold>Primary hyperoxaluria type 3</bold></related-object>
<bold>(PH3)</bold> is caused by a defect in the hepatocyte-specific mitochondrial enzyme 4-hydroxy-2-oxoglutarate aldolase (HOGA) [<xref ref-type="bibr" rid="ph1.REF.belostotsky.2010.392">Belostotsky et al 2010</xref>], which appears to lead to excess metabolism of hydroxyproline with the forward reaction product (HOG) itself being converted to pyruvate or glyoxalate [<xref ref-type="bibr" rid="ph1.REF.riedel.2011.e26021">Riedel et al 2011</xref>, <xref ref-type="bibr" rid="ph1.REF.pitt.2015.1">Pitt et al 2015</xref>] or perhaps actually inhibiting mitochondrial GRHPR (effectively causing &#x02018;secondary&#x02019; PH2) [<xref ref-type="bibr" rid="ph1.REF.belostotsky.2012.1497">Belostotsky et al 2012</xref>, <xref ref-type="bibr" rid="ph1.REF.riedel.2012.1544">Riedel et al 2012</xref>]. Elevated levels of oxalate and glycolate have been seen in about 5% of affected individuals [<xref ref-type="bibr" rid="ph1.REF.monico.2002.392">Monico et al 2002</xref>, <xref ref-type="bibr" rid="ph1.REF.hoppe.2009.1264">Hoppe et al 2009</xref>]. Mutation of <italic toggle="yes">HOGA1</italic> encoding 2-keto-4-hydroxy-glutarate aldolase is causative [<xref ref-type="bibr" rid="ph1.REF.belostotsky.2010.392">Belostotsky et al 2010</xref>, <xref ref-type="bibr" rid="ph1.REF.monico.2011.2289">Monico et al 2011</xref>, <xref ref-type="bibr" rid="ph1.REF.belostotsky.2012.1497">Belostotsky et al 2012</xref>, <xref ref-type="bibr" rid="ph1.REF.williams.2012.3191">Williams et al 2012</xref>]. Diagnosis is by exclusion of PH1 and PH2 with confirmation by DNA sequence analysis of <italic toggle="yes">HOGA1</italic>. Inheritance is autosomal recessive.</p>
        <p>See <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/phenotypicSeries/PS259900">Hyperoxaluria, primary: OMIM Phenotypic Series</ext-link> to view genes associated with this phenotype in OMIM.</p>
        <p><bold>Enteric hyperoxaluria.</bold> Diseases affecting the small bowel, including <related-object link-type="booklink" source-id="gene" document-id="celiac" document-type="chapter">celiac disease</related-object> [<xref ref-type="bibr" rid="ph1.REF.ciacci.2008.974">Ciacci et al 2008</xref>], Crohn's disease, <related-object link-type="booklink" source-id="gene" document-id="pancreatitis-ov" document-type="chapter">pancreatitis</related-object>, and short bowel syndrome can be associated with hyperoxaluria. The precipitation of enteric calcium by non-absorbed free fatty acids leads to loss of the normal inhibition in oxalate reabsorption from the gut, increasing plasma oxalate concentration by increasing paracellular and transcellular transport. Delivery of excess fatty acids and bile salts to the colon also injures the mucosa and increases oxalate absorption [<xref ref-type="bibr" rid="ph1.REF.milliner.2005.154">Milliner 2005</xref>, <xref ref-type="bibr" rid="ph1.REF.hoppe.2009.1264">Hoppe et al 2009</xref>]. Individuals with PH1 show low to normal levels of oxalate absorption [<xref ref-type="bibr" rid="ph1.REF.sikora.2008.1181">Sikora et al 2008</xref>]. Gastric bypass procedures used in the treatment of obesity have been associated with increased oxalate absorption, high levels of hyperoxaluria, and increased risk of kidney stone formation [<xref ref-type="bibr" rid="ph1.REF.asplin.2007.565">Asplin &#x00026; Coe 2007</xref>, <xref ref-type="bibr" rid="ph1.REF.kleinman.2007.8">Kleinman 2007</xref>, <xref ref-type="bibr" rid="ph1.REF.duffey.2008.1145">Duffey et al 2008</xref>, <xref ref-type="bibr" rid="ph1.REF.lieske.2008.163">Lieske et al 2008</xref>]. Urinary risk factors for stones such as hyperoxaluria occur more commonly in individuals with Roux-en-Y gastric bypass than gastric banding [<xref ref-type="bibr" rid="ph1.REF.semins.2010.826">Semins et al 2010</xref>, <xref ref-type="bibr" rid="ph1.REF.kumar.2011.654">Kumar et al 2011</xref>, <xref ref-type="bibr" rid="ph1.REF.tasca.2011.129">Tasca 2011</xref>].</p>
        <p><bold>Dietary hyperoxaluria.</bold> Excess intake of foods high in oxalate including chocolate, cocoa, leafy greens (especially rhubarb and spinach), black tea, nuts, peanut butter, or starfruit [<xref ref-type="bibr" rid="ph1.REF.holmes.2000.1662">Holmes &#x00026; Kennedy 2000</xref>, <xref ref-type="bibr" rid="ph1.REF.monk.2000">Monk &#x00026; Bushinsky 2000</xref>] may lead to elevated plasma concentration of oxalate and hence increased urinary concentration of oxalate.</p>
        <p>It was previously thought that dietary oxalate accounted for little of the urinary oxalate levels (&#x0003c;10%), but <xref ref-type="bibr" rid="ph1.REF.holmes.2001.270">Holmes et al [2001]</xref> showed that between 24% and 53% of urinary oxalate is attributable to oxalate from the diet [<xref ref-type="bibr" rid="ph1.REF.holmes.2004.311">Holmes &#x00026; Assimos 2004</xref>]. Therapy consists of dietary oxalate restriction and use of calcium carbonate or calcium citrate at meal times to bind dietary oxalate [<xref ref-type="bibr" rid="ph1.REF.penniston.2009.484">Penniston &#x00026; Nakada 2009</xref>].</p>
        <p><bold>Idiopathic calcium oxalate urolithiasis</bold> is associated with "mild metabolic hyperoxaluria." Features that often differentiate this from PH1:</p>
        <list list-type="bullet">
          <list-item>
            <p>Lower urinary oxalate excretion (see <xref ref-type="table" rid="ph1.T.urinary_oxalate_excretion_rates_in">Table 5</xref>)</p>
          </list-item>
          <list-item>
            <p>Less severe stone disease</p>
          </list-item>
          <list-item>
            <p>Less common development of ESRD</p>
          </list-item>
          <list-item>
            <p>Tendency to hypercalciuria as opposed to hypocalciuria in PH1 (or PH2)</p>
          </list-item>
          <list-item>
            <p>Day-to-day variability in the levels of urinary oxalate excretion in contrast to PH1, in which levels are persistently elevated in the urine [<xref ref-type="bibr" rid="ph1.REF.milliner.2005.154">Milliner 2005</xref>]</p>
          </list-item>
        </list>
        <table-wrap id="ph1.T.urinary_oxalate_excretion_rates_in" position="anchor" orientation="portrait">
          <label>Table 5. </label>
          <caption>
            <p>Urinary Oxalate Excretion Rates in Disorders Considered in the Differential Diagnosis of PH1</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_ph1.T.urinary_oxalate_excretion_rates_in_1_1_1_1" valign="middle" colspan="6" align="left" scope="colgroup" rowspan="1">Customary Urinary Oxalate Excretion Rates&#x000a0;<sup>1</sup></th>
              </tr>
              <tr>
                <th headers="hd_h_ph1.T.urinary_oxalate_excretion_rates_in_1_1_1_1 hd_h_ph1.T.urinary_oxalate_excretion_rates_in_1_1_2_1" id="hd_h_ph1.T.urinary_oxalate_excretion_rates_in_1_1_2_1" rowspan="2" valign="middle" align="left" scope="col" colspan="1">Normal</th>
                <th headers="hd_h_ph1.T.urinary_oxalate_excretion_rates_in_1_1_1_1" id="hd_h_ph1.T.urinary_oxalate_excretion_rates_in_1_1_2_2" valign="middle" colspan="5" align="left" scope="colgroup" rowspan="1">In Individuals with:</th>
              </tr>
              <tr>
                <th headers="hd_h_ph1.T.urinary_oxalate_excretion_rates_in_1_1_1_1 hd_h_ph1.T.urinary_oxalate_excretion_rates_in_1_1_2_2" id="hd_h_ph1.T.urinary_oxalate_excretion_rates_in_1_1_3_1" valign="middle" colspan="1" align="left" scope="colgroup" rowspan="1">PH1</th>
                <th headers="hd_h_ph1.T.urinary_oxalate_excretion_rates_in_1_1_1_1 hd_h_ph1.T.urinary_oxalate_excretion_rates_in_1_1_2_2" id="hd_h_ph1.T.urinary_oxalate_excretion_rates_in_1_1_3_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">PH2&#x000a0;<sup>2</sup></th>
                <th headers="hd_h_ph1.T.urinary_oxalate_excretion_rates_in_1_1_1_1 hd_h_ph1.T.urinary_oxalate_excretion_rates_in_1_1_2_2" id="hd_h_ph1.T.urinary_oxalate_excretion_rates_in_1_1_3_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Enteric hyperoxaluria</th>
                <th headers="hd_h_ph1.T.urinary_oxalate_excretion_rates_in_1_1_1_1 hd_h_ph1.T.urinary_oxalate_excretion_rates_in_1_1_2_2" id="hd_h_ph1.T.urinary_oxalate_excretion_rates_in_1_1_3_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Dietary hyperoxaluria</th>
                <th headers="hd_h_ph1.T.urinary_oxalate_excretion_rates_in_1_1_1_1 hd_h_ph1.T.urinary_oxalate_excretion_rates_in_1_1_2_2" id="hd_h_ph1.T.urinary_oxalate_excretion_rates_in_1_1_3_5" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Idiopathic calcium oxalate urolithiasis</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_ph1.T.urinary_oxalate_excretion_rates_in_1_1_1_1 hd_h_ph1.T.urinary_oxalate_excretion_rates_in_1_1_2_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x0003c;0.45</td>
                <td headers="hd_h_ph1.T.urinary_oxalate_excretion_rates_in_1_1_1_1 hd_h_ph1.T.urinary_oxalate_excretion_rates_in_1_1_2_2 hd_h_ph1.T.urinary_oxalate_excretion_rates_in_1_1_3_1" valign="middle" align="left" rowspan="1" colspan="1">&#x0003e;1<break/>(usually &#x0003e;2)</td>
                <td headers="hd_h_ph1.T.urinary_oxalate_excretion_rates_in_1_1_1_1 hd_h_ph1.T.urinary_oxalate_excretion_rates_in_1_1_2_2 hd_h_ph1.T.urinary_oxalate_excretion_rates_in_1_1_3_2" valign="middle" align="left" rowspan="1" colspan="1">&#x0003e;0.46</td>
                <td headers="hd_h_ph1.T.urinary_oxalate_excretion_rates_in_1_1_1_1 hd_h_ph1.T.urinary_oxalate_excretion_rates_in_1_1_2_2 hd_h_ph1.T.urinary_oxalate_excretion_rates_in_1_1_3_3" valign="middle" align="left" rowspan="1" colspan="1">&#x0003e;1<break/>(fluctuates with diet)</td>
                <td headers="hd_h_ph1.T.urinary_oxalate_excretion_rates_in_1_1_1_1 hd_h_ph1.T.urinary_oxalate_excretion_rates_in_1_1_2_2 hd_h_ph1.T.urinary_oxalate_excretion_rates_in_1_1_3_4" valign="middle" align="left" rowspan="1" colspan="1">&#x0003c;0.6</td>
                <td headers="hd_h_ph1.T.urinary_oxalate_excretion_rates_in_1_1_1_1 hd_h_ph1.T.urinary_oxalate_excretion_rates_in_1_1_2_2 hd_h_ph1.T.urinary_oxalate_excretion_rates_in_1_1_3_5" valign="middle" align="left" rowspan="1" colspan="1">&#x0003c;0.7</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>Based on data from algorithm in <xref ref-type="bibr" rid="ph1.REF.milliner.2005.154">Milliner [2005]</xref>, with permission from S Karger AG, publisher</p>
            </fn>
            <fn id="ph1.TF.5.1">
              <label>1. </label>
              <p>Calculated as mmol/1.73 m<sup>2</sup>/day</p>
            </fn>
            <fn id="ph1.TF.5.2">
              <label>2. </label>
              <p>PH2 information based on <xref ref-type="bibr" rid="ph1.REF.kemper.1997.509">Kemper et al [1997]</xref></p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p><related-object link-type="booklink" source-id="gene" document-id="dent" document-type="chapter"><bold>Dent disease</bold></related-object><bold>.</bold> The clinical features of Dent disease may overlap those of PH1. Both are associated with nephrocalcinosis and urolithiasis in childhood and progress to renal failure (see <xref ref-type="table" rid="ph1.T.clinical_and_diagnostic_features_o">Table 6</xref>) [<xref ref-type="bibr" rid="ph1.REF.milliner.2006.27">Milliner 2006</xref>].</p>
        <table-wrap id="ph1.T.clinical_and_diagnostic_features_o" position="anchor" orientation="portrait">
          <label>Table 6. </label>
          <caption>
            <p>Clinical and Diagnostic Features of Dent Disease and Primary Hyperoxaluria Type 1</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_1" valign="middle" colspan="2" align="left" scope="colgroup" rowspan="1"/>
                <th id="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Dent Disease</th>
                <th id="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">PH1</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_1" rowspan="4" valign="middle" align="left" scope="row" colspan="1">
                  <bold>Clinical Features</bold>
                </td>
                <td headers="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_1" valign="middle" align="left" rowspan="1" colspan="1">Nephrocalcinosis</td>
                <td headers="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">3+</td>
                <td headers="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">2+</td>
              </tr>
              <tr>
                <td headers="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Urolithiasis</td>
                <td headers="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">3+</td>
                <td headers="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">4+</td>
              </tr>
              <tr>
                <td headers="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Osteodystrophy</td>
                <td headers="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">1+</td>
                <td headers="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">1+&#x000a0;<sup>1</sup></td>
              </tr>
              <tr>
                <td headers="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Renal failure</td>
                <td headers="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">2+</td>
                <td headers="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">2+</td>
              </tr>
              <tr>
                <td headers="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_1" rowspan="5" valign="middle" align="left" scope="row" colspan="1">
                  <bold>Differentiating Findings</bold>
                </td>
                <td headers="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_1" valign="middle" align="left" rowspan="1" colspan="1">Hypercalciuria</td>
                <td headers="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">1+</td>
                <td headers="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">&#x02014;</td>
              </tr>
              <tr>
                <td headers="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Hyperoxaluria</td>
                <td headers="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">&#x02014;</td>
                <td headers="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">3+</td>
              </tr>
              <tr>
                <td headers="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Low-molecular-weight proteinuria</td>
                <td headers="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">1+</td>
                <td headers="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                  <list list-type="bullet">
                    <list-item>
                      <label>&#x02014;</label>
                      <p>
                        <sup>2</sup>
                      </p>
                    </list-item>
                  </list>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Gene</td>
                <td headers="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">CLCN-5</italic>
                </td>
                <td headers="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">AGXT</italic>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Inheritance</td>
                <td headers="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">X-linked</td>
                <td headers="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Autosomal recessive</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>From <xref ref-type="bibr" rid="ph1.REF.milliner.2006.27">Milliner [2006]</xref></p>
            </fn>
            <fn id="ph1.TF.6.1">
              <label>1. </label>
              <p>After renal failure established</p>
            </fn>
            <fn id="ph1.TF.6.2">
              <label>2. </label>
              <p>May be observed following renal damage but not an early or characteristic finding</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p><bold>Other hereditary causes of kidney stones</bold>. A number of common and rare forms of nephrocalcinosis or urolithiasis may be associated with kidney disease [<xref ref-type="bibr" rid="ph1.REF.monico.2011.151">Monico &#x00026; Milliner 2011</xref>, <xref ref-type="bibr" rid="ph1.REF.edvardsson.2013.1923">Edvardsson et al 2013</xref>].</p>
        <list list-type="bullet">
          <list-item>
            <p>A condition that may present with findings of nephrolcalcinosis in addition to PH1 or Dent disease is familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/248250">OMIM</ext-link>).</p>
          </list-item>
          <list-item>
            <p>While not associated with nephrocalcinosis, children with adenine phosphoribosyltransferase (APRT) deficiency (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/614723">OMIM</ext-link>) can develop crystal nephropathy and chronic kidney disease, as do children with PH and FHHNC.</p>
          </list-item>
        </list>
        <p><bold>Other.</bold> Acute renal failure secondary to oxalate deposition in the kidneys has occurred in persons taking large doses ("megadoses") of ascorbic acid (vitamin C) [<xref ref-type="bibr" rid="ph1.REF.petrarulo.1998.23">Petrarulo et al 1998</xref>, <xref ref-type="bibr" rid="ph1.REF.mashour.2000.561">Mashour et al 2000</xref>] as well as in a number of persons who were &#x0201c;juicing&#x0201d; (extraction of juice from vegetables or fruit) with high oxalate-containing foods [<xref ref-type="bibr" rid="ph1.REF.getting.2013.768">Getting et al 2013</xref>].</p>
        <p>Ingestion of ethylene glycol, an oxalate precursor, can lead to excess production and increased concentrations of oxalate in both the plasma and urine [<xref ref-type="bibr" rid="ph1.REF.milliner.2005.154">Milliner 2005</xref>].</p>
        <p>Hyperoxaluria in association with total parenteral nutrition (TPN) has been described in premature infants [<xref ref-type="bibr" rid="ph1.REF.sikora.2003.2194">Sikora et al 2003</xref>] and adults [<xref ref-type="bibr" rid="ph1.REF.buchman.1995.24">Buchman et al 1995</xref>].</p>
        <p>Hyperoxaluria has been documented in <related-object link-type="booklink" source-id="gene" document-id="pbd" document-type="chapter">peroxisomal biogenesis disorders, Zellweger spectrum</related-object> despite the apparent cytoplasmic stability of AGT [<xref ref-type="bibr" rid="ph1.REF.van_woerden.2006.346">van Woerden et al 2006</xref>]. The presence of hyperoxaluria was statistically correlated with the degree of neurologic involvement.</p>
      </sec>
      <sec id="ph1.Management">
        <title>Management</title>
        <sec id="ph1.Evaluations_Following_Initial_Diagno">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with primary hyperoxaluria type 1 (PH1), the following evaluations are recommended based on the guidelines and suggestions of <xref ref-type="bibr" rid="ph1.REF.hoppe.2003.986">Hoppe &#x00026; Langman [2003]</xref>, two recent reviews by the European Hyperoxaluria Consortium, OxalEurope [<xref ref-type="bibr" rid="ph1.REF.cochat.2012.1729">Cochat et al 2012</xref>] (see <xref ref-type="table" rid="ph1.T.organ_involvement_in_individuals_w">Table 4</xref>), and a recent review by <xref ref-type="bibr" rid="ph1.REF.hoppe.2012.467">Hoppe [2012]</xref>.</p>
          <p>The following are recommended in all cases:</p>
          <list list-type="bullet">
            <list-item>
              <p>Molecular genetic testing to determine the <italic toggle="yes">AGXT</italic> genotype if not already performed</p>
            </list-item>
            <list-item>
              <p>Clinical genetics consultation</p>
            </list-item>
          </list>
          <p>The further extent of the initial evaluation of patients with PH1 should depend on their baseline renal function at the time of diagnosis and the evaluations performed as part of the diagnostic work up.</p>
          <list list-type="bullet">
            <list-item>
              <p>For those with preserved renal function (i.e., measured or estimated GFR &#x0003e;60 mL/min/1.73 m<sup>2</sup>):</p>
              <list list-type="bullet">
                <list-item>
                  <p>Renal ultrasound examination and fundoscopic eye examination to identify the presence/extent of oxalate deposition</p>
                </list-item>
                <list-item>
                  <p>Baseline urinalysis (spot and 24 hour collection)</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>For those with a GFR &#x0003c;60 mL/min/1.73 m<sup>2</sup>. In addition to the above evaluations: measurement of plasma oxalate</p>
            </list-item>
            <list-item>
              <p>For those with a GFR &#x0003c;30 mL/min/1.73 m<sup>2</sup> or in whom there is a rapid deterioration in function. In addition to the above evaluations:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Bone x-rays to evaluate for radiodense metaphyseal bands and diffuse demineralization, potentially bone marrow examination may also be required</p>
                </list-item>
                <list-item>
                  <p>Thyroid function testing</p>
                </list-item>
                <list-item>
                  <p>Electrocardiogram to evaluate for an associated atrioventricular block</p>
                </list-item>
                <list-item>
                  <p>Ultrasound and/or CT scan of the heart and viscera allows evaluation of calcification in such organs</p>
                </list-item>
                <list-item>
                  <p>Hemoglobin to evaluate for anemia associated with either renal dysfunction or marrow deposition of oxalate</p>
                </list-item>
                <list-item>
                  <p>History and physical examination to assess the risk of arterial insufficiency or ischemia based on vessel wall deposition</p>
                </list-item>
              </list>
            </list-item>
          </list>
        </sec>
        <sec id="ph1.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <sec id="ph1.Reduction_of_Calcium_Oxalate_Supersa">
            <title>Reduction of Calcium Oxalate Supersaturation</title>
            <p>The general therapies for nephrolithiasis benefit all individuals with PH1. Early diagnosis and initiation of conservative therapy are critical in preserving adequate renal function for as long as possible [<xref ref-type="bibr" rid="ph1.REF.fargue.2009.767">Fargue et al 2009</xref>].</p>
            <p>The following recommendations are universally embraced, and those listed here can all be found in the following recent reviews [<xref ref-type="bibr" rid="ph1.REF.cochat.2012.1729">Cochat et al 2012</xref>, <xref ref-type="bibr" rid="ph1.REF.hoppe.2012.467">Hoppe 2012</xref>, <xref ref-type="bibr" rid="ph1.REF.cochat.2013.649">Cochat &#x00026; Rumsby 2013</xref>].</p>
            <list list-type="bullet">
              <list-item>
                <p>Drinking large volumes of fluid (2-3 L/m<sup>2</sup>/24 hours) at regular intervals over the entire day/night prevents calcium oxalate supersaturation and is effective for all genotypes. Note that small children may require gastrostomy or nasogastric tube insertion for both feeds and fluid supplementation. Extreme care should be taken during any illness that could lead to hypovolemia or decreased oral fluid intake; patients should be advised to seek early medical attention.</p>
              </list-item>
              <list-item>
                <p>Alkalinzation of urine (pH 6.2-6.8) to inhibit calcium oxalate crystallization can be targeted using oral potassium citrate at a dose of 0.1-0.15 mg/kg or 0.3-0.5 mmol/kg per day in 3-4 divided doses so long as the GFR is preserved. When the GFR is reduced or concerns about potassium levels ensue, alkalinization can be achieved with sodium citrate.</p>
              </list-item>
              <list-item>
                <p>Moderate doses of pyrophosphate-containing solutions may also inhibit crystal formation, and may be dosed as 20-30 mg/kg per day of phosphate.</p>
              </list-item>
              <list-item>
                <p>Drugs such as thiazides can decrease urinary calcium excretion and may inhibit stone formation, in particular in patients with PH3.</p>
              </list-item>
              <list-item>
                <p>Any significant intake of vitamin C or D is to be avoided as both may promote stone formation.</p>
              </list-item>
              <list-item>
                <p>Supplementation of dietary calcium (300 mg) or provision of supplemental calcium (300-500 mg) at each meal significantly has been shown to decrease urinary calcium oxalate without altering calcium excretion [<xref ref-type="bibr" rid="ph1.REF.penniston.2009.484">Penniston &#x00026; Nakada 2009</xref>]. While promising, this strategy remains unproven in individuals with PH1.</p>
              </list-item>
              <list-item>
                <p>Dietary restriction of oxalate as such is not supported as being an effective therapy for patients with PH1, although the principle of careful food choices (avoid high oxalate food and drink) would seem reasonable.</p>
              </list-item>
            </list>
          </sec>
          <sec id="ph1.Treatment_of_Kidney_Stones">
            <title>Treatment of Kidney Stones</title>
            <p>The stone type most prevalent in PH1 is calcium oxalate monohydrate or whewellite [<xref ref-type="bibr" rid="ph1.REF.daudon.2008.100">Daudon et al 2008</xref>].</p>
            <p>Patients must be counseled regarding the different success rates among the following three surgical modalities:</p>
            <list list-type="bullet">
              <list-item>
                <p>Shockwave lithotripsy (SWL) is a viable first option, but only if patients are willing to accept a lower success rate and higher rate of subsequent endoscopic surgery.</p>
              </list-item>
              <list-item>
                <p>For larger, bulky stone burdens (&#x0003e;15 mm), percutaneous nephrolithotomy should be considered as first-line therapy.</p>
              </list-item>
              <list-item>
                <p>Ureteroscopy holds a very good record for success of stone clearance with minimal complication rates and may be supplanting SWL as first-line therapy at many centers.</p>
              </list-item>
            </list>
            <p><bold>SWL.</bold> While SWL is often the first choice for treatment of kidney stones given its minimally invasive nature and requirement for only sedative anesthesia, its value has been questioned as the first-line treatment for stones in children with PH1 and PH2 as calcium oxalate monohydrate stones are among the hardest stones, and are thus more likely to be resistant to extracorporeal shockwave lithotripsy (SWL) [<xref ref-type="bibr" rid="ph1.REF.williams.2003.1092">Williams et al 2003</xref>].</p>
            <p>A retrospective review of 36 individuals with PH who were treated with SWL between 1987 and 2009 in Birmingham, UK revealed that those who were treated with SWL required more subsequent treatments to render them stone free [<xref ref-type="bibr" rid="ph1.REF.alabadi.2013.1085">Al-Abadi &#x00026; Hulton 2013</xref>]. Whereas SWL was effective in 43%, repeat SWL was required in 61%. Stones in the lower pole of the kidney or parenchymal stones did not respond as well to SWL as stones in other locations. There is good evidence that any given stone(s) should not be treated with more than two SWL sessions, particularly if no change is observed with treatment [<xref ref-type="bibr" rid="ph1.REF.pace.2000.1905">Pace et al 2000</xref>].</p>
            <p><bold>Ureteroscopy.</bold> Of note, in the endourology literature the trend is toward endoscopic treatment (ureteroscopy) over SWL for all stone types because of its higher success rate, but with the recognition of a potentially higher complication rate and longer hospital stay [<xref ref-type="bibr" rid="ph1.REF.aboumarzouk.2012.cd006029">Aboumarzouk et al 2012</xref>, <xref ref-type="bibr" rid="ph1.REF.matlaga.2012.130">Matlaga et al 2012</xref>].</p>
            <p><bold>Percutaneous nephrolithotomy and ureteroscopy</bold>. In the cohort of <xref ref-type="bibr" rid="ph1.REF.alabadi.2013.1085">Al-Abadi &#x00026; Hulton [2013]</xref>, percutaneous nephrolithotomy or ureteroscopy both resulted in better stone-free rates and lower retreatment rates. While the two latter modalities are more effective at rendering the patient stone free, they have higher rates of potential complications than SWL. Percutaneous nephrolithotomy is still the best modality for large, bulky stone burdens.</p>
          </sec>
          <sec id="ph1.Reduction_of_Oxalate_Biosynthesis">
            <title>Reduction of Oxalate Biosynthesis</title>
            <p>AGT is a pyridoxal phosphate (PLP)-dependent enzyme. Approximately 10%-30% of individuals with PH1 respond to treatment with pyridoxine (vitamin B<sub>6</sub>, precursor to PLP as defined by a greater than 30% reduction in plasma oxalate concentration or normalization of urinary oxalate excretion after a minimum of three months of maximal therapy [<xref ref-type="bibr" rid="ph1.REF.watts.1985.87">Watts et al 1985</xref>, <xref ref-type="bibr" rid="ph1.REF.leumann.2001.1986">Leumann &#x00026; Hoppe 2001</xref>]. Of this group, only 40% show normalization and the other 60% a partial reduction in the concentration of plasma and urine oxalate [<xref ref-type="bibr" rid="ph1.REF.toussaint.1998.49">Toussaint 1998</xref>].</p>
            <p><xref ref-type="bibr" rid="ph1.REF.monico.2005b.1704">Monico et al [2005b]</xref> showed that the presence of the <xref ref-type="table" rid="ph1.T.agxt_allelic_variants_discussed_in">p.Gly170Arg</xref> pathogenic variant was associated with pyridoxine responsiveness &#x02014; homozygotes showing normalization (urine oxalate concentration &#x0003c;0.5-0.7 mmol/1.73 m<sup>2</sup>/day) and compound heterozygotes demonstrating a partial reduction in plasma oxalate concentration by at least 30% of prior documented levels. The same result was seen in patients with at least one <xref ref-type="table" rid="ph1.T.agxt_allelic_variants_discussed_in">p.Phe152Ile</xref> pathogenic allele.</p>
            <p>At present, two different approaches are used to titrate the pyridoxine dose:</p>
            <list list-type="bullet">
              <list-item>
                <p>A stepwise increase from initial low levels (1-2 mg/kg/day) [<xref ref-type="bibr" rid="ph1.REF.bobrowski.2008.152">Bobrowski &#x00026; Langman 2008</xref>]</p>
              </list-item>
              <list-item>
                <p>Initial high doses to maximize oxalate removal, with subsequent reduction to establish the minimal effective dose</p>
              </list-item>
            </list>
            <p>With either approach, doses of pyridoxine in the range of 5 mg/kg/day appear adequate in the treatment of those likely to respond, with no additional benefit expected at doses higher than 10 mg/kg/day [<xref ref-type="bibr" rid="ph1.REF.monico.2005b.1704">Monico et al 2005b</xref>, <xref ref-type="bibr" rid="ph1.REF.bobrowski.2008.152">Bobrowski &#x00026; Langman 2008</xref>, <xref ref-type="bibr" rid="ph1.REF.hoppe.2009.1264">Hoppe et al 2009</xref>]. In adults, a dose of 500 mg is felt to remain below the toxic range. Paresthesias, a known complication of large doses of pyridoxine [<xref ref-type="bibr" rid="ph1.REF.toussaint.1998.49">Toussaint 1998</xref>], have only developed in one individual on a dose of 2.1 mg/kg/day and resolved following discontinuation of the drug.</p>
            <p>Pyridoxal phosphate levels may be followed in individuals to ensure that adequate absorption is occurring [<xref ref-type="bibr" rid="ph1.REF.harambat.2011">Harambat et al 2011</xref>].</p>
            <p>Individuals responsive to pyridoxine should continue this therapy to decrease the burden of oxalate on the kidney, even when on hemodialysis or following successful kidney transplantation.</p>
            <p>Note: It is recommended that all patients with PH1, even those diagnosed in ESRD and on dialysis, receive a minimum three-month trial of pyridoxine at the time of initial diagnosis [<xref ref-type="bibr" rid="ph1.REF.milliner.2005.154">Milliner 2005</xref>].</p>
          </sec>
          <sec id="ph1.Dialysis">
            <title>Dialysis</title>
            <p>The issues related to the removal of oxalate and current modalities of dialysis are quite complex. Interested readers are directed to two papers outlining the specific details of extracorporeal removal of oxalate [<xref ref-type="bibr" rid="ph1.REF.cochat.2012.1729">Cochat et al 2012</xref>, <xref ref-type="bibr" rid="ph1.REF.plumb.2013.1155">Plumb et al 2013</xref>].</p>
            <p>In brief, despite the small size of the oxalate molecule (90 daltons), the rate of oxalate production in persons with PH1-related ESRD (4-7 mmol/1.73 m<sup>2</sup>/day) vastly outstrips the ability to remove it via conventional dialysis in adults (1-2 mmol/1.73 m<sup>2</sup>/day) or children (3-4 mmol/1.73 m<sup>2</sup>/day). The sequestration of oxalate in tissue compartments outside the vascular space makes it difficult to effectively remove it from the body. Current guidelines suggest that the intent of dialysis is to reduce and maintain the plasma oxalate level as long as possible below 30-45 &#x000b5;mol/L (the calcium/oxalate supersaturation threshold at which tissue deposition occurs).</p>
            <p>While more aggressive strategies using high flux dialyzers, daily hemodialysis (HD), combined HD and peritoneal dialysis (PD), hemodialfiltration, and even charcoal perfusion have all been reported [reviewed in detail by <xref ref-type="bibr" rid="ph1.REF.plumb.2013.1155">Plumb et al 2013</xref>], the end result is that while plasma removal rates of oxalate can be achieved in the range of greater than 60%, the total body store of oxalate rebounds (in general) to a level of 80% of the predialysis levels within 24 hours of the last HD run.</p>
            <p>A case report of one patient treated with aggressive HD (8-10 hrs, 7 nights/wk) does suggest that this level of intense dialysis allows for maintenance of the pre-dialysis oxalate levels at or just below the tissue saturation point (30-45 &#x000b5;mol/L), but further studies are needed before these data can be confirmed [<xref ref-type="bibr" rid="ph1.REF.plumb.2013.1155">Plumb et al 2013</xref>].</p>
            <p>Despite the limitations of dialysis, <xref ref-type="bibr" rid="ph1.REF.cochat.2010.590">Cochat et al [2010]</xref> have suggested six situations in which dialysis may be indicated:</p>
            <list list-type="bullet">
              <list-item>
                <p>When PH1 is not yet diagnosed in an individual requiring dialysis for other reasons</p>
              </list-item>
              <list-item>
                <p>In a small child/infant with oxalosis awaiting liver/kidney transplantation</p>
              </list-item>
              <list-item>
                <p>As a strategy to deplete body oxalate burden preceding or after liver transplantation</p>
              </list-item>
              <list-item>
                <p>As an adjunct therapy to decrease oxalate burden in the presence of delayed or poor renal function after liver/kidney transplantation</p>
              </list-item>
              <list-item>
                <p>In older individuals if liver/kidney transplantation is not deemed an option</p>
              </list-item>
              <list-item>
                <p>In countries with no access to organ transplantation [<xref ref-type="bibr" rid="ph1.REF.cochat.2006.1075">Cochat et al 2006</xref>]</p>
              </list-item>
            </list>
          </sec>
          <sec id="ph1.Organ_Transplantation">
            <title>Organ Transplantation</title>
            <p>As neither maintenance hemodialysis (HD), peritoneal dialysis (PD), nor a combination of the two clears oxalate quickly enough to prevent systemic oxalosis in an individual with a glomerular filtration rate (GFR) lower than 25-30 mL/min/1.73 m<sup>2</sup> [<xref ref-type="bibr" rid="ph1.REF.thamilselvan.1998.66">Thamilselvan &#x00026; Khan 1998</xref>], organ transplantation is an acceptable option for disease therapy or perhaps cure [<xref ref-type="bibr" rid="ph1.REF.marangella.2001">Marangella et al 2001</xref>]. Much discussion has occurred regarding the best transplantation strategy for an individual with PH1.</p>
            <p>The following recommendations and suggested approaches to this issue are all well summarized in three current reviews of PH1 [<xref ref-type="bibr" rid="ph1.REF.cochat.2012.1729">Cochat et al 2012</xref>, <xref ref-type="bibr" rid="ph1.REF.hoppe.2012.467">Hoppe 2012</xref>, <xref ref-type="bibr" rid="ph1.REF.cochat.2013.649">Cochat &#x00026; Rumsby 2013</xref>]. Specific percentages and outcome numbers can be extracted from these papers.</p>
            <p>The reader is strongly encouraged to review (and consider as current best practice level recommendations) the recently published suggestions on organ transplant of non-pyridoxine sensitive patients with PH1 from the European Hyperoxaluria Consortium [<xref ref-type="bibr" rid="ph1.REF.cochat.2012.1729">Cochat et al 2012</xref>]. These guidelines (see <xref ref-type="table" rid="ph1.T.suggested_transplantation_options">Table 7</xref>) also take into consideration the patient&#x02019;s age (infantile form), residual GFR, and evidence of systemic oxalate deposition in extrarenal organs.</p>
            <table-wrap id="ph1.T.suggested_transplantation_options" position="anchor" orientation="portrait">
              <label>Table 7. </label>
              <caption>
                <p>Suggested Transplantation Options for Individuals with Pyridoxine-Resistant PH1 Based on Residual GFR and Systemic Involvement</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_ph1.T.suggested_transplantation_options_1_1_1_1" valign="middle" colspan="2" align="left" scope="colgroup" rowspan="1">Transplantation (Tx) Options:</th>
                    <th id="hd_h_ph1.T.suggested_transplantation_options_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Simultaneous liver - kidney</th>
                    <th id="hd_h_ph1.T.suggested_transplantation_options_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Sequential liver - kidney</th>
                    <th id="hd_h_ph1.T.suggested_transplantation_options_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Isolated kidney</th>
                    <th id="hd_h_ph1.T.suggested_transplantation_options_1_1_1_5" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Isolated liver</th>
                  </tr>
                  <tr>
                    <th headers="hd_h_ph1.T.suggested_transplantation_options_1_1_1_1" id="hd_h_ph1.T.suggested_transplantation_options_1_1_2_1" valign="middle" colspan="2" align="left" scope="colgroup" rowspan="1">Hemodialysis (HD) Strategy:</th>
                    <th headers="hd_h_ph1.T.suggested_transplantation_options_1_1_1_2" id="hd_h_ph1.T.suggested_transplantation_options_1_1_2_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Perioperative &#x000b1; postoperative based on POx &#x00026; GFR</th>
                    <th headers="hd_h_ph1.T.suggested_transplantation_options_1_1_1_3" id="hd_h_ph1.T.suggested_transplantation_options_1_1_2_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Standard HD after liver Tx aiming at POx &#x0003c;20 &#x000b5;mol/L</th>
                    <th headers="hd_h_ph1.T.suggested_transplantation_options_1_1_1_4" id="hd_h_ph1.T.suggested_transplantation_options_1_1_2_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Preoperative &#x00026; perioperative</th>
                    <th headers="hd_h_ph1.T.suggested_transplantation_options_1_1_1_5" id="hd_h_ph1.T.suggested_transplantation_options_1_1_2_5" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Sometimes perioperative</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_ph1.T.suggested_transplantation_options_1_1_1_1 hd_h_ph1.T.suggested_transplantation_options_1_1_2_1" rowspan="4" valign="middle" align="left" scope="row" colspan="1">
                      <bold>CKD Category / Residual GFR</bold>
                    </td>
                    <td headers="hd_h_ph1.T.suggested_transplantation_options_1_1_1_1 hd_h_ph1.T.suggested_transplantation_options_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">
                      <bold>CKD Category 3 (30&#x0003c;GFR&#x0003c;59)</bold>
                    </td>
                    <td headers="hd_h_ph1.T.suggested_transplantation_options_1_1_1_2 hd_h_ph1.T.suggested_transplantation_options_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">No</td>
                    <td headers="hd_h_ph1.T.suggested_transplantation_options_1_1_1_3 hd_h_ph1.T.suggested_transplantation_options_1_1_2_3" valign="middle" align="left" rowspan="1" colspan="1">No</td>
                    <td headers="hd_h_ph1.T.suggested_transplantation_options_1_1_1_4 hd_h_ph1.T.suggested_transplantation_options_1_1_2_4" valign="middle" align="left" rowspan="1" colspan="1">No</td>
                    <td headers="hd_h_ph1.T.suggested_transplantation_options_1_1_1_5 hd_h_ph1.T.suggested_transplantation_options_1_1_2_5" valign="middle" align="left" rowspan="1" colspan="1">Option in carefully selected patients</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_ph1.T.suggested_transplantation_options_1_1_1_1 hd_h_ph1.T.suggested_transplantation_options_1_1_2_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">
                      <bold>CKD Category 4 (15&#x0003c;GFR&#x0003c;29)</bold>
                    </td>
                    <td headers="hd_h_ph1.T.suggested_transplantation_options_1_1_1_2 hd_h_ph1.T.suggested_transplantation_options_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Yes</td>
                    <td headers="hd_h_ph1.T.suggested_transplantation_options_1_1_1_3 hd_h_ph1.T.suggested_transplantation_options_1_1_2_3" valign="middle" align="left" rowspan="1" colspan="1">Option</td>
                    <td headers="hd_h_ph1.T.suggested_transplantation_options_1_1_1_4 hd_h_ph1.T.suggested_transplantation_options_1_1_2_4" valign="middle" align="left" rowspan="1" colspan="1">
                      <bold>Only if affected person is known to be B<sub>6</sub> responsive</bold>
                    </td>
                    <td headers="hd_h_ph1.T.suggested_transplantation_options_1_1_1_5 hd_h_ph1.T.suggested_transplantation_options_1_1_2_5" valign="middle" align="left" rowspan="1" colspan="1">No</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_ph1.T.suggested_transplantation_options_1_1_1_1 hd_h_ph1.T.suggested_transplantation_options_1_1_2_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">
                      <bold>CKD Category 5 <break/>(GFR &#x0003c;15)</bold>
                    </td>
                    <td headers="hd_h_ph1.T.suggested_transplantation_options_1_1_1_2 hd_h_ph1.T.suggested_transplantation_options_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Yes</td>
                    <td headers="hd_h_ph1.T.suggested_transplantation_options_1_1_1_3 hd_h_ph1.T.suggested_transplantation_options_1_1_2_3" valign="middle" align="left" rowspan="1" colspan="1">Yes</td>
                    <td headers="hd_h_ph1.T.suggested_transplantation_options_1_1_1_4 hd_h_ph1.T.suggested_transplantation_options_1_1_2_4" valign="middle" align="left" rowspan="1" colspan="1">
                      <bold>Only if affected person is known to be B<sub>6</sub> responsive</bold>
                    </td>
                    <td headers="hd_h_ph1.T.suggested_transplantation_options_1_1_1_5 hd_h_ph1.T.suggested_transplantation_options_1_1_2_5" valign="middle" align="left" rowspan="1" colspan="1">No</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_ph1.T.suggested_transplantation_options_1_1_1_1 hd_h_ph1.T.suggested_transplantation_options_1_1_2_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">
                      <bold>Infantile form (ESRD &#x0003c;2 yrs)</bold>
                    </td>
                    <td headers="hd_h_ph1.T.suggested_transplantation_options_1_1_1_2 hd_h_ph1.T.suggested_transplantation_options_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Yes</td>
                    <td headers="hd_h_ph1.T.suggested_transplantation_options_1_1_1_3 hd_h_ph1.T.suggested_transplantation_options_1_1_2_3" valign="middle" align="left" rowspan="1" colspan="1">Yes</td>
                    <td headers="hd_h_ph1.T.suggested_transplantation_options_1_1_1_4 hd_h_ph1.T.suggested_transplantation_options_1_1_2_4" valign="middle" align="left" rowspan="1" colspan="1">No</td>
                    <td headers="hd_h_ph1.T.suggested_transplantation_options_1_1_1_5 hd_h_ph1.T.suggested_transplantation_options_1_1_2_5" valign="middle" align="left" rowspan="1" colspan="1">No</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn>
                  <p>From <xref ref-type="bibr" rid="ph1.REF.cochat.2012.1729">Cochat et al [2012]</xref>; recommendations assume the availability of facilities.</p>
                </fn>
                <fn>
                  <p>POx= plasma oxalate</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <p>The three organ transplantation strategies that have been considered and implemented in the past are:</p>
            <list list-type="bullet">
              <list-item>
                <p>Isolated kidney transplantation (restores oxalate excretion to "normal");</p>
              </list-item>
              <list-item>
                <p>"Preemptive" liver transplantation before end-stage renal disease (restores AGT enzyme activity, decreases ongoing oxalate synthesis); or</p>
              </list-item>
              <list-item>
                <p>Combined liver-kidney transplantation, either concurrent or sequential (reduces oxalate synthesis and increases oxalate excretion).</p>
              </list-item>
            </list>
            <p>In almost all other situations, the current recommendations are for dual liver/kidney transplant in patients with PH1. In the majority of these situations, the only three issues to be considered are:</p>
            <list list-type="bullet">
              <list-item>
                <p>Order of transplant (liver/kidney and sequential vs concurrent);</p>
              </list-item>
              <list-item>
                <p>Timing of transplant (at what level of renal dysfunction to consider liver transplant); and</p>
              </list-item>
              <list-item>
                <p>Use of deceased vs. living donors for either or both organs.</p>
              </list-item>
            </list>
            <p>Certainly the overall survival numbers for any version of dual transplant greatly outstrip those seen from historic results for isolated kidney transplant: adult five-year survival numbers for kidney vs dual transplant are 45% vs 67% [<xref ref-type="bibr" rid="ph1.REF.bergstralh.2010.2493">Bergstralh et al 2010</xref>]; those for children are 14% vs 76% [<xref ref-type="bibr" rid="ph1.REF.harambat.2012.458">Harambat et al 2012</xref>].</p>
            <p>Isolated liver transplant as such may be a consideration with respect to a patient with significant residual renal function (e.g., GFR &#x0003e;60 mL/min/1.73 m<sup>2</sup> or above), with the presumption that decline in renal function will be arrested and only a single organ transplant required. However, in such scenarios the concerns regarding risk of liver transplant morbidity and mortality in the face of an uncertain rate of decline in renal function often delay the decision to proceed to a point at which it is clear that dual transplantation will still be required.</p>
            <p>In general it is believed that simultaneous liver/kidney transplant is the most logical for any patient, adult or child, with CKD Category 4 or below, given the need for renal function to excrete the body burden of oxalate. That decision, however, may be mitigated by concerns for patients with CKD Category 5 or on dialysis, as they often face severe oxalate burden that can overwhelm a new renal graft following transplant and lead to graft failure caused by oxalate stones/deposition. The choice in such patients, and often in small children/infants where anatomy may preclude a simultaneous approach, is to proceed with a sequential liver transplant followed at an indeterminate time later by a single kidney transplant.</p>
            <p>Most of the published literature still reports the majority of organs used as being from deceased donors; however, living/living related donation of a split liver graft if the recipient is small enough and/or living donor kidney is certainly a viable alternative in some situations. Note: The appropriateness of using a parent or sib who is heterozygous for a <italic toggle="yes">AGXT</italic> pathogenic variant as a donor remains unclear in the literature.</p>
            <p>Finally, the importance of establishing the diagnosis of PH1 before transplantation is illustrated by two recent reports of individuals with undiagnosed late-onset PH1 who received isolated kidney transplants and subsequently experienced unexpected rapid recurrence of stones and systemic oxalosis. In both cases a diagnosis of PH1 was made post transplant [<xref ref-type="bibr" rid="ph1.REF.kim.2005.1738">Kim et al 2005</xref>, <xref ref-type="bibr" rid="ph1.REF.madiwale.2008.206">Madiwale et al 2008</xref>].</p>
            <p>It is also important to note that in all forms of transplantation, in particular isolated kidney, the individual must:</p>
            <list list-type="bullet">
              <list-item>
                <p>Be monitored closely and even dialyzed following surgery to prevent further calcium oxalate deposition in the kidney graft from mobilization of the body burden of oxalate;</p>
              </list-item>
              <list-item>
                <p>Continue pyridoxine supplementation to promote excretion of the total body store of oxalate if responsiveness has been documented prior to transplantation [<xref ref-type="bibr" rid="ph1.REF.marangella.1999.301">Marangella 1999</xref>].</p>
              </list-item>
            </list>
          </sec>
        </sec>
        <sec id="ph1.Prevention_of_Primary_Manifestations">
          <title>Prevention of Primary Manifestations</title>
          <p>Recommendations can all be found in Treatment of Manifestations, specifically in the sub-sections on <xref ref-type="sec" rid="ph1.Reduction_of_Calcium_Oxalate_Supersa">Reduction of Calcium Oxalate Supersaturation</xref> and <xref ref-type="sec" rid="ph1.Reduction_of_Oxalate_Biosynthesis">Reduction of Oxalate Biosynthesis</xref>.</p>
        </sec>
        <sec id="ph1.Prevention_of_Secondary_Complication">
          <title>Prevention of Secondary Complications</title>
          <p>Secondary complications may arise as a result of systemic oxalosis. <xref ref-type="table" rid="ph1.T.organ_involvement_in_individuals_w">Table 4</xref> lists the broad range of tissues and organs that suffer consequences of oxalosis.</p>
          <p>Regular dental care and ophthalmologic follow up should be part of patient management.</p>
        </sec>
        <sec id="ph1.Surveillance">
          <title>Surveillance</title>
          <p>According to the European Hyperoxaluria Consortium (OxalEurope) [<xref ref-type="bibr" rid="ph1.REF.cochat.2012.1729">Cochat et al 2012</xref>] individuals with:</p>
          <list list-type="bullet">
            <list-item>
              <p>Preserved renal function (i.e., measured or estimated GFR &#x0003e;60 mL/min/1.73 m<sup>2</sup>) likely require only the following to evaluate/ensure treatment efficacy:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Regular renal ultrasound examinations and fundoscopic eye examinations to identify the extent of any oxalate deposition</p>
                </list-item>
                <list-item>
                  <p>Ongoing urinalysis (spot and 24-hour collections)</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>GFR &#x0003c;60 mL/min/1.73 m<sup>2</sup> should have the above evaluations as well as regular (not defined) measurements of plasma oxalate.</p>
            </list-item>
            <list-item>
              <p>GFR &#x0003c;30 mL/min/1.73 m<sup>2</sup> or a rapid deterioration in function should have the above evaluations as well as the following testing (performed prior to initiation of dialysis if possible, and repeated as needed):</p>
              <list list-type="bullet">
                <list-item>
                  <p>Bone x-rays to evaluate for radiodense metaphyseal bands and diffuse demineralization, potentially bone marrow examination may also be required</p>
                </list-item>
                <list-item>
                  <p>Thyroid function testing</p>
                </list-item>
                <list-item>
                  <p>Electrocardiogram to evaluate for an associated atrioventricular block</p>
                </list-item>
                <list-item>
                  <p>Ultrasound and/or CT scan of the heart and viscera for evaluation of calcification in such organs</p>
                </list-item>
                <list-item>
                  <p>Hemoglobin to evaluate for anemia associated with either renal dysfunction or marrow deposition of oxalate</p>
                </list-item>
                <list-item>
                  <p>History and physical examination to assess the risk of arterial insufficiency or ischemia based on vessel wall deposition</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <p>Further testing and surveillance of other organ involvement can be inferred from the list in <xref ref-type="table" rid="ph1.T.organ_involvement_in_individuals_w">Table 4</xref> &#x02013; noting that at GFR &#x0003c;30 mL/min/1.73 m<sup>2</sup> the ongoing deposition of tissue oxalate (oxalosis) will, of course, predispose all patients to multi-organ involvement, and this will worsen/accelerate as the patient enters ESRD/ initiates dialysis.</p>
          <p>Note: Investigations should likely occur more often in newly diagnosed symptomatic individuals or in children younger than age two to three years.</p>
        </sec>
        <sec id="ph1.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Avoid the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Intravascular volume depletion. The importance of maintaining dilute urine <bold>cannot</bold> be overemphasized.</p>
            </list-item>
            <list-item>
              <p>Foods high in oxalate (chocolate, rhubarb, and starfruit in particular)</p>
            </list-item>
            <list-item>
              <p>Any significant intake of vitamin C or D, as both may promote stone formation</p>
            </list-item>
            <list-item>
              <p>Loop diuretics to maintain dilute urine, as they can lead to hypercalciuria and increase the production of calcium oxalate stones</p>
            </list-item>
          </list>
          <p>One infant with PH1 developed hepatitis after exposure to the anesthetic sevoflurane; this was felt to be an idiosyncratic reaction [<xref ref-type="bibr" rid="ph1.REF.reich.2004.370">Reich et al 2004</xref>]</p>
        </sec>
        <sec id="ph1.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>Consideration should be given to testing asymptomatic at-risk family members in order to plan early treatment, monitoring, and preventive intervention [<xref ref-type="bibr" rid="ph1.REF.cochat.2012.1729">Cochat et al 2012</xref>]. If the <italic toggle="yes">AGXT</italic> pathogenic variants in the family are known, the affected/carrier status of at-risk family members can be confirmed by molecular genetic testing. The benefits of early initiation of conservative measures cannot be ignored [<xref ref-type="bibr" rid="ph1.REF.chand.2009.670">Chand &#x00026; Kaskel 2009</xref>, <xref ref-type="bibr" rid="ph1.REF.fargue.2009.767">Fargue et al 2009</xref>, <xref ref-type="bibr" rid="ph1.REF.mart_n.2011.227">Mart&#x000ed;n et al 2011</xref>].</p>
          <p>Asymptomatic individuals:</p>
          <list list-type="bullet">
            <list-item>
              <p>Can be monitored periodically for renal function and urinary oxalate;</p>
            </list-item>
            <list-item>
              <p>Should maintain adequate hydration and avoid high-oxalate foods.</p>
            </list-item>
          </list>
          <p>In addition:</p>
          <list list-type="bullet">
            <list-item>
              <p>Potassium citrate administration may also be considered as an aid to reducing calcium oxalate excretion [<xref ref-type="bibr" rid="ph1.REF.leumann.2001.1986">Leumann &#x00026; Hoppe 2001</xref>].</p>
            </list-item>
            <list-item>
              <p>For those with the pathogenic variant p.Gly170Arg or p.Phe152Ile, pyridoxine should be supplemented.</p>
            </list-item>
          </list>
          <p>See <xref ref-type="sec" rid="ph1.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="ph1.Pregnancy_Management">
          <title>Pregnancy Management</title>
          <p>Pregnancy does not appear to be an important risk factor for the development of end-stage renal disease (ESRD) in the majority of women with PH1 [<xref ref-type="bibr" rid="ph1.REF.norby.2004.277">Norby &#x00026; Milliner 2004</xref>]; however, women in whom renal function deteriorated during the pregnancy and remained abnormal post-delivery have been reported [<xref ref-type="bibr" rid="ph1.REF.cimino.2005.341">Cimino et al 2005</xref>].</p>
          <p>Of particular note, pregnant women with PH1 warrant close monitoring during pregnancy by both an obstetrician and nephrologist because of the increased risk of developing nephrolithiasis after delivery.</p>
        </sec>
        <sec id="ph1.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Several novel therapies are under investigation.</p>
          <p><bold>Oxalate-degrading bacteria.</bold> Approaches involving oral administration of bacteria such as <italic toggle="yes">Oxalobacter formigenes</italic> (<italic toggle="yes">O. formigenes</italic>) or lactic acid bacteria to degrade oxalate [<xref ref-type="bibr" rid="ph1.REF.sidhu.2001.1487">Sidhu et al 2001</xref>] and reduce the amount of oxalate available for intestinal absorption [<xref ref-type="bibr" rid="ph1.REF.campieri.2001.1097">Campieri et al 2001</xref>, <xref ref-type="bibr" rid="ph1.REF.lieske.2005a.1244">Lieske et al 2005a</xref>, <xref ref-type="bibr" rid="ph1.REF.azcarateperil.2006.1891">Azcarate-Peril et al 2006</xref>] are being investigated. Unfortunately this bacteria currently remains off the Qualified Presumption of Safety and Generally Recognized as Safe lists as maintained by the FDA, limiting the use in humans.</p>
          <p><bold><italic toggle="yes">O. formigenes</italic></bold> shows the most promise as a potential therapy for the hyperoxalurias. Although it is a normal component of the intestinal flora, many individuals do not maintain colonization. <italic toggle="yes">O. formigenes</italic> is also thought to stimulate secretion of endogenous oxalate into the intestine for its own metabolic use [<xref ref-type="bibr" rid="ph1.REF.hatch.2006.691">Hatch et al 2006</xref>, <xref ref-type="bibr" rid="ph1.REF.hatch.2008.143">Hatch &#x00026; Freel 2008</xref>]. A human strain of <italic toggle="yes">O. formigenes</italic> (HC-1) has been shown to promote oxalate secretion into the intestine of a mouse model of primary hyperoxaluria [<xref ref-type="bibr" rid="ph1.REF.hatch.2013.379">Hatch &#x00026; Freel 2013</xref>] in which there was more secretion of oxalate via the distal ileum, cecum, and distal colon into the luminal side and, thus, into the feces. Administration of the HC-1 strain reduced the amount of oxalate excreted via the kidney and has potential as a probiotic.</p>
          <p>A controlled diet was compared to two probiotic preparations to evaluate urinary oxalate levels and calcium oxalate supersaturation in individuals with hyperoxaluria and calcium oxalate stones of unknown etiology [<xref ref-type="bibr" rid="ph1.REF.lieske.2010.1178">Lieske et al 2010</xref>]: (1) the probiotic Oxadrop contains <italic toggle="yes">Lactobacillus acidophilus, L. brevis, Streptococcus thermophilus,</italic> and <italic toggle="yes">Bifidobacterium infantis</italic>; (2) AKSB, a formulation designed by the Mayo Clinic, contains <italic toggle="yes">Enterococcus faecium, Saccharomyces cerevisiae</italic> subspecies <italic toggle="yes">boulardi,</italic> LEVUCELL SB (yeast), <italic toggle="yes">S. cerevisiae</italic>, and fructooligosaccharide<italic toggle="yes">.</italic> When administered to stone formers, neither formulation reduced the amount of urinary oxalate excreted by affected individuals or the urinary calcium-oxalate supersaturation levels. However, an oxalate-restricted diet alone for one week significantly reduced the calcium oxalate supersaturation and the urinary levels of oxalate.</p>
          <p>A probiotic, VSL#3 (Sigma-Tau Pharmaceuticals, Inc., Gaithersburg, MD, USA), which contains freeze-dried live lactic acid bacteria made up of <italic toggle="yes">Streptococcus thermophilus, Bifidobacterium breve, B. longum, B. infantis, Lactobactillus acidophlus, L. plantarum, L. paracasei,</italic> and <italic toggle="yes">L. delbrueckii</italic> subspecies <italic toggle="yes">bulgaricus</italic> was administered to 13 healthy volunteers who were then challenged to an oral load of 80 mg oxalate [<xref ref-type="bibr" rid="ph1.REF.okombo.2010.169">Okombo &#x00026; Liebman 2010</xref>]. Four of the subjects who started with higher baseline oxalate levels showed the largest reduction in urinary oxalate levels compared to the other subjects. The authors suggest that individuals who are hyperabsorbers of oxalate may benefit most from the probiotic VSL#3. This study must be validated in individuals with PH1.</p>
          <p>Similar studies have been performed in mice genetically altered to mimic PH1. AGXT-deficient mice were both hyperoxaluric and hyperoxalemic [<xref ref-type="bibr" rid="ph1.REF.hatch.2011.g461">Hatch et al 2011</xref>]. In AGXT-deficient mice colonized with <italic toggle="yes">O. formigenes</italic>, urinary and plasma levels of oxalate decreased by 50%.</p>
          <p>Advances have been made to circumvent the colonization of <italic toggle="yes">O. formigenes</italic> by expressing bacterial oxalyl-CoA decarboxylase and formyl-CoA transferase in human embryo kidney (HEK) 293 cells [<xref ref-type="bibr" rid="ph1.REF.ye.2007.521">Ye et al 2007</xref>]. Further experiments have shown that the enzymes are expressed in the cytosol of cells and transfected cells were able to degrade oxalate to some degree. Although still in the experimental stages, the transfer of genes encoding oxalate-degrading enzymes may be a potential candidate for gene therapy of hyperoxalurias.</p>
          <p><bold>Other bacterial species.</bold>
<xref ref-type="bibr" rid="ph1.REF.giardina.2014.m384">Giardina et al [2014]</xref> looked at a number of other bacteria with potential for oxalate degradation in the gut. These in vitro studies demonstrated (in addition to <italic toggle="yes">O. formigenes</italic>) four probiotic strains which appeared promising: <italic toggle="yes">Lactobacillus plantarum</italic>, <italic toggle="yes">L. acidophilus</italic>, <italic toggle="yes">Bifidobacgerium breve</italic>, and <italic toggle="yes">B. longum</italic>.</p>
          <p>Finally, in a different approach, a crystalline-stabilized oxalate-degrading enzyme has been used successfully in a mouse model system and may avoid the colonization issue [<xref ref-type="bibr" rid="ph1.REF.grujic.2009.86">Grujic et al 2009</xref>].</p>
          <p><bold>Hepatocyte transplantation.</bold> Repopulation of the liver of an individual with PH1 with normal or genetically corrected hepatocytes is less invasive than liver transplantation. However, host cells must be ablated as they would continue to produce oxalate and the donor hepatocytes would then require a growth advantage to achieve repopulation. The effectiveness of this approach has been demonstrated in a mouse model of PH1 [<xref ref-type="bibr" rid="ph1.REF.guha.2005.161">Guha et al 2005</xref>, <xref ref-type="bibr" rid="ph1.REF.jiang.2008.1253">Jiang et al 2008</xref>]. <xref ref-type="bibr" rid="ph1.REF.koul.2005.176">Koul et al [2005]</xref> transfected <italic toggle="yes">AGXT</italic> (genetically engineered for selective peroxisomal delivery) into cultured human hepatocytes by amplifying the cDNA and using liposomal transfection techniques. They demonstrated high efficiency of transfection and appropriate intracellular localization to peroxisomes [<xref ref-type="bibr" rid="ph1.REF.koul.2005.176">Koul et al 2005</xref>].</p>
          <p>Recently, liver cell transplantation was performed &#x02018;successfully&#x02019; in a 15-month old girl with PH1 as a bridge to an older age/larger size to allow for orthotopic liver transplant [<xref ref-type="bibr" rid="ph1.REF.beck.2012.2984">Beck et al 2012</xref>]. The exact protocol is outlined in the paper; the child tolerated both the cellular infusions and the immunosuppression. Initially no significant change was seen in plasma oxalate levels post infusion; however, the plasma oxalate levels slowly decreased over the next two weeks from a mean of 105 to a lower mean of 70, and eventually fell to approximately 35 &#x000b5;mol/L at day 29. Long-term follow up (2-11 months) demonstrated persistently elevated (mean 80 &#x000b5;mol/L) &#x02013; albeit improved over baseline &#x02013; levels of plasma oxalate. Of note, clinically the patient improved from week two onward, despite the fact that donor chimerism was not demonstrated during the protocol biopsy at five months or at the time of liver harvest prior to the eventual orthotopic liver transplant.</p>
          <p><bold>Gene therapy.</bold>
<xref ref-type="bibr" rid="ph1.REF.salido.2011.870">Salido et al [2011]</xref> have demonstrated successful replacement of AGT enzyme activity in the livers of a knockout mouse model of PH1 utilizing a somatic gene transfer via two adeno-associated viral vectors. That they were able to do so in the absence of either hepatic toxicity or immunogenicity for at least the first 50 days is very encouraging.</p>
          <p><bold>Pyridoxamine.</bold> This approach aims to reduce oxalate by targeting precursors in the metabolic pathway and preventing their eventual metabolism to oxalate. Pyridoxamine, a drug touted as therapy for human diabetic nephropathy, is used to trap glycoaldehyde and glyoxylate. Animal studies have shown 50% reduction of urinary oxalate excretion [<xref ref-type="bibr" rid="ph1.REF.chetyrkin.2005.53">Chetyrkin et al 2005</xref>, <xref ref-type="bibr" rid="ph1.REF.scheinman.2005.368">Scheinman et al 2005</xref>]; current evidence from preclinical and phase II trials in humans appears to demonstrate a favorable toxicity profile of pyridoxamine.</p>
          <p><bold>Chemical chaperones.</bold> These small molecules facilitate folding of new proteins offering protection from cellular quality-control degradative processes. Stabilization of missense AGT may permit the protein to achieve a folded state with some degree of enzymatic activity [<xref ref-type="bibr" rid="ph1.REF.danpure.2005a.1525">Danpure 2005a</xref>, <xref ref-type="bibr" rid="ph1.REF.danpure.2005b.303">Danpure 2005b</xref>]. In PH1 specifically, this type of effect has been demonstrated in vitro for both mistargeting and aggregation/accelerated degradation polymorphism-pathogenic variant combinations [<xref ref-type="bibr" rid="ph1.REF.lumb.2003.79">Lumb et al 2003</xref>, <xref ref-type="bibr" rid="ph1.REF.coultermackie.2008.368">Coulter-Mackie &#x00026; Lian 2008</xref>, <xref ref-type="bibr" rid="ph1.REF.hopper.2008.30493">Hopper et al 2008</xref>]. Chemical chaperones may have general stabilizing functions or they may be designed to target specific pathogenic variants. Pyridoxine, commonly used in treatment of PH1, has been shown in vitro to act as a chemical chaperone increasing expression and correcting peroxisomal targeting, particularly for the three common <italic toggle="yes">AGXT</italic> alleles encoding protein variants <xref ref-type="table" rid="ph1.T.agxt_allelic_variants_discussed_in">p.Gly170Arg</xref>, <xref ref-type="table" rid="ph1.T.agxt_allelic_variants_discussed_in">p.Phe152Ile</xref>,or <xref ref-type="table" rid="ph1.T.agxt_allelic_variants_discussed_in">p.Ile244Thr</xref> [<xref ref-type="bibr" rid="ph1.REF.fargue.2013a.1776">Fargue et al 2013a</xref>, <xref ref-type="bibr" rid="ph1.REF.fargue.2013b.2475">Fargue et al 2013b</xref>, <xref ref-type="bibr" rid="ph1.REF.cellini.2014.158">Cellini et al 2014</xref>]. Pathogenic missense variants &#x02013; in which the mode of action is not through loss of stability &#x02013; are not suitable candidates for this pharmacogenetic approach; nor are insertions, deletions, nonsense variants, or splice junction changes, which usually do not produce a protein product.</p>
          <p><bold>Manipulation of the metabolic pathway.</bold> The concept of substrate depletion is aimed at reducing the amount of available glyoxylate, the immediate precursor of oxalate, thereby reducing the oxalate concentration [<xref ref-type="bibr" rid="ph1.REF.coultermackie.2006.1891">Coulter-Mackie 2006</xref>]. An <italic toggle="yes">Agxt</italic> knockout mouse model has been developed to explore the effects of substrate depletion and to clarify the various adjustments in the metabolic pathway that result from absence of AGT [<xref ref-type="bibr" rid="ph1.REF.hern_ndezfernaud.2010.4766">Hern&#x000e1;ndez-Fernaud &#x00026; Salido 2010</xref>, <xref ref-type="bibr" rid="ph1.REF.knight.2012.f688">Knight et al 2012</xref>]. A model system developed in CHO cells uses stable transfection with all combinations of recombinant genes that encode glycolate oxidase, glyoxylate reductase, and AGT, allowing investigation of the interaction of these enzymes and the effects of deficiencies of one or more [<xref ref-type="bibr" rid="ph1.REF.behnam.2006.409">Behnam et al 2006</xref>]. Another study examined the effect on urinary oxalate of dietary hydroxyproline from collagen, which enters the pathway farther upstream. Results suggested that hydroxyproline metabolism may be a significant contributor to glyoxylate and oxalate [<xref ref-type="bibr" rid="ph1.REF.knight.2006.1929">Knight et al 2006</xref>].</p>
          <p>A study of eight recombinant cytosolic aminotransferases suggested that phosphoserine aminotransferase and alanine transaminase were able to transaminate glyoxylate to glycine efficiently. These reactions may compete with conversion of glyoxylate to oxalate [<xref ref-type="bibr" rid="ph1.REF.donini.2009.265">Donini et al 2009</xref>].</p>
          <p>Severe dietary restriction of either oxalate [<xref ref-type="bibr" rid="ph1.REF.hatch.1995">Hatch &#x00026; Freel 1995</xref>] or glycine, a glyoxylate precursor, is of little utility in decreasing the accumulation of oxalate in individuals with PH1 [<xref ref-type="bibr" rid="ph1.REF.danpure.2001">Danpure 2001</xref>].</p>
          <p>Trapping glycine in the liver utilizing benzoate or inhibiting the conversion of glycine to glyoxylate is of little or no clinical utility [<xref ref-type="bibr" rid="ph1.REF.danpure.2001">Danpure 2001</xref>].</p>
          <p><bold>Auxiliary liver transplant.</bold> A previously heretical approach to organ transplant, auxiliary liver transplant has been proposed and demonstrated to &#x02018;be effective&#x02019; in two published cases [<xref ref-type="bibr" rid="ph1.REF.onaca.2005.421">Onaca et al 2005</xref>, <xref ref-type="bibr" rid="ph1.REF.elias.2013.2739">Elias et al 2013</xref>] and to potentially provide effective oxalate clearance for some patients with PH1. This approach is not universally accepted as such, however [<xref ref-type="bibr" rid="ph1.REF.trotter.2014.241">Trotter &#x00026; Milliner 2014</xref>], and the basic principle behind the need to remove the native liver <bold>in addition to</bold> &#x02018;replacing liver mass with a transplanted organ&#x02019; (namely the ongoing and overwhelming production of oxalate from the abnormal liver cells) would seem to suggest that the addition of a small piece of normal liver and its normal AGT enzymatic function would not be enough to provide sufficient metabolic clearance of oxalate being produced by the remaining PH1 liver tissue.</p>
          <p><xref ref-type="bibr" rid="ph1.REF.onaca.2005.421">Onaca et al [2005]</xref> and <xref ref-type="bibr" rid="ph1.REF.elias.2013.2739">Elias et al [2013]</xref> have each reported at least one patient with PH1 in whom this approach appeared to protect against oxalosis &#x02013; without necessitating a high-risk full liver transplant.</p>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
      </sec>
      <sec id="ph1.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="ph1.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Primary hyperoxaluria type 1 (PH1) is inherited in an autosomal recessive manner.</p>
        </sec>
        <sec id="ph1.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of a child affected with PH1 are obligate heterozygotes (i.e., carriers of one <italic toggle="yes">AGXT</italic> pathogenic variant).</p>
            </list-item>
            <list-item>
              <p>Heterozygotes are asymptomatic.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of a proband with PH1 has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.Note: In a very rare exception to this generalization, one case of PH1 caused by maternal chromosome 2 telomeric isodisomy has been reported [<xref ref-type="bibr" rid="ph1.REF.chevalierporst.2005.80">Chevalier-Porst et al 2005</xref>]. The mother was a heterozygous carrier of the common c.33dupC pathogenic variant. This situation would alter the recurrence risk. Confirmation of carrier status of both parents is appropriate.</p>
            </list-item>
            <list-item>
              <p>Once an at-risk sib is known to be unaffected, the risk of his/her being a carrier is 2/3.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> The offspring of an individual with PH1 are obligate heterozygotes (carriers) for a pathogenic variant in <italic toggle="yes">AGXT</italic>. <xref ref-type="bibr" rid="ph1.REF.hoppe.1997.36">Hoppe et al [1997]</xref> described a family with pseudo-dominant inheritance: offspring of an affected individual (p.[Gly170Arg]+[Ser187Phe]) and a carrier (p.Gly170Arg) were affected.</p>
          <p><bold>Other family members of a proband.</bold> Each sib of the proband's parents is at a 50% risk of being a carrier.</p>
        </sec>
        <sec id="ph1.Carrier_Detection">
          <title>Carrier Detection</title>
          <p>Carrier testing using molecular genetic testing is possible for at-risk family members if the <italic toggle="yes">AGXT</italic> pathogenic variants in the family are known. If the proband's pathogenic variants are not identified using currently available methods, linkage analysis may be considered (see <xref ref-type="sec" rid="ph1.Molecular_Genetic_Testing">Molecular Genetic Testing</xref>).</p>
        </sec>
        <sec id="ph1.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="ph1.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="ph1.Prenatal_Testing_and_Preimplantation">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p><bold>Molecular genetic testing.</bold> Once the <italic toggle="yes">AGXT</italic> pathogenic variants have been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic diagnosis are possible options.</p>
          <p>
            <bold>Biochemical testing</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Biochemical testing has been supplanted by molecular genetic testing.</p>
            </list-item>
            <list-item>
              <p>Assay of AGT enzymatic activity prenatally is not generally offered because the enzyme is not expressed in amniocytes or chorionic villi and, thus, the assay of enzyme activity requires a fetal liver biopsy. AGT is not detectable in fetal liver until after 14 weeks&#x02019; gestation [<xref ref-type="bibr" rid="ph1.REF.danpure.1989.271">Danpure et al 1989</xref>].</p>
            </list-item>
          </list>
          <p>Requests for prenatal testing for conditions which (like PH1) do not affect intellect and have some treatment available are not common. Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although most centers would consider decisions about prenatal testing to be the choice of the parents, discussion of these issues is appropriate. Side effects of renal and/or liver transplantation and scarcity of suitable organs for transplantation may be a consideration for parents who already have one affected child.</p>
        </sec>
      </sec>
      <sec id="ph1.Resources">
        <title>Resources</title>
      </sec>
      <sec id="ph1.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <sec id="ph1.Molecular_Genetic_Pathogenesis">
          <title>Molecular Genetic Pathogenesis</title>
          <p>When alanine:glyoxylate aminotransferase (AGT) enzymatic activity is deficient, the substrate glyoxylate accumulates and is converted to oxalate by glycolate oxidase in peroxisomes or in the cytosol by lactate dehydrogenase [<xref ref-type="bibr" rid="ph1.REF.holmes.1998.1617">Holmes &#x00026; Assimos 1998</xref>, <xref ref-type="bibr" rid="ph1.REF.danpure.2001">Danpure 2001</xref>]. Oxalate forms insoluble calcium oxalate salts that the body cannot readily eliminate. In the most common pathogenic allele (<xref ref-type="table" rid="ph1.T.agxt_allelic_variants_discussed_in">c.508G&#x0003e;A</xref> (p.Gly170Arg), the AGT enzyme is mistargeted to the mitochondria rather than to the peroxisomes, where the substrate is localized. The mistargeted AGT enzyme retains substantial enzymatic activity but has no contact with its substrate, and thus the functional consequences are the same as for other pathogenic variants which result in no enzymatic activity. Mistargeting and high residual activity are seen in heterozygotes and homozygotes for the <xref ref-type="table" rid="ph1.T.agxt_allelic_variants_discussed_in">c.508G&#x0003e;A</xref> variant that causes mistargeting [<xref ref-type="bibr" rid="ph1.REF.danpure.1998.8">Danpure 1998</xref>, <xref ref-type="bibr" rid="ph1.REF.danpure.2001">Danpure 2001</xref>]. (See <bold>&#x0201c;Major&#x0201d; and &#x0201c;minor&#x0201d; <italic toggle="yes">AGXT</italic> alleles</bold>.)</p>
          <p><bold>Gene structure.</bold>
<italic toggle="yes">AGXT</italic> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=NM_000030.2">NM_000030.2</ext-link>) spans approximately 10 kb and comprises 11 exons. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="ph1" object-id="ph1.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
          <p><bold>Benign allelic variants.</bold> Three benign single-base substitution variants that do not result in amino acid substitutions are reported [<xref ref-type="bibr" rid="ph1.REF.purdue.1990.2341">Purdue et al 1990</xref>, <xref ref-type="bibr" rid="ph1.REF.von_schnakenburg.1997.489">von Schnakenburg &#x00026; Rumsby 1997</xref>].</p>
          <p><bold>&#x0201c;Major&#x0201d; and &#x0201c;minor&#x0201d; <italic toggle="yes">AGXT</italic> alleles.</bold> Two common normal alleles of <italic toggle="yes">AGXT</italic> are known: the most frequent is commonly termed the &#x0201c;major allele&#x0201d; (80% frequency in individuals of European origin) and the less frequent the &#x0201c;minor allele&#x0201d; (20% frequency in individuals of European origin, 2% in Japanese, 3% in South African blacks) [<xref ref-type="bibr" rid="ph1.REF.danpure.1994b.487">Danpure et al 1994b</xref>, <xref ref-type="bibr" rid="ph1.REF.coultermackie.2003.44">Coulter-Mackie et al 2003</xref>].</p>
          <p>The &#x0201c;major allele&#x0201d; is the haplotype defined by <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=NM_000030.2">NM_000030.2</ext-link>, while the &#x0201c;minor allele&#x0201d; haplotype has two single amino acid substitutions (p.Pro11Leu and p.Ile340Met among other genomic changes in strong disequilibrium [reviewed by <xref ref-type="bibr" rid="ph1.REF.pey.2013">Pey et al 2013</xref>].</p>
          <p>In the &#x0201c;minor allele,&#x0201d; the only normal allelic variant of functional significance is <xref ref-type="table" rid="ph1.T.agxt_allelic_variants_discussed_in">p.Pro11Leu</xref>, which alters the amino acid sequence and creates a cryptic N-terminal mitochondrial targeting sequence [<xref ref-type="bibr" rid="ph1.REF.purdue.1991.10900">Purdue et al 1991</xref>, <xref ref-type="bibr" rid="ph1.REF.fargue.2013b.2475">Fargue et al 2013b</xref>]. The mitochondrial targeting sequence of the minor allele is functionally ineffective due to protein conformation; about 5% of AGT encoded by the minor allele is found in the mitochondria [see <xref ref-type="bibr" rid="ph1.REF.pey.2013">Pey et al 2013</xref> and references therein]. However, certain pathogenic variants on the minor allele disrupt AGT folding, thereby unmasking the mitochondrial targeting signal, resulting in efficient mislocalization of AGT. Therefore, when in <italic toggle="yes">cis</italic> configuration the minor allele acts synergistically with some pathogenic variants (see <bold>Pathogenic allelic variants</bold>).</p>
          <p>Other <italic toggle="yes">AGXT</italic> allelic haplotypes have been reported [<xref ref-type="bibr" rid="ph1.REF.danpure.1994a.55">Danpure et al 1994a</xref>, <xref ref-type="bibr" rid="ph1.REF.tarn.1997.689">Tarn et al 1997</xref>, <xref ref-type="bibr" rid="ph1.REF.coultermackie.2003.44">Coulter-Mackie et al 2003</xref>]. These normal variants may be useful intragenic markers for linkage analysis [<xref ref-type="bibr" rid="ph1.REF.tarn.1997.689">Tarn et al 1997</xref>] and for determination of phase of pathogenic variants.</p>
          <p><bold>Pathogenic allelic variants.</bold> More than 170 <italic toggle="yes">AGXT</italic> pathogenic variants have been documented [<xref ref-type="bibr" rid="ph1.REF.williams.2009.910">Williams et al 2009</xref>]. A <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.uclh.nhs.uk/OurServices/ServiceA-Z/PATH/PATHBIOMED/CBIO/Pages/Phmdatabase.aspx">database of <italic toggle="yes">AGXT</italic> pathogenic variants</ext-link> is available on Dr Gill Rumsby&#x02019;s website. Pathogenic missense variants make up approximately 50% of PH1-causing variants.</p>
          <p>There are four common pathogenic variants and a few with ethnic associations. Most of the additional pathogenic variants are private (i.e., they have not been documented in more than one family).</p>
          <p>The four common pathogenic variants p.Gly170Arg, p.Phe152Ile, and p.Ile244Thr (which occur on the &#x0201c;minor allele&#x0201d;) and c.33dupC (on the &#x0201c;major allele&#x0201d;) together account for more than 50% of PH1-causing alleles.</p>
          <list list-type="bullet">
            <list-item>
              <p>An AGT &#x0201c;minor allele&#x0201d; background may exacerbate at least one copy of the <italic toggle="yes">AGXT</italic> &#x0201c;minor allele&#x0201d; with one of the following common pathogenic variants in <italic toggle="yes">cis</italic> configuration.</p>
              <list list-type="bullet">
                <list-item>
                  <p><xref ref-type="table" rid="ph1.T.agxt_allelic_variants_discussed_in"><bold>p.Gly170Arg</bold></xref>, the most common pathogenic variant, accounts for approximately 25%-40% of PH1-causing alleles. When in <italic toggle="yes">cis</italic> configuration with the p.Pro11Leu variant of the &#x0201c;minor allele,&#x0201d; p.Gly170Arg slows the rate of dimerization of AGT monomers, exposing the cryptic mitochondrial targeting signal resulting in efficient import of monomers to the mitochrondrion, rather than to the peroxisome [<xref ref-type="bibr" rid="ph1.REF.lumb.1999.20587">Lumb et al 1999</xref>, <xref ref-type="bibr" rid="ph1.REF.lumb.2000.36415">Lumb &#x00026; Danpure 2000</xref>]. Denaturation studies support a destabilizing effect of p.Gly170Arg [<xref ref-type="bibr" rid="ph1.REF.cellini.2010a.1801">Cellini et al 2010a</xref>]. Analysis of the crystal structure of AGT with p.Gly170Arg indicates significant local structural changes that may be associated with decreased protein stability [<xref ref-type="bibr" rid="ph1.REF.djordjevic.2010.233">Djordjevic et al 2010</xref>].In individuals with the p.Gly170Arg variant, the therapeutic response to pyridoxine is likely attributable at least in part to enhancement of the dimerization process by increased pyridoxal phosphate (PLP) [<xref ref-type="bibr" rid="ph1.REF.cellini.2011.1577">Cellini et al 2011</xref>].</p>
                </list-item>
                <list-item>
                  <p><xref ref-type="table" rid="ph1.T.agxt_allelic_variants_discussed_in"><bold>p.Phe152Ile</bold></xref><bold>.</bold> When in <italic toggle="yes">cis</italic> configuration with the p.Pro11Leu variant of the &#x0201c;minor allele,&#x0201d; p.Phe152Ile is also associated with mitochondrial mistargeting. In the absence of saturating PLP, p.Phe152Ile is thought to monomerize and be susceptible to mistargeting [<xref ref-type="bibr" rid="ph1.REF.cellini.2009.8349">Cellini et al 2009</xref>, <xref ref-type="bibr" rid="ph1.REF.cellini.2011.1577">Cellini et al 2011</xref>, <xref ref-type="bibr" rid="ph1.REF.fargue.2013b.2475">Fargue et al 2013b</xref>]. This is consistent with the positive response to pyridoxine in affected individuals with the p.Phe152Ile variant.</p>
                </list-item>
                <list-item>
                  <p><xref ref-type="table" rid="ph1.T.agxt_allelic_variants_discussed_in"><bold>p.Ile244Thr</bold></xref> appears to be the result of a founder effect within the Canary Islands population [<xref ref-type="bibr" rid="ph1.REF.santana.2003.7277">Santana et al 2003</xref>]. AGT with the p.Ile244Thr pathogenic variant on the minor allele apparently has an altered conformation [<xref ref-type="bibr" rid="ph1.REF.santana.2003.7277">Santana et al 2003</xref>]. This variant is also apparently associated with mistargeting [<xref ref-type="bibr" rid="ph1.REF.fargue.2013b.2475">Fargue et al 2013b</xref>].</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p><xref ref-type="table" rid="ph1.T.agxt_allelic_variants_discussed_in"><bold>c.33dupC</bold></xref> (p.Lys12GlnfsTer156), the fourth common pathogenic variant, occurs on the &#x0201c;major <italic toggle="yes">AGXT</italic> allele&#x0201d; and accounts for about 30% of PH1-causing alleles [<xref ref-type="bibr" rid="ph1.REF.coultermackie.2004.64">Coulter-Mackie et al 2004</xref>]. This allele occurs in a variety of ethnic groups and results in a frameshift that predicts nonsense mediated decay and deficiency of AGT.</p>
            </list-item>
          </list>
          <p>Pathogenic variants documented in more than one family include p.Gly82Glu and p.Gly156Arg on the major allele, p.Arg233Cys on the minor allele, and p.Gly41Arg on both the major and minor alleles.</p>
          <p>Most missense variants have not had specific biochemical phenotypes associated with them other than degradation and loss of enzymatic activity [<xref ref-type="bibr" rid="ph1.REF.coultermackie.2006.349">Coulter-Mackie &#x00026; Lian 2006</xref>]. The pathogenic mechanism of a few of the rarer missense variants is known:</p>
          <list list-type="bullet">
            <list-item>
              <p>p.Gly82Glu (on the major allele) apparently prevents binding of the essential cofactor pyridoxine (vitamin B<sub>6</sub>) [<xref ref-type="bibr" rid="ph1.REF.lumb.2000.36415">Lumb &#x00026; Danpure 2000</xref>, <xref ref-type="bibr" rid="ph1.REF.cellini.2007.39">Cellini et al 2007</xref>]. Rather than an intrinsic inability to bind PLP, this is now thought to be due to an altered binding state of PLP and the AGT-PMP intermediate [<xref ref-type="bibr" rid="ph1.REF.cellini.2011.1577">Cellini et al 2011</xref>].</p>
            </list-item>
            <list-item>
              <p>p.Gly41Arg (on the minor allele) results in intraperoxisomal aggregation of AGT protein [<xref ref-type="bibr" rid="ph1.REF.danpure.1993.417">Danpure et al 1993</xref>]. In vitro studies of Gly41 pathogenic variants demonstrate a propensity for aggregation particularly in the absence of bound PLP [<xref ref-type="bibr" rid="ph1.REF.cellini.2010b.2896">Cellini et al 2010b</xref>, <xref ref-type="bibr" rid="ph1.REF.cellini.2011.1577">Cellini et al 2011</xref>].</p>
            </list-item>
            <list-item>
              <p>p.Ser205Pro (on the major allele) results in an unstable protein that is rapidly degraded [<xref ref-type="bibr" rid="ph1.REF.nishiyama.1993.1237">Nishiyama et al 1993</xref>, <xref ref-type="bibr" rid="ph1.REF.coultermackie.2008.368">Coulter-Mackie &#x00026; Lian 2008</xref>].</p>
            </list-item>
          </list>
          <p>See <xref ref-type="table" rid="ph1.T.agxt_allelic_variants_discussed_in">Table 8</xref>.</p>
          <p>In addition to the missense variants, splicing and nonsense variants and several small insertions and deletions are known [reviewed by <xref ref-type="bibr" rid="ph1.REF.coultermackie.2004.38">Coulter-Mackie &#x00026; Rumsby 2004</xref>, <xref ref-type="bibr" rid="ph1.REF.williams.2009.910">Williams et al 2009</xref>].</p>
          <p>Large documented deletions include:</p>
          <list list-type="bullet">
            <list-item>
              <p>Two deletions of the entire 5' one third to one half of the gene and contiguous upstream regions [<xref ref-type="bibr" rid="ph1.REF.nogueira.2000.384">Nogueira et al 2000</xref>, <xref ref-type="bibr" rid="ph1.REF.coultermackie.2001.314">Coulter-Mackie et al 2001</xref>];</p>
            </list-item>
            <list-item>
              <p>Two other large intragenic deletions and one extending into the 3&#x02019; untranslated region [<xref ref-type="bibr" rid="ph1.REF.coultermackie.2005.172">Coulter-Mackie et al 2005</xref>, <xref ref-type="bibr" rid="ph1.REF.monico.2007.1905">Monico et al 2007</xref>, <xref ref-type="bibr" rid="ph1.REF.williams.2009.910">Williams et al 2009</xref>];</p>
            </list-item>
            <list-item>
              <p>A telomeric deletion of chromosome 2q encompassing <italic toggle="yes">AGXT</italic> [<xref ref-type="bibr" rid="ph1.REF.tammachote.2012.2124">Tammachote et al 2012</xref>].</p>
            </list-item>
          </list>
          <table-wrap id="ph1.T.agxt_allelic_variants_discussed_in" position="anchor" orientation="portrait">
            <label>Table 8. </label>
            <caption>
              <p><italic toggle="yes">AGXT</italic> Allelic Variants Discussed in This <italic toggle="yes">GeneReview</italic></p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_ph1.T.agxt_allelic_variants_discussed_in_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Variant Classification</th>
                  <th id="hd_h_ph1.T.agxt_allelic_variants_discussed_in_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change<break/>(Alias&#x000a0;<sup>1</sup>)</th>
                  <th id="hd_h_ph1.T.agxt_allelic_variants_discussed_in_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change</th>
                  <th id="hd_h_ph1.T.agxt_allelic_variants_discussed_in_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_ph1.T.agxt_allelic_variants_discussed_in_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                    <bold>Defines &#x0201c;minor <italic toggle="yes">AGXT</italic> allele&#x0201d;</bold>
                  </td>
                  <td headers="hd_h_ph1.T.agxt_allelic_variants_discussed_in_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.32C&#x0003e;T</td>
                  <td headers="hd_h_ph1.T.agxt_allelic_variants_discussed_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Pro11Leu&#x000a0;<sup>2</sup></td>
                  <td headers="hd_h_ph1.T.agxt_allelic_variants_discussed_in_1_1_1_4" rowspan="13" valign="middle" align="left" colspan="1">
                    <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=NM_000030.2">NM_000030.2</ext-link>
                    <break/>
                    <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=NP_000021.1">NP_000021.1</ext-link>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_ph1.T.agxt_allelic_variants_discussed_in_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.1020A&#x0003e;G</td>
                  <td headers="hd_h_ph1.T.agxt_allelic_variants_discussed_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Ile340Met&#x000a0;<sup>2</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_ph1.T.agxt_allelic_variants_discussed_in_1_1_1_1" rowspan="11" valign="middle" align="left" scope="row" colspan="1">
                    <bold>Pathogenic</bold>
                  </td>
                  <td headers="hd_h_ph1.T.agxt_allelic_variants_discussed_in_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.33dupC<break/>(33_34insC)</td>
                  <td headers="hd_h_ph1.T.agxt_allelic_variants_discussed_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Lys12GlnfsTer156</td>
                </tr>
                <tr>
                  <td headers="hd_h_ph1.T.agxt_allelic_variants_discussed_in_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.121G&#x0003e;A</td>
                  <td headers="hd_h_ph1.T.agxt_allelic_variants_discussed_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Gly41Arg</td>
                </tr>
                <tr>
                  <td headers="hd_h_ph1.T.agxt_allelic_variants_discussed_in_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.245G&#x0003e;A</td>
                  <td headers="hd_h_ph1.T.agxt_allelic_variants_discussed_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Gly82Glu</td>
                </tr>
                <tr>
                  <td headers="hd_h_ph1.T.agxt_allelic_variants_discussed_in_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.454T&#x0003e;A</td>
                  <td headers="hd_h_ph1.T.agxt_allelic_variants_discussed_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Phe152Ile</td>
                </tr>
                <tr>
                  <td headers="hd_h_ph1.T.agxt_allelic_variants_discussed_in_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.466G&#x0003e;A</td>
                  <td headers="hd_h_ph1.T.agxt_allelic_variants_discussed_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Gly156Arg</td>
                </tr>
                <tr>
                  <td headers="hd_h_ph1.T.agxt_allelic_variants_discussed_in_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.508G&#x0003e;A</td>
                  <td headers="hd_h_ph1.T.agxt_allelic_variants_discussed_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Gly170Arg</td>
                </tr>
                <tr>
                  <td headers="hd_h_ph1.T.agxt_allelic_variants_discussed_in_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.560C&#x0003e;T</td>
                  <td headers="hd_h_ph1.T.agxt_allelic_variants_discussed_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Ser187Phe</td>
                </tr>
                <tr>
                  <td headers="hd_h_ph1.T.agxt_allelic_variants_discussed_in_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.613T&#x0003e;C</td>
                  <td headers="hd_h_ph1.T.agxt_allelic_variants_discussed_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Ser205Pro</td>
                </tr>
                <tr>
                  <td headers="hd_h_ph1.T.agxt_allelic_variants_discussed_in_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.697C&#x0003e;T</td>
                  <td headers="hd_h_ph1.T.agxt_allelic_variants_discussed_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg233Cys</td>
                </tr>
                <tr>
                  <td headers="hd_h_ph1.T.agxt_allelic_variants_discussed_in_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.731T&#x0003e;C</td>
                  <td headers="hd_h_ph1.T.agxt_allelic_variants_discussed_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Ile244Thr</td>
                </tr>
                <tr>
                  <td headers="hd_h_ph1.T.agxt_allelic_variants_discussed_in_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.738G&#x0003e;A</td>
                  <td headers="hd_h_ph1.T.agxt_allelic_variants_discussed_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Trp246Ter</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
              </fn>
              <fn>
                <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
              </fn>
              <fn id="ph1.TF.8.1">
                <label>1. </label>
                <p>Variant designation that does not conform to current naming conventions</p>
              </fn>
              <fn id="ph1.TF.8.2">
                <label>2. </label>
                <p>Two of the variants that define the haplotype of the &#x0201c;minor <italic toggle="yes">AGXT</italic> allele&#x0201d;</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Normal gene product.</bold> The mRNA (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/115583676?report=genbank">NM_000030.2</ext-link>) encodes a 392-amino acid with a molecular mass of 43 kd. In humans, alanine:glyoxylate aminotransferase (AGT) is synthesized mainly in the liver and is normally located exclusively in the peroxisomes [<xref ref-type="bibr" rid="ph1.REF.danpure.2001">Danpure 2001</xref>]. The enzyme is translated in the cytosol and transported into the peroxisomes. A C-terminal peroxisomal targeting signal is recognized by the peroxisomal receptor, Pex5p, allowing translocation into the peroxisome [<xref ref-type="bibr" rid="ph1.REF.fodor.2012.e1001309">Fodor et al 2012</xref>]. AGT is a key enzyme in the detoxification of glyoxylate, converting glyoxylate to glycine [<xref ref-type="bibr" rid="ph1.REF.holmes.1998.1617">Holmes &#x00026; Assimos 1998</xref>, <xref ref-type="bibr" rid="ph1.REF.danpure.2001">Danpure 2001</xref>]. In humans, glyoxylate is produced in the peroxisomes. PLP is an essential cofactor for AGT activity. The PLP site in AGT lies in a highly conserved amino acid sequence and is critical in the catalytic activity of the enzyme. The crystal structure of the normal AGT protein has been determined [<xref ref-type="bibr" rid="ph1.REF.zhang.2003.643">Zhang et al 2003</xref>], allowing a delineation of the active site and the dimerization interface.</p>
          <p>Note that <italic toggle="yes">AGXT</italic> encodes alanine:glyoxylate aminotransferase (AGT;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://enzyme.expasy.org/EC/2.6.1.44">EC 2.6.1.44</ext-link>), whose activity is largely confined to peroxisomes in the liver. This protein also shows serine:pyruvate aminotransferase activity (SPT;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://enzyme.expasy.org/EC/2.6.1.51">EC 2.6.1.51</ext-link>) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/604285">OMIM</ext-link>). AGT and SPT are two separate enzymatic activities on the same protein coded by <italic toggle="yes">AGXT</italic>. AGT is the major activity; when it is deficient, PH1 results.</p>
          <p><bold>Abnormal gene product.</bold> Approximately 50% of all individuals with PH1 show no AGT enzymatic activity and produce no immunologically detectable AGT protein.</p>
          <p>Mutation resulting in nonsense codons, frameshifts, or splice junction variants is usually predicted to result in little or no functional protein.</p>
          <p>Approximately 30% of affected individuals display a high level of residual AGT activity. Most of these individuals exhibit the mistargeting defect in which an otherwise functional AGT enzyme is synthesized in adequate amounts but is mislocalized to mitochondria instead of peroxisomes, where it is normally found and where the substrate glycolate remains. These individuals have classic PH1 despite the residual AGT enzymatic activity.</p>
          <p>Pathogenic variants that cause true partial enzymatic activity appear to be rare and may be associated with late-onset or mild disease.</p>
          <p>With many genetic diseases, it is now clear that a common consequence of pathogenic missense variants is protein misfolding and subsequent elimination by intracellular quality-control processes [<xref ref-type="bibr" rid="ph1.REF.waters.2001.57">Waters 2001</xref>]. This biologic instability of protein carrying a missense change has been documented in p.Ser205Pro [<xref ref-type="bibr" rid="ph1.REF.nishiyama.1993.1237">Nishiyama et al 1993</xref>] and with a variety of other pathogenic missense variants in AGT [<xref ref-type="bibr" rid="ph1.REF.coultermackie.2006.349">Coulter-Mackie &#x00026; Lian 2006</xref>, <xref ref-type="bibr" rid="ph1.REF.coultermackie.2008.368">Coulter-Mackie &#x00026; Lian 2008</xref>, <xref ref-type="bibr" rid="ph1.REF.hopper.2008.30493">Hopper et al 2008</xref>]. Biochemical studies of a broad range of individual pathogenic variants has revealed a diversity of effects both structural and functional, such as altered PLP or substrate binding, thermostability changes, altered interactions with peroxisomal targeting components, and misfolding with subsequent aggregation or degradation [<xref ref-type="bibr" rid="ph1.REF.cellini.2007.39">Cellini et al 2007</xref>, <xref ref-type="bibr" rid="ph1.REF.cellini.2012.621">Cellini et al 2012</xref>, <xref ref-type="bibr" rid="ph1.REF.fodor.2012.e1001309">Fodor et al 2012</xref>, <xref ref-type="bibr" rid="ph1.REF.oppici.2012.132">Oppici et al 2012</xref>, <xref ref-type="bibr" rid="ph1.REF.mesatorres.2013.e71963">Mesa-Torres et al 2013</xref>, <xref ref-type="bibr" rid="ph1.REF.pey.2013">Pey et al 2013</xref>]. The findings may provide clues to potential therapeutic strategies as well as clues to the response to PLP. For instance, p.Gly82Glu has been demonstrated to have a reduced affinity for the pyridoxal phosphate cofactor [<xref ref-type="bibr" rid="ph1.REF.cellini.2007.39">Cellini et al 2007</xref>].</p>
          <p>It has been reported recently that the protein encoded by four pathogenic variants that occur on the minor allele (p.Gly170Arg, p.Ile244Arg, p.Phe152Ile, and p.Gly41Arg) undergo mistargeting [<xref ref-type="bibr" rid="ph1.REF.fargue.2013b.2475">Fargue et al 2013b</xref>]. It is speculated that this is a common feature of variants occurring on the minor allele. Variant AGT proteins with p.Gly170Arg, p.Ile244Thr, p.Ile244Arg, and p.Phe162Ile are able to dimerize and are catalytically active although functionally ineffective if located in the mitochondria. The variant p.Gly41Arg tends to aggregate and is inactive.</p>
          <p>The effect of a given pathogenic missense variant may be exacerbated if it occurs on the AGT &#x0201c;minor allele.&#x0201d; In vitro studies have shown increased stability and enzymatic activity for some pathogenic variants when expressed on a &#x0201c;major allele&#x0201d; haplotype compared to a &#x0201c;minor allele&#x0201d; [<xref ref-type="bibr" rid="ph1.REF.williams.2007.1216">Williams &#x00026; Rumsby 2007</xref>, <xref ref-type="bibr" rid="ph1.REF.coultermackie.2008.368">Coulter-Mackie &#x00026; Lian 2008</xref>, <xref ref-type="bibr" rid="ph1.REF.williams.2009.910">Williams et al 2009</xref>]. It has been speculated that some missense variants found on the &#x0201c;minor allele&#x0201d; in association with PH1 may not cause disease if they occurred on the major allele. However, some missense variants (e.g., p.Gly41Arg) found on both major and minor alleles cause disease in both instances.</p>
          <p>The recent determination of a crystal structure for AGT [<xref ref-type="bibr" rid="ph1.REF.zhang.2003.643">Zhang et al 2003</xref>] has permitted the rationalization of the functional consequences of selected missense pathogenic protein variants: p.Gly170Arg (mitochondrial mistargeting), p.Gly82Glu (prevention of cofactor binding), p.Gly41Arg (protein aggregation) [<xref ref-type="bibr" rid="ph1.REF.danpure.2004.e39">Danpure 2004</xref>, <xref ref-type="bibr" rid="ph1.REF.danpure.2004.1">Danpure &#x00026; Rumsby 2004</xref>, <xref ref-type="bibr" rid="ph1.REF.danpure.2006.1776">Danpure 2006</xref>], p.Gly47Arg (affects dimerization), and p.Ser81Leu (no effect on dimerization) [<xref ref-type="bibr" rid="ph1.REF.robbiano.2010.667">Robbiano et al 2010</xref>]. See <bold>Pathogenic allelic variants</bold> for additional descriptions of abnormal proteins.</p>
        </sec>
      </sec>
      <sec id="ph1.References">
        <title>References</title>
        <sec id="ph1.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="ph1.Literature_Cited.reflist0">
            <ref id="ph1.REF.aboumarzouk.2012.cd006029">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Aboumarzouk</surname>
                    <given-names>OM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kata</surname>
                    <given-names>SG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Keeley</surname>
                    <given-names>FX</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McClinton</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nabi</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Extracorporeal shock wave lithotripsy (ESWL) versus ureteroscopic management for ureteric calculi.</article-title>
                <source>Cochrane Database Syst Rev.</source>
                <year>2012</year>
                <volume>5</volume>
                <fpage>CD006029</fpage>
                <pub-id pub-id-type="pmid">22592707</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.alabadi.2013.1085">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Al-Abadi</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hulton</surname>
                    <given-names>SA</given-names>
                  </name>
                </person-group>
                <year>2013</year>
                <article-title>Extracorporal shock wave lithotripsy in the management of stones in children with oxalosis--still the first choice?</article-title>
                <source>Pediatr Nephrol</source>
                <volume>28</volume>
                <fpage>1085</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">23397522</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.aleisa.2004.1788">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Al-Eisa</surname>
                    <given-names>AA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Samhan</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Naseef</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>End-stage renal disease in Kuwaiti children: an 8-year experience.</article-title>
                <source>Transplant Proc</source>
                <volume>36</volume>
                <fpage>1788</fpage>
                <lpage>91</lpage>
                <pub-id pub-id-type="pmid">15350478</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.alfadhel.2012.373">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Alfadhel</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alhasan</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alotaibi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al Fakeeh</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Extreme intrafamilial variability of Saudi brothers with primary hyperoxaluria type 1.</article-title>
                <source>Ther Clin Risk Manag</source>
                <volume>8</volume>
                <fpage>373</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">22956877</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.amoroso.2001.2072">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Amoroso</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pirulli</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Florian</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Puzzer</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boniotto</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crovella</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zezlina</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spano</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mazzola</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Savoldi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferrettini</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berutti</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Petrarulo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marangella</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>AGXT gene mutations and their influence on clinical heterogeneity of type 1 primary hyperoxaluria.</article-title>
                <source>J Am Soc Nephrol</source>
                <volume>12</volume>
                <fpage>2072</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">11562405</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.applegarth.2000.e10">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Applegarth</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Toone</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lowry</surname>
                    <given-names>RB</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Incidence of inborn errors of metabolism in British Columbia, 1969-1996.</article-title>
                <source>Pediatrics</source>
                <volume>105</volume>
                <fpage>e10</fpage>
                <pub-id pub-id-type="pmid">10617747</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.asplin.2007.565">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Asplin</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coe</surname>
                    <given-names>FL</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Hyperoxaluria in kidney stone formers treated with modern bariatric surgery.</article-title>
                <source>J Urol</source>
                <volume>177</volume>
                <fpage>565</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">17222634</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.azcarateperil.2006.1891">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Azcarate-Peril</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bruno-Barcena</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hassan</surname>
                    <given-names>HM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klaenhammer</surname>
                    <given-names>TR</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Transcriptional and functional analysis of oxalyl-coenzyme A (CoA) decarboxylase and formyl-CoA transferase genes from Lactobacillus acidophilus.</article-title>
                <source>Appl Environ Microbiol</source>
                <volume>72</volume>
                <fpage>1891</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">16517636</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.barrett.1999">
              <mixed-citation publication-type="book">Barrett TM, Danpure CJ. Hyperoxalurias. In: Barrett TM, Avner ED, Harmon WE, eds. <italic toggle="yes">Pediatric Nephrology</italic>. 4 ed. Baltimore, MD: Lippincott Williams and Wilkens; 1999:609-19.</mixed-citation>
            </ref>
            <ref id="ph1.REF.beck.2006.984">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Beck</surname>
                    <given-names>BB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoppe</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Is there a genotype-phenotype correlation in primary hyperoxaluria type1?</article-title>
                <source>Kidney Int</source>
                <volume>70</volume>
                <fpage>984</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">16957746</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.beck.2012.2984">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Beck</surname>
                    <given-names>BB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Habbig</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dittrich</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stippel</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaul</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koerber</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goebel</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salido</surname>
                    <given-names>EC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kemper</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meyburg</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoppe</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Liver cell transplantation in severe infantile oxalosis &#x02013; a potential bridging procedure to orthotopic liver transplantation.</article-title>
                <source>Nephrol Dial Transplant</source>
                <volume>27</volume>
                <fpage>2984</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">22287658</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.behnam.2006.409">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Behnam</surname>
                    <given-names>JT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Williams</surname>
                    <given-names>EL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brink</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rumsby</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Danpure</surname>
                    <given-names>CJ</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Reconstruction of human hepatocyte glyoxylate metabolic pathways in stably transformed Chinese hamster ovary cells.</article-title>
                <source>Biochem J</source>
                <volume>394</volume>
                <fpage>409</fpage>
                <lpage>16</lpage>
                <pub-id pub-id-type="pmid">16309382</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.behnke.2001.2236">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Behnke</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kemper</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kruse</surname>
                    <given-names>HP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>M&#x000fc;ller-Wiefel</surname>
                    <given-names>DE</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Bone mineral density in children with primary hyperoxaluria type I.</article-title>
                <source>Nephrol Dial Transplant.</source>
                <volume>16</volume>
                <fpage>2236</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">11682674</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.belostotsky.2010.392">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Belostotsky</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sebourn</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Idelson</surname>
                    <given-names>GH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Milliner</surname>
                    <given-names>DS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Becker-Cohen</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rinat</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Monico</surname>
                    <given-names>CG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feinstein</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ben-Shalom</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Magen</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weissman</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Charon</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frishberg</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Mutations in DHDPSL are responsible for primary hyperoxaluria type III</article-title>
                <source>Am J Hum Genet</source>
                <volume>87</volume>
                <fpage>392</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">20797690</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.belostotsky.2012.1497">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Belostotsky</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pitt</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frishberg</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Primary hyperoxaluria type III &#x02013; a model for studying perturbations in glyoxylate metabolism.</article-title>
                <source>J Mol Med</source>
                <volume>90</volume>
                <fpage>1497</fpage>
                <lpage>504</lpage>
                <pub-id pub-id-type="pmid">22729392</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.bergstralh.2010.2493">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bergstralh</surname>
                    <given-names>EJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Monico</surname>
                    <given-names>CG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lieske</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Herges</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Langman</surname>
                    <given-names>CB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoppe</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Milliner</surname>
                    <given-names>DS</given-names>
                  </name>
                </person-group>
                <article-title>IPHR Investigators. Transplantation outcomes in primary hyperoxaluria.</article-title>
                <source>Am J Transplant.</source>
                <year>2010</year>
                <month>Nov</month>
                <volume>10</volume>
                <issue>11</issue>
                <fpage>2493</fpage>
                <lpage>501</lpage>
                <pub-id pub-id-type="pmid">20849551</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.bobrowski.2008.152">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bobrowski</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Langman</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>The primary hyperoxalurias.</article-title>
                <source>Semin Nephrol</source>
                <volume>28</volume>
                <fpage>152</fpage>
                <lpage>62</lpage>
                <pub-id pub-id-type="pmid">18359396</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.buchman.1995.24">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Buchman</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moukarzel</surname>
                    <given-names>AA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ament</surname>
                    <given-names>ME</given-names>
                  </name>
                </person-group>
                <year>1995</year>
                <article-title>Excessive urinary oxalate excretion occurs in long-term TPN patients both with and without ileostomies.</article-title>
                <source>J Am Coll Nutr</source>
                <volume>14</volume>
                <fpage>24</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">7706606</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.campieri.2001.1097">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Campieri</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Campieri</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertuzzi</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Swennen</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matteuzzi</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stefoni</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pirovano</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Centi</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ulisse</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Famularo</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Simone</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Reduction of oxaluria after an oral course of lactic acid bacteria at high concentration.</article-title>
                <source>Kidney Int</source>
                <volume>60</volume>
                <fpage>1097</fpage>
                <lpage>105</lpage>
                <pub-id pub-id-type="pmid">11532105</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.cellini.2007.39">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cellini</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertoldi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Montioli</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paiardini</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Voltattorni</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Human wild-type alanine:glyoxylate aminotransferase and its naturally occurring G82E variant: functional properties and physiological implications.</article-title>
                <source>Biochem J</source>
                <volume>408</volume>
                <fpage>39</fpage>
                <lpage>50</lpage>
                <pub-id pub-id-type="pmid">17696873</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.cellini.2010a.1801">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cellini</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lorezetto</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Montioli</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oppici</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Voltattorni</surname>
                    <given-names>CB</given-names>
                  </name>
                </person-group>
                <year>2010a</year>
                <article-title>Human liver peroxisomal alanine:glyoxylate aminotransferase: Different stability under chemical stress of the major allele, the minor allele, and its pathogenic G170R variant.</article-title>
                <source>Biochimie</source>
                <volume>92</volume>
                <fpage>1801</fpage>
                <lpage>11</lpage>
                <pub-id pub-id-type="pmid">20713123</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.cellini.2014.158">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cellini</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Montioli</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oppici</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Astegno</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Voltattorni</surname>
                    <given-names>CB</given-names>
                  </name>
                </person-group>
                <article-title>The chaperone role of the pyridoxal 5'-phosphate and its implications for rare diseases involving B6-dependent enzymes.</article-title>
                <source>Clin Biochem.</source>
                <year>2014</year>
                <volume>47</volume>
                <fpage>158</fpage>
                <lpage>65</lpage>
                <pub-id pub-id-type="pmid">24355692</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.cellini.2010b.2896">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cellini</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Montioli</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paiardini</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lorenzetto</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maset</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bellini</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oppici</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Voltattorni</surname>
                    <given-names>CB</given-names>
                  </name>
                </person-group>
                <year>2010b</year>
                <article-title>Molecular defects of the glycine 41 variants of alanine:glyoxylate aminotransferase associated with primary hyperoxaluria type 1.</article-title>
                <source>Proc Nat Acad Sci</source>
                <volume>107</volume>
                <fpage>2896</fpage>
                <lpage>901</lpage>
                <pub-id pub-id-type="pmid">20133649</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.cellini.2009.8349">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cellini</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Montioli</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paiardini</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lorenzetto</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Voltatorni</surname>
                    <given-names>CB</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Molecular insight into the synergism between the minor allele of human liver peroxisomal alanine:glyoxylate aminotransferase and the F152I mutation.</article-title>
                <source>J Biol Chem</source>
                <volume>284</volume>
                <fpage>8349</fpage>
                <lpage>58</lpage>
                <pub-id pub-id-type="pmid">19155213</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.cellini.2011.1577">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cellini</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Montioli</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Voltattorni</surname>
                    <given-names>CB</given-names>
                  </name>
                </person-group>
                <article-title>Human liver peroxisomal alanine:glyoxylate aminotransferase: characterization of the two allelic forms and their pathogenic variants.</article-title>
                <source>Biochim Biophys Acta.</source>
                <year>2011</year>
                <month>Nov</month>
                <volume>1814</volume>
                <issue>11</issue>
                <fpage>1577</fpage>
                <lpage>84</lpage>
                <pub-id pub-id-type="pmid">21176891</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.cellini.2012.621">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cellini</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oppici</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paiardini</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Montioli</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <article-title>Molecular insights into primary hyperoxaluria type 1 pathogenesis.</article-title>
                <source>Front Biosci (Landmark Ed)</source>
                <year>2012</year>
                <volume>17</volume>
                <fpage>621</fpage>
                <lpage>34</lpage>
                <pub-id pub-id-type="pmid">22201765</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.chand.2009.670">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chand</surname>
                    <given-names>AQ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaskel</surname>
                    <given-names>FJ</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Timely diagnosis of primary hyperoxaluria type 1.</article-title>
                <source>Nat Rev Nephrol</source>
                <volume>5</volume>
                <fpage>670</fpage>
                <lpage>1</lpage>
                <pub-id pub-id-type="pmid">19935811</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.chetyrkin.2005.53">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chetyrkin</surname>
                    <given-names>SV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kim</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Belmont</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scheinman</surname>
                    <given-names>JI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hudson</surname>
                    <given-names>BG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Voziyan</surname>
                    <given-names>PA</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Pyridoxamine lowers kidney crystals in experimental hyperoxaluria: a potential therapy for primary hyperoxaluria.</article-title>
                <source>Kidney Int</source>
                <volume>67</volume>
                <fpage>53</fpage>
                <lpage>60</lpage>
                <pub-id pub-id-type="pmid">15610227</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.chevalierporst.2005.80">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chevalier-Porst</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rolland</surname>
                    <given-names>MO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cochat</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bozon</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Maternal isodisomy of the telomeric end of chromosome 2 is responsible for a case of primary hyperoxaluria type 1.</article-title>
                <source>Am J Med Genet A</source>
                <volume>132A</volume>
                <fpage>80</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">15580638</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.ciacci.2008.974">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ciacci</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spagnuolo</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tortora</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bucci</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Franzese</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zingone</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cirillo</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Urinary stone disease in adults with celiac disease: prevalence, incidence and urinary determinants.</article-title>
                <source>J Urol.</source>
                <volume>180</volume>
                <fpage>974</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">18639267</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.cimino.2005.341">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cimino</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ranno</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garozzo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reggio</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Battaglia</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maugeri</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ventimiglia</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <comment>[Primary hyperoxaluria and pregnancy]</comment>
                <source>Minerva Urol Nefrol</source>
                <volume>57</volume>
                <fpage>341</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">16247357</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.cochat.2010.590">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cochat</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fargue</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harambat</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Primary hyperoxaluria type 1: strategy for organ transplantation.</article-title>
                <source>Curr Opin Organ Transplant</source>
                <volume>15</volume>
                <fpage>590</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">20733487</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.cochat.1999.746">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cochat</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koch Nogueira</surname>
                    <given-names>PC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mahmoud</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jamieson</surname>
                    <given-names>NV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scheinman</surname>
                    <given-names>JI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rolland</surname>
                    <given-names>MO</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Primary hyperoxaluria in infants: medical, ethical, and economic issues.</article-title>
                <source>J Pediatr</source>
                <volume>135</volume>
                <fpage>746</fpage>
                <lpage>50</lpage>
                <pub-id pub-id-type="pmid">10586179</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.cochat.2006.1075">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cochat</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liutkus</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fargue</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Basmaison</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ranchin</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rolland</surname>
                    <given-names>MO</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Primary hyperoxaluria type 1: still challenging!</article-title>
                <source>Pediatr Nephrol</source>
                <volume>21</volume>
                <fpage>1075</fpage>
                <lpage>81</lpage>
                <pub-id pub-id-type="pmid">16810517</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.cochat.2003">
              <mixed-citation publication-type="book">Cochat P, Rolland M-O. The primary hyperoxalurias. In: Davison AM, Cameron JS, Grunfeld JP, Ponticelli C, Ritz E, Winearls CG, Van Ypersele C, eds. <italic toggle="yes">Oxford Textbook of Clinical Nephrology</italic>. New York, NY: Oxford University Press; 2003:2374-80.</mixed-citation>
            </ref>
            <ref id="ph1.REF.cochat.2012.1729">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cochat</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hulton</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Acquaviva</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Danpure</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Daudon</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Marchi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fargue</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Groothoff</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harambat</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoppe</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jamieson</surname>
                    <given-names>NV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kemper</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mandrile</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marangella</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Picca</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rumsby</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salido</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Straub</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Woerden</surname>
                    <given-names>CS</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Primary hyerpoxaluria type 1: indications for screening and guidance for diagnosis and treatment.</article-title>
                <source>Nephrol Dial Transplant</source>
                <volume>27</volume>
                <fpage>1729</fpage>
                <lpage>36</lpage>
                <pub-id pub-id-type="pmid">22547750</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.cochat.2013.649">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cochat</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rumsby</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2013</year>
                <article-title>Primary hyperoxaluria.</article-title>
                <source>New Engl J Med</source>
                <volume>369</volume>
                <fpage>649</fpage>
                <lpage>58</lpage>
                <pub-id pub-id-type="pmid">23944302</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.coultermackie.2005.264">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Coulter-Mackie</surname>
                    <given-names>MB</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Preliminary evidence for ethnic differences in primary hyperoxaluria type 1 genotype.</article-title>
                <source>Am J Nephrol</source>
                <volume>25</volume>
                <fpage>264</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">15961945</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.coultermackie.2006.1891">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Coulter-Mackie</surname>
                    <given-names>MB</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>4-hydroxyproline metabolism and glyxoylate production: A target for substrate depletion in primary hyperoxaluria?</article-title>
                <source>Kidney Int</source>
                <volume>70</volume>
                <fpage>1891</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">17130820</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.coultermackie.2004.64">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Coulter-Mackie</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Applegarth</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Toone</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Henderson</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>The major allele of the alanine:glyoxylate aminotransferase gene: seven novel mutations causing primary hyperoxaluria type 1.</article-title>
                <source>Mol Genet Metab</source>
                <volume>82</volume>
                <fpage>64</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">15110324</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.coultermackie.2008.368">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Coulter-Mackie</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lian</surname>
                    <given-names>Q</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Partial trypsin digestion as an indicator of mis-folding of mutant alanine:glyoxylate aminotransferase and chaperone effects of specific ligands. Study of a spectrum of missense mutants.</article-title>
                <source>Mol Genet Metab</source>
                <volume>94</volume>
                <fpage>368</fpage>
                <lpage>74</lpage>
                <pub-id pub-id-type="pmid">18448374</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.coultermackie.2005.172">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Coulter-Mackie</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lian</surname>
                    <given-names>Q</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Applegarth</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Toone</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>The major allele of the alanine:glyoxylate aminotransferase gene: nine novel mutations and polymorphisms associated with primary hyperoxaluria type 1.</article-title>
                <source>Mol Genet Metab</source>
                <volume>86</volume>
                <fpage>172</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">15963748</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.coultermackie.2008.598">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Coulter-Mackie</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lian</surname>
                    <given-names>Q</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Applegarth</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Toone</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waters</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vallance</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Mutation-based diagnostic testing for primary hyperoxaluria type 1: survey of results.</article-title>
                <source>Clin Biochem</source>
                <volume>41</volume>
                <fpage>598</fpage>
                <lpage>602</lpage>
                <pub-id pub-id-type="pmid">18282470</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.coultermackie.2006.349">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Coulter-Mackie</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lian</surname>
                    <given-names>Q</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Consequences of missense mutations for dimerization and turnover of alanine:glyoxylate aminotransferase: Study of a spectrum of mutations.</article-title>
                <source>Mol Genet Metab</source>
                <volume>89</volume>
                <fpage>349</fpage>
                <lpage>59</lpage>
                <pub-id pub-id-type="pmid">16971151</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.coultermackie.2004.38">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Coulter-Mackie</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rumsby</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Genetic heterogeneity in primary hyperoxaluria type 1: impact on diagnosis.</article-title>
                <source>Mol Genet Metab</source>
                <volume>83</volume>
                <fpage>38</fpage>
                <lpage>46</lpage>
                <pub-id pub-id-type="pmid">15464418</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.coultermackie.2001.314">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Coulter-Mackie</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rumsby</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Applegarth</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Toone</surname>
                    <given-names>JR</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Three novel deletions in the alanine:glyoxylate aminotransferase gene of three patients with type 1 hyperoxaluria.</article-title>
                <source>Mol Genet Metab</source>
                <volume>74</volume>
                <fpage>314</fpage>
                <lpage>21</lpage>
                <pub-id pub-id-type="pmid">11708860</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.coultermackie.2003.44">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Coulter-Mackie</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tung</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Henderson</surname>
                    <given-names>HE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Toone</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Applegarth</surname>
                    <given-names>DA</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>The AGT gene in Africa: a distinctive minor allele haplotype, a polymorphism (V326I), and a novel PH1 mutation (A112D) in Black Africans.</article-title>
                <source>Mol Genet Metab</source>
                <volume>78</volume>
                <fpage>44</fpage>
                <lpage>50</lpage>
                <pub-id pub-id-type="pmid">12559847</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.cregeen.2003.497">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cregeen</surname>
                    <given-names>DP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Williams</surname>
                    <given-names>EL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hulton</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rumsby</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Molecular analysis of the glyoxylate reductase (GPHPR) gene and description of mutations underlying primary hyperoxaluria type 2.</article-title>
                <source>Hum Mutat</source>
                <volume>22</volume>
                <fpage>497</fpage>
                <pub-id pub-id-type="pmid">14635115</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.danpure.2004.e39">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Danpure</surname>
                    <given-names>CJ</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Molecular aetiology of primary hyperoxaluria type 1.</article-title>
                <source>Nephron Exp Nephrol</source>
                <volume>98</volume>
                <fpage>e39</fpage>
                <lpage>e44</lpage>
                <pub-id pub-id-type="pmid">15499210</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.danpure.2006.1776">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Danpure</surname>
                    <given-names>CJ</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Primary hyperoxaluria type 1: AGT mistargeting highlights the fundamental differences between the peroxisomal and mitochondrial protein import pathways.</article-title>
                <source>Biochim Biophys Acta</source>
                <volume>1763</volume>
                <fpage>1776</fpage>
                <lpage>84</lpage>
                <pub-id pub-id-type="pmid">17027096</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.danpure.1998.8">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Danpure</surname>
                    <given-names>CJ</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>The molecular basis of alanine: glyoxylate aminotransferase mistargeting: the most common single cause of primary hyperoxaluria type 1.</article-title>
                <source>J Nephrol</source>
                <volume>11</volume>
                <fpage>8</fpage>
                <lpage>12</lpage>
                <pub-id pub-id-type="pmid">9604801</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.danpure.2001">
              <mixed-citation publication-type="webpage">Danpure CJ. Primary hyperoxaluria. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, Gibson K, Mitchell G, eds. <italic toggle="yes">The Online Metabolic and Molecular Bases of Inherited Disease (OMMBID).</italic> Chap 133. 8 ed. New York, NY: McGraw-Hill. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://ommbid.mhmedical.com/">online</ext-link>. 2001:3323-67.</mixed-citation>
            </ref>
            <ref id="ph1.REF.danpure.2005a.1525">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Danpure</surname>
                    <given-names>CJ</given-names>
                  </name>
                </person-group>
                <year>2005a</year>
                <article-title>Primary hyperoxaluria: from gene defects to designer drugs?</article-title>
                <source>Nephrol Dial Transplant</source>
                <volume>20</volume>
                <fpage>1525</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">15956068</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.danpure.2005b.303">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Danpure</surname>
                    <given-names>CJ</given-names>
                  </name>
                </person-group>
                <year>2005b</year>
                <article-title>Molecular etiology of primary hyperoxaluria type 1: new directions for treatment.</article-title>
                <source>Am J Nephrol</source>
                <volume>25</volume>
                <fpage>303</fpage>
                <lpage>10</lpage>
                <pub-id pub-id-type="pmid">15961951</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.danpure.1994a.55">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Danpure</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Birdsey</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rumsby</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lumb</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Purdue</surname>
                    <given-names>PE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Allsop</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>1994a</year>
                <article-title>Molecular characterization and clinical use of a polymorphic tandem repeat in an intron of the human alanine:glyoxylate aminotransferase gene.</article-title>
                <source>Hum Genet</source>
                <volume>94</volume>
                <fpage>55</fpage>
                <lpage>64</lpage>
                <pub-id pub-id-type="pmid">8034295</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.danpure.1994b.487">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Danpure</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jennings</surname>
                    <given-names>PR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fryer</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Purdue</surname>
                    <given-names>PE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Allsop</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>1994b</year>
                <article-title>Primary hyperoxaluria type 1: genotypic and phenotypic heterogeneity.</article-title>
                <source>J Inherit Metab Dis</source>
                <volume>17</volume>
                <fpage>487</fpage>
                <lpage>99</lpage>
                <pub-id pub-id-type="pmid">7967498</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.danpure.1989.271">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Danpure</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jennings</surname>
                    <given-names>PR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Penketh</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wise</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cooper</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodeck</surname>
                    <given-names>CH</given-names>
                  </name>
                </person-group>
                <year>1989</year>
                <article-title>Fetal liver alanine: glyoxylate aminotransferase and the prenatal diagnosis of primary hyperoxaluria type 1.</article-title>
                <source>Prenat Diagn</source>
                <volume>9</volume>
                <fpage>271</fpage>
                <lpage>81</lpage>
                <pub-id pub-id-type="pmid">2717533</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.danpure.1993.417">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Danpure</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Purdue</surname>
                    <given-names>PE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fryer</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Griffiths</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Allsop</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lumb</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guttridge</surname>
                    <given-names>KM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jennings</surname>
                    <given-names>PR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scheinman</surname>
                    <given-names>JI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mauer</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Davidson</surname>
                    <given-names>NO</given-names>
                  </name>
                </person-group>
                <year>1993</year>
                <article-title>Enzymological and mutational analysis of a complex primary hyperoxaluria type 1 phenotype involving alanine:glyoxylate aminotransferase peroxisome-to-mitochondrion mistargeting and intraperoxisomal aggregation.</article-title>
                <source>Am J Hum Genet</source>
                <volume>53</volume>
                <fpage>417</fpage>
                <lpage>32</lpage>
                <pub-id pub-id-type="pmid">8101040</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.danpure.2004.1">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Danpure</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rumsby</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Molecular aetiology of primary hyperoxaluria and its implications for clinical management.</article-title>
                <source>Expert Rev Mol Med</source>
                <volume>6</volume>
                <fpage>1</fpage>
                <lpage>16</lpage>
                <pub-id pub-id-type="pmid">14987413</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.daudon.2008.100">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Daudon</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jungers</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bazin</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Peculiar morphology of stones in primary hyperoxaluria.</article-title>
                <source>N Engl J Med</source>
                <volume>359</volume>
                <fpage>100</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">18596285</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.devriendt.2011.107">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Devriendt</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Damry</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hall</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mesquita</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Avni</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>A rare case of primary hyperoxaluria type 1 co-existing with autosomal dominant polycystic kidney disease in a newborn.</article-title>
                <source>Pediatr Radiol</source>
                <volume>41</volume>
                <fpage>107</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">20490484</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.diallo.2004.1767">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Diallo</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Janssens</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hall</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Avni</surname>
                    <given-names>EF</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Type 1 primary hyperoxaluria in pediatric patients: renal sonographic patterns.</article-title>
                <source>AJR Am J Roentgenol</source>
                <volume>183</volume>
                <fpage>1767</fpage>
                <lpage>70</lpage>
                <pub-id pub-id-type="pmid">15547226</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.djordjevic.2010.233">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Djordjevic</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bartlam</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ye</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rao</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Danpure</surname>
                    <given-names>CJ</given-names>
                  </name>
                </person-group>
                <article-title>Structural implications of a G170R mutation of alanine:glyoxylate aminotransferase that is associated with peroxisome-to-mitochondrion mistargeting.</article-title>
                <source>Acta Crystallogr Sect F Struct Biol Cryst Commun.</source>
                <year>2010</year>
                <volume>66</volume>
                <fpage>233</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">20208150</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.donini.2009.265">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Donini</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferrari</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fedeli</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Faini</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lamberto</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marletta</surname>
                    <given-names>AS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mellini</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Panini</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Percudani</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pollegioni</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caldinelli</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Petrucco</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peracchi</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Recombinant production of eight human cytosolic aminotransferases and assessment of their potential involvement in glyoxylate metabolism.</article-title>
                <source>Biochem J</source>
                <volume>422</volume>
                <fpage>265</fpage>
                <lpage>72</lpage>
                <pub-id pub-id-type="pmid">19545238</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.duffey.2008.1145">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Duffey</surname>
                    <given-names>BG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pedro</surname>
                    <given-names>RN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Makhlouf</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kriedberg</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stessman</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hinck</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ikramuddin</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kellogg</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Slusarek</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Monga</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Roux-en-Y gastric bypass is associated with early increased risk factors for development of calcium oxalate nephrolithiasis.</article-title>
                <source>J Am Coll Surg</source>
                <volume>206</volume>
                <fpage>1145</fpage>
                <lpage>53</lpage>
                <pub-id pub-id-type="pmid">18501812</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.edvardsson.2013.1923">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Edvardsson</surname>
                    <given-names>VO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goldfarb</surname>
                    <given-names>DS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lieske</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beara-Lasic</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Auglani</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Milliner</surname>
                    <given-names>DS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Palsson</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2013</year>
                <article-title>Hereditary causes of kidney stones and chronic kidney disease.</article-title>
                <source>Pediatr Nephrol</source>
                <volume>28</volume>
                <fpage>1923</fpage>
                <lpage>42</lpage>
                <pub-id pub-id-type="pmid">23334384</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.elias.2013.2739">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Elias</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kawai</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ko</surname>
                    <given-names>DS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saidi</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tolkoff-Rubin</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wicky</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cosimi</surname>
                    <given-names>AB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hertl</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2013</year>
                <article-title>Native portal vein embolization for persistent hyperoxaluria following kidney and auxiliary partial liver transplantation.</article-title>
                <source>Am J Transplant</source>
                <volume>13</volume>
                <fpage>2739</fpage>
                <lpage>42</lpage>
                <pub-id pub-id-type="pmid">23915277</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.fargue.2009.767">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fargue</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harambat</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gagnadoux</surname>
                    <given-names>M-F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsimaratos</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Janssen</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Llanas</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertheleme</surname>
                    <given-names>J-P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boudailliez</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Champion</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guyot</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Macher</surname>
                    <given-names>M-Q</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nivet</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ranchin</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salomon</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taque</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rolland</surname>
                    <given-names>M-O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cochat</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Effect of conservative treatment on the renal outcome of children with primary hyperoxaluria type 1.</article-title>
                <source>Kidney Int</source>
                <volume>76</volume>
                <fpage>767</fpage>
                <lpage>73</lpage>
                <pub-id pub-id-type="pmid">19571789</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.fargue.2013a.1776">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fargue</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rumsby</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Danpure</surname>
                    <given-names>CJ</given-names>
                  </name>
                </person-group>
                <year>2013a</year>
                <article-title>Multiple mechanisms of action of pyridoxine in primary hyperoxaluria type 1.</article-title>
                <source>Biochim Biophys Acta</source>
                <volume>1832</volume>
                <fpage>1776</fpage>
                <lpage>83</lpage>
                <pub-id pub-id-type="pmid">23597595</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.fargue.2013b.2475">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fargue</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lewin</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rumsby</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Danpure</surname>
                    <given-names>CJ</given-names>
                  </name>
                </person-group>
                <year>2013b</year>
                <article-title>Four of the most common mutations in primary hyperoxaluria type 1 unmask the cryptic mitochondrial targeting sequence of alanine:glyoxylate aminotransferase encoded by the polymorphic minor allele.</article-title>
                <source>J Biol Chem</source>
                <volume>288</volume>
                <fpage>2475</fpage>
                <lpage>84</lpage>
                <pub-id pub-id-type="pmid">23229545</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.fishbein.2008.117">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fishbein</surname>
                    <given-names>GA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Micheletti</surname>
                    <given-names>RG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Currier</surname>
                    <given-names>JS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Singer</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fishbein</surname>
                    <given-names>MC</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Atherosclerotic oxalosis in coronary arteries.</article-title>
                <source>Cardiovasc Pathol</source>
                <volume>17</volume>
                <fpage>117</fpage>
                <lpage>23</lpage>
                <pub-id pub-id-type="pmid">18329558</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.frishberg.2005.269">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Frishberg</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rinat</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shalata</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Khatib</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feinstein</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Becker-Cohen</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weismann</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rumsby</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roels</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mandel</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Intra-familial clinical heterogeneity: absence of genotype-phenotype correlation in primary hyperoxaluria type 1 in Israel.</article-title>
                <source>Am J Nephrol</source>
                <volume>25</volume>
                <fpage>269</fpage>
                <lpage>75</lpage>
                <pub-id pub-id-type="pmid">15961946</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.fodor.2012.e1001309">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fodor</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wolf</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Erdmann</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schliebs</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilmanns</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Molecular requirements for peroxisomal targeting of alanine-glyoxylate aminotransferase as an essential determinant in primary hyperoxaluria type 1.</article-title>
                <source>PLoS Biol.</source>
                <year>2012</year>
                <volume>10</volume>
                <fpage>e1001309</fpage>
                <pub-id pub-id-type="pmid">22529745</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.getting.2013.768">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Getting</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gregoire</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Phul</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kasten</surname>
                    <given-names>MJ</given-names>
                  </name>
                </person-group>
                <year>2013</year>
                <article-title>Oxalate nephropathy due to &#x02018;juicing&#x02019;: case report and review.</article-title>
                <source>Am J Med</source>
                <volume>126</volume>
                <fpage>768</fpage>
                <lpage>72</lpage>
                <pub-id pub-id-type="pmid">23830537</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.giardina.2014.m384">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Giardina</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scilironi</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Michelotti</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Samuele</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Borella</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Daglia</surname>
                    <given-names>M.</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marzatico</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>2014</year>
                <article-title>In vitro anti-inflammatory activity of selected oxalate-degrading probiotic bacteria: potential applications in the prevention and treatment of hyperoxaluria.</article-title>
                <source>J Food Sci</source>
                <volume>79</volume>
                <fpage>M384</fpage>
                <lpage>90</lpage>
                <pub-id pub-id-type="pmid">24471378</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.grujic.2009.86">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Grujic</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salido</surname>
                    <given-names>EC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shenoy</surname>
                    <given-names>BC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Langman</surname>
                    <given-names>CB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McGrath</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Patel</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rashid</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mandapati</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jung</surname>
                    <given-names>CW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Margolin</surname>
                    <given-names>AL</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Hyperoxaluria is reduced and nephrocalcinosis prevented with an oxalate-degrading enzyme in mice with hyperoxaluria.</article-title>
                <source>Am J Nephrol</source>
                <volume>29</volume>
                <fpage>86</fpage>
                <lpage>93</lpage>
                <pub-id pub-id-type="pmid">18698135</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.guha.2005.161">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Guha</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamanouchi</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jiang</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roy Chowdhury</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santana</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shapiro</surname>
                    <given-names>LJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salido</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roy-Chowdhury</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Feasibility of hepatocyte transplantation-based therapies for primary hyperoxalurias.</article-title>
                <source>Am J Nephrol</source>
                <volume>25</volume>
                <fpage>161</fpage>
                <lpage>70</lpage>
                <pub-id pub-id-type="pmid">15849463</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.harambat.2010.443">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Harambat</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fargue</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Acquaviva</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gagnadoux</surname>
                    <given-names>MF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Janssen</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liutkus</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mourani</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Macher</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abramowicz</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Legendre</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Durrbach</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsimaratos</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nivet</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Girardin</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schott</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rolland</surname>
                    <given-names>MO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cochat</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Genotype-phenotype correlation in primary hyperoxaluria type 1: the p.Gly170Arg AGXT mutation is associated with a better outcome.</article-title>
                <source>Kidney Int.</source>
                <volume>77</volume>
                <fpage>443</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">20016466</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.harambat.2011">
              <mixed-citation publication-type="other">Harambat J, Fargue S, Bacchetta J, Acquaviva C, Cochat P. Primary hyperoxaluria. Int J Nephrol. 2011;2011:864580.</mixed-citation>
            </ref>
            <ref id="ph1.REF.harambat.2012.458">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Harambat</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Stralen</surname>
                    <given-names>KJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Espinosa</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Groothoff</surname>
                    <given-names>JQ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hulton</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cerkausiene</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schaefer</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verrina</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jager</surname>
                    <given-names>KJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cochat</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Characteristics and outcomes of children with primary oxalosis requiring renal replacement therapy.</article-title>
                <source>Clin J Am Soc Nephrol</source>
                <volume>7</volume>
                <fpage>458</fpage>
                <lpage>65</lpage>
                <pub-id pub-id-type="pmid">22223608</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.hatch.2006.691">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hatch</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cornelius</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sidhu</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peck</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Freel</surname>
                    <given-names>RW</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Oxalobacter sp. reduces urinary oxalate excretion by promoting enteric oxalate secretion.</article-title>
                <source>Kidney Int</source>
                <volume>69</volume>
                <fpage>691</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">16518326</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.hatch.2013.379">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hatch</surname>
                    <given-names>M.</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Freel</surname>
                    <given-names>RW</given-names>
                  </name>
                </person-group>
                <year>2013</year>
                <article-title>A human strain of Oxalobacter (HC-1) promotes enteric oxalate secretion in the small intestine of mice and reduces urinary oxalate excretion.</article-title>
                <source>Urolithiasis.</source>
                <volume>41</volume>
                <fpage>379</fpage>
                <lpage>84</lpage>
                <pub-id pub-id-type="pmid">23959075</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.hatch.1995">
              <mixed-citation publication-type="book">Hatch M, Freel RW. Oxalate transport across intestinal and renal epithelia. In: Khan SR, ed. <italic toggle="yes">Calcium Oxalate in Biological Systems.</italic> New York: CRC Press; 1995:217-38.</mixed-citation>
            </ref>
            <ref id="ph1.REF.hatch.2008.143">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hatch</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Freel</surname>
                    <given-names>RW</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>The roles and mechanisms of intestinal oxalate transport in oxalate homeostasis.</article-title>
                <source>Semin Nephrol</source>
                <volume>28</volume>
                <fpage>143</fpage>
                <lpage>51</lpage>
                <pub-id pub-id-type="pmid">18359395</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.hatch.2011.g461">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hatch</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gjymishka</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salido</surname>
                    <given-names>EC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Allison</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Freel</surname>
                    <given-names>RW</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Enteric oxalate elimination is induced and oxalate is normalized in a mouse model of primary hyperoxaluria following intestinal colonization with Oxalobacter.</article-title>
                <source>Am J Physiol Gastrointest Liver Physiol.</source>
                <volume>300</volume>
                <fpage>G461</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">21163900</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.hern_ndezfernaud.2010.4766">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hern&#x000e1;ndez-Fernaud</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salido</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Differential expression of liver and kidney proteins in a mouse model for primary hyperoxaluria type 1.</article-title>
                <source>FEBS Journal</source>
                <volume>277</volume>
                <fpage>4766</fpage>
                <lpage>74</lpage>
                <pub-id pub-id-type="pmid">20977670</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.holmes.1998.1617">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Holmes</surname>
                    <given-names>RP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Assimos</surname>
                    <given-names>DG</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Glyoxylate synthesis, and its modulation and influence on oxalate synthesis.</article-title>
                <source>J Urol</source>
                <volume>160</volume>
                <fpage>1617</fpage>
                <lpage>24</lpage>
                <pub-id pub-id-type="pmid">9783918</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.holmes.2004.311">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Holmes</surname>
                    <given-names>RP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Assimos</surname>
                    <given-names>DG</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>The impact of dietary oxalate on kidney stone formation.</article-title>
                <source>Urol Res</source>
                <volume>32</volume>
                <fpage>311</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">15221245</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.holmes.2000.1662">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Holmes</surname>
                    <given-names>RP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kennedy</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Estimation of the oxalate content of foods and daily oxalate intake.</article-title>
                <source>Kidney Int</source>
                <volume>57</volume>
                <fpage>1662</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">10760101</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.holmes.2001.270">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Holmes</surname>
                    <given-names>RP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goodman</surname>
                    <given-names>HO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Assimos</surname>
                    <given-names>DG</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Contribution of dietary oxalate to urinary oxalate excretion.</article-title>
                <source>Kidney Int</source>
                <volume>59</volume>
                <fpage>270</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">11135080</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.hoppe.2010.383">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hoppe</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Evidence of true genotype-phenotype correlation in primary hyperoxaluria type 1.</article-title>
                <source>Kidney Int</source>
                <volume>77</volume>
                <fpage>383</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">20150937</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.hoppe.2012.467">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hoppe</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>An update on primary hyperoxaluria.</article-title>
                <source>Nat Rev Nephrol</source>
                <volume>8</volume>
                <fpage>467</fpage>
                <lpage>75</lpage>
                <pub-id pub-id-type="pmid">22688746</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.hoppe.2009.1264">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hoppe</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beck</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Milliner</surname>
                    <given-names>DS</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>The primary hyperoxalurias.</article-title>
                <source>Kidney Int.</source>
                <volume>75</volume>
                <fpage>1264</fpage>
                <lpage>71</lpage>
                <pub-id pub-id-type="pmid">19225556</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.hoppe.1997.36">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hoppe</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Danpure</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rumsby</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fryer</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jennings</surname>
                    <given-names>PR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blau</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schubiger</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neuhaus</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leumann</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>1997</year>
                <article-title>A vertical (pseudodominant) pattern of inheritance in the autosomal recessive disease primary hyperoxaluria type 1: lack of relationship between genotype, enzymic phenotype, and disease severity.</article-title>
                <source>Am J Kidney Dis</source>
                <volume>29</volume>
                <fpage>36</fpage>
                <lpage>44</lpage>
                <pub-id pub-id-type="pmid">9002528</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.hoppe.2003.986">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hoppe</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Langman</surname>
                    <given-names>CB</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>A United States survey on diagnosis, treatment, and outcome of primary hyperoxaluria.</article-title>
                <source>Pediatr Nephrol</source>
                <volume>18</volume>
                <fpage>986</fpage>
                <lpage>91</lpage>
                <pub-id pub-id-type="pmid">12920626</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.hoppe.2005.276">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hoppe</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Latta</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>von Schnakenburg</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kemper</surname>
                    <given-names>MJ</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Primary hyperoxaluria &#x02013; the German experience.</article-title>
                <source>Am J Nephrol</source>
                <volume>25</volume>
                <fpage>276</fpage>
                <lpage>81</lpage>
                <pub-id pub-id-type="pmid">15961947</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.hopper.2008.30493">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hopper</surname>
                    <given-names>ED</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pittman</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fitzgerald</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tucker</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>In vivo and in vitro examination of stability of primary hyperoxaluria-associated human alanine:glyoxylate aminotransferase.</article-title>
                <source>J Biol Chem</source>
                <volume>283</volume>
                <fpage>30493</fpage>
                <lpage>502</lpage>
                <pub-id pub-id-type="pmid">18782763</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.horv_th.1994.336">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Horv&#x000e1;th</surname>
                    <given-names>VA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <year>1994</year>
                <article-title>Rapid identification of primary hyperoxaluria type I patients using a novel, fully automated method for measurement of hepatic alanine: glyoxylate aminotransferase.</article-title>
                <source>J Inherit Metab Dis</source>
                <volume>17</volume>
                <fpage>336</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">7807946</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.andy.1995.105">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Andy</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Horv&#x000e1;th</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <article-title>Aminooxy acetic acid: a selective inhibitor of alanine:glyoxylate aminotransferase and its use in the diagnosis of primary hyperoxaluria type I.</article-title>
                <source>Clin Chim Acta.</source>
                <year>1995</year>
                <volume>243</volume>
                <fpage>105</fpage>
                <lpage>14</lpage>
                <pub-id pub-id-type="pmid">8747487</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.hoyerkuhn.2014.468">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hoyer-Kuhn</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kohbrok</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Volland</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Franklin</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beck</surname>
                    <given-names>BB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoppe</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <year>2014</year>
                <article-title>Vitamin B6 in primary hyperoxaluria 1: first prospective trial after 40 years of practice.</article-title>
                <source>Clin J Am Soc Nephrol</source>
                <volume>9</volume>
                <fpage>468</fpage>
                <lpage>77</lpage>
                <pub-id pub-id-type="pmid">24385516</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.jamieson.2000.b32">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jamieson</surname>
                    <given-names>DH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lirenman</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hurley</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coulter-Mackie</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Primary hyperoxaluria.</article-title>
                <source>Pediatr Radiol</source>
                <volume>30</volume>
                <fpage>B32</fpage>
              </element-citation>
            </ref>
            <ref id="ph1.REF.jiang.2008.1253">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jiang</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salido</surname>
                    <given-names>EC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guha</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moitra</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liu</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roy-Chowdhury</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roy-Chowdhury</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Correction of hyperoxaluria by liver repopulation with hepatocytes in a mouse model of primary hyperoxaluria type1.</article-title>
                <source>Transplantation</source>
                <volume>85</volume>
                <fpage>1253</fpage>
                <lpage>60</lpage>
                <pub-id pub-id-type="pmid">18475180</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.kamoun.1996.479">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kamoun</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lakhoua</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>1996</year>
                <article-title>End-stage renal disease of the Tunisian child: epidemiology, etiologies, and outcome.</article-title>
                <source>Pediatr Nephrol</source>
                <volume>10</volume>
                <fpage>479</fpage>
                <lpage>82</lpage>
                <pub-id pub-id-type="pmid">8865247</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.kemper.1997.509">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kemper</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Conrad</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muller-Wiefel</surname>
                    <given-names>DE</given-names>
                  </name>
                </person-group>
                <year>1997</year>
                <article-title>Primary hyperoxaluria type 2.</article-title>
                <source>Eur J Pediatr</source>
                <volume>156</volume>
                <fpage>509</fpage>
                <lpage>12</lpage>
                <pub-id pub-id-type="pmid">9243228</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.khoo.2006.371">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Khoo</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pee</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kamaludin</surname>
                    <given-names>DP</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Infantile primary hyperoxaluria type 1 with end stage renal failure.</article-title>
                <source>Pathology</source>
                <volume>38</volume>
                <fpage>371</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">16916735</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.kim.2005.1738">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kim</surname>
                    <given-names>HH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koh</surname>
                    <given-names>HI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ku</surname>
                    <given-names>BI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>HS</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Late onset primary hyperoxaluria diagnosed after renal transplantation presented with early recurrence of disease.</article-title>
                <source>Nephrol Dial Transplant</source>
                <volume>20</volume>
                <fpage>1738</fpage>
                <lpage>40</lpage>
                <pub-id pub-id-type="pmid">15919697</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.kleinman.2007.8">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kleinman</surname>
                    <given-names>JG</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Bariatric surgery, hyperoxaluria, and nephrolithiasis: a plea for close postoperative management of risk factors.</article-title>
                <source>Kidney Int</source>
                <volume>72</volume>
                <fpage>8</fpage>
                <lpage>10</lpage>
                <pub-id pub-id-type="pmid">17597787</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.knight.2012.f688">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Knight</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holmes</surname>
                    <given-names>RP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cramer</surname>
                    <given-names>SD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takayama</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salido</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <article-title>Hydroxyproline metabolism in mouse models of primary hyperoxaluria.</article-title>
                <source>Am J Physiol Renal Physiol.</source>
                <year>2012</year>
                <volume>302</volume>
                <fpage>F688</fpage>
                <lpage>93</lpage>
                <pub-id pub-id-type="pmid">22189945</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.knight.2006.1929">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Knight</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jiang</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Assimos</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holmes</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Hydroxyproline ingestion and urinary oxalate and glycolate excretion.</article-title>
                <source>Kidney Int</source>
                <volume>70</volume>
                <fpage>1929</fpage>
                <lpage>34</lpage>
                <pub-id pub-id-type="pmid">17021603</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.koul.2005.176">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Koul</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Johnson</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pramanik</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koul</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Cellular transfection to deliver alanine-glyoxylate aminotransferase to hepatocytes: a rational gene therapy for primary hyperoxaluria-1 (PH-1).</article-title>
                <source>Am J Nephrol</source>
                <volume>25</volume>
                <fpage>176</fpage>
                <lpage>82</lpage>
                <pub-id pub-id-type="pmid">15849465</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.kumar.2011.654">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kumar</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lieske</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Collazo-Clavell</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sarr</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olson</surname>
                    <given-names>ER</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vrtiska</surname>
                    <given-names>TJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bergstralh</surname>
                    <given-names>EJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>X</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Fat malabsorption and increased intestinal oxalate absorption are common after Roux-en-Y gastric bypass surgery.</article-title>
                <source>Surgery</source>
                <volume>149</volume>
                <fpage>654</fpage>
                <lpage>61</lpage>
                <pub-id pub-id-type="pmid">21295813</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.leumann.1990.493">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Leumann</surname>
                    <given-names>EP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dietl</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matasovic</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>1990</year>
                <article-title>Urinary oxalate and glycolate excretion in healthy infants and children.</article-title>
                <source>Pediatr Nephrol</source>
                <volume>4</volume>
                <fpage>493</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">2242313</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.leumann.2001.1986">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Leumann</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoppe</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>The primary hyperoxalurias.</article-title>
                <source>J Am Soc Nephrol</source>
                <volume>12</volume>
                <fpage>1986</fpage>
                <lpage>93</lpage>
                <pub-id pub-id-type="pmid">11518794</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.lieske.2005a.1244">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lieske</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goldfarb</surname>
                    <given-names>DS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Simone</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Regnier</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2005a</year>
                <article-title>Use of a probiotic to decrease enteric hyperoxaluria.</article-title>
                <source>Kidney Int</source>
                <volume>68</volume>
                <fpage>1244</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">16105057</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.lieske.2008.163">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lieske</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kumar</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Collazo-Clavell</surname>
                    <given-names>ML</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Nephrolithiasis after bariatric surgery for obesity.</article-title>
                <source>Semin Nephrol</source>
                <volume>28</volume>
                <fpage>163</fpage>
                <lpage>73</lpage>
                <pub-id pub-id-type="pmid">18359397</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.lieske.2005b.290">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lieske</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Monico</surname>
                    <given-names>CG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holmes</surname>
                    <given-names>WS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bergstralh</surname>
                    <given-names>EJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Slezak</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rohlinger</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olson</surname>
                    <given-names>JB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Milliner</surname>
                    <given-names>DS</given-names>
                  </name>
                </person-group>
                <year>2005b</year>
                <article-title>International registry for primary hyperoxaluria.</article-title>
                <source>Am J Nephrol</source>
                <volume>25</volume>
                <fpage>290</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">15961949</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.lieske.2010.1178">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lieske</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tremaine</surname>
                    <given-names>WJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Simone</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O'Connor</surname>
                    <given-names>HM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bergstralh</surname>
                    <given-names>EJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goldfarb</surname>
                    <given-names>DS</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Diet, but not oral probiotics, effectively reduces urinary oxalate excretion and calcium oxalate supersaturation.</article-title>
                <source>Kidney Int</source>
                <volume>78</volume>
                <fpage>1178</fpage>
                <lpage>85</lpage>
                <pub-id pub-id-type="pmid">20736987</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.lorenzo.2006.1115">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lorenzo</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alvarez</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Torres</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Torregrosa</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hernandez</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salido</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Presentation and role of transplantation in adult patients with type 1 primary hyper&#x000ac;oxaluria and the I244T AGXT mutation: single-centre experience.</article-title>
                <source>Kidney Int</source>
                <volume>70</volume>
                <fpage>1115</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">16912707</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.lumb.2003.79">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lumb</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Birdsey</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Danpure</surname>
                    <given-names>CJ</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Correction of an enzyme trafficking defect in hereditary kidney stone disease in vitro.</article-title>
                <source>Biochem J</source>
                <volume>374</volume>
                <fpage>79</fpage>
                <lpage>87</lpage>
                <pub-id pub-id-type="pmid">12737622</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.lumb.2000.36415">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lumb</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Danpure</surname>
                    <given-names>CJ</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Functional synergism between the most common polymorphism in human alanine: glyoxylate aminotransferase and four of the most common disease-causing mutations.</article-title>
                <source>J Biol Chem</source>
                <volume>275</volume>
                <fpage>36415</fpage>
                <lpage>22</lpage>
                <pub-id pub-id-type="pmid">10960483</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.lumb.1999.20587">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lumb</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Drake</surname>
                    <given-names>AF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Danpure</surname>
                    <given-names>CJ</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Effect of N-terminal alpha-helix formation on the dimerization and intracellular targeting of alanine:glyoxylate aminotransferase.</article-title>
                <source>J Biol Chem</source>
                <volume>274</volume>
                <fpage>20587</fpage>
                <lpage>96</lpage>
                <pub-id pub-id-type="pmid">10400689</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.luyckx.2005.s68">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Luyckx</surname>
                    <given-names>VA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brenner</surname>
                    <given-names>BM</given-names>
                  </name>
                </person-group>
                <article-title>Low birth weight, nephron number, and kidney disease.</article-title>
                <source>Kidney Int Suppl.</source>
                <year>2005</year>
                <volume>97</volume>
                <fpage>S68</fpage>
                <lpage>77</lpage>
                <pub-id pub-id-type="pmid">16014104</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.luyckx.2010.898">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Luyckx</surname>
                    <given-names>VA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brenner</surname>
                    <given-names>BM</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>The Clinical Importance of Nephron Mass.</article-title>
                <source>J Am Soc Nephrol</source>
                <volume>21</volume>
                <fpage>898</fpage>
                <lpage>910</lpage>
                <pub-id pub-id-type="pmid">20150537</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.madani.2001.140">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Madani</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Otoukesh</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rastegar</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Why</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Chronic renal failure in Iranian children.</article-title>
                <source>Pediatr Nephrol</source>
                <volume>16</volume>
                <fpage>140</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">11261681</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.madiwale.2008.206">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Madiwale</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murlidharan</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hase</surname>
                    <given-names>NK</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Recurrence of primary hyperoxaluria: an avoidable catastrophe following kidney transplant.</article-title>
                <source>J Postgrad Med</source>
                <volume>54</volume>
                <fpage>206</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">18626169</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.mandrile.2008.309">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mandrile</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robbiano</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giachino</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sebastriano</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dondi</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fenoglio</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stratta</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caruso</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Petrarulo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marangella</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Marchi</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Primary hyperoxaluira: report of an Italian family with clear sex conditioned penetrance.</article-title>
                <source>Urol Res</source>
                <volume>36</volume>
                <fpage>309</fpage>
                <lpage>12</lpage>
                <pub-id pub-id-type="pmid">18985333</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.marangella.1999.301">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Marangella</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Transplantation strategies in type 1 primary hyperoxaluria: the issue of pyridoxine responsiveness.</article-title>
                <source>Nephrol Dial Transplant</source>
                <volume>14</volume>
                <fpage>301</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">10069180</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.marangella.1995">
              <mixed-citation publication-type="book">Marangella M, Petrarulo M. Oxalate measurements in biological fluids. In: Khan SR, ed. <italic toggle="yes">Calcium Oxalate in Biological Systems.</italic> New York, NY: CRC Press; 1995:239-63.</mixed-citation>
            </ref>
            <ref id="ph1.REF.marangella.2001">
              <mixed-citation publication-type="book">Marangella M, Petrarulo M, Vitale C, Bagnis C, Berutti S, Ramello A, Amoroso A. The primary hyperoxalurias. In: Schieppati A, Daina E, Sessa A, Remuzzi G, eds. <italic toggle="yes">Rare Kidney Diseases. Contributions to Nephrology.</italic> Vol 136. Basel, Switzerland: Karger; 2001:11-32</mixed-citation>
            </ref>
            <ref id="ph1.REF.mart_n.2011.227">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mart&#x000ed;n</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mart&#x000ed;n Reyes</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Torres de Rueda</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Toledo Rojas</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jironda</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garc&#x000ed;a</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garc&#x000ed;a de la Oliva</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>P&#x000e9;rez Vaca</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hern&#x000e1;ndez</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Delayed diagnosis of primary hyperoxaluria type in a young patient with advanced chronic renal failure.</article-title>
                <source>Nefrologia</source>
                <volume>31</volume>
                <fpage>227</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">21461022</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.mashour.2000.561">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mashour</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Turner</surname>
                    <given-names>JF</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Merrell</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Acute renal failure, oxalosis, and vitamin C supplementation: a case report and review of the literature.</article-title>
                <source>Chest</source>
                <volume>118</volume>
                <fpage>561</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">10936161</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.matlaga.2012.130">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Matlaga</surname>
                    <given-names>BR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jansen</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meckley</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Byrne</surname>
                    <given-names>TW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lingeman</surname>
                    <given-names>JE</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Treatment of ureteral and renal stones: a systematic review and meta-analysis of randomized, controlled trial.</article-title>
                <source>J Urol.</source>
                <volume>188</volume>
                <fpage>130</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">22591962</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.mayordomocolunga.2011.173">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mayordomo-Colunga</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Riverol</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salido</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santos</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Primary hyperoxaluria in a compound heterozygote infant.</article-title>
                <source>World J Pediatr</source>
                <volume>7</volume>
                <fpage>173</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">20549407</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.mesatorres.2013.e71963">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mesa-Torres</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fabelo-Rosa</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Riverol</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yunta</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Albert</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salido</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pey</surname>
                    <given-names>AL</given-names>
                  </name>
                </person-group>
                <article-title>The role of protein denaturation energetics and molecular chaperones in the aggregation and mistargeting of mutants causing primary hyperoxaluria type I.</article-title>
                <source>PLoS One.</source>
                <year>2013</year>
                <volume>8</volume>
                <fpage>e71963</fpage>
                <pub-id pub-id-type="pmid">24205397</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.millan.2003.1458">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Millan</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berquist</surname>
                    <given-names>WE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>So</surname>
                    <given-names>SK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sarwal</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wayman</surname>
                    <given-names>KI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cox</surname>
                    <given-names>KL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Filler</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salvatierra</surname>
                    <given-names>O</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Esquivel</surname>
                    <given-names>CO</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>One hundred percent patient and kidney allograft survival with simultaneous liver and kidney transplantation in infants with primary hyperoxaluria: a single-center experience.</article-title>
                <source>Transplantation</source>
                <volume>76</volume>
                <fpage>1458</fpage>
                <lpage>63</lpage>
                <pub-id pub-id-type="pmid">14657686</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.milliner.2005.154">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Milliner</surname>
                    <given-names>DS</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>The primary hyperoxalurias: an algorithm for diagnosis.</article-title>
                <source>Am J Nephrol</source>
                <volume>25</volume>
                <fpage>154</fpage>
                <lpage>60</lpage>
                <pub-id pub-id-type="pmid">15855742</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.milliner.2006.27">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Milliner</surname>
                    <given-names>DS</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Stones, bones, and heredity.</article-title>
                <source>Acta Paediatr Suppl</source>
                <volume>95</volume>
                <fpage>27</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">16801162</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.milliner.2001.31">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Milliner</surname>
                    <given-names>DS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilson</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>LH</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Phenotypic expression of primary hyperoxaluria: comparative features of types I and II.</article-title>
                <source>Kidney Int</source>
                <volume>59</volume>
                <fpage>31</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">11135054</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.mitsimponas.2012.e301">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mitsimponas</surname>
                    <given-names>KT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wehrhan</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Falk</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wehrhan</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neukam</surname>
                    <given-names>FW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schlegel</surname>
                    <given-names>KA</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Oral findings associated with primary hyperoxaluria type 1.</article-title>
                <source>J Craniomaxillofac Surg</source>
                <volume>40</volume>
                <fpage>e301</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">22417769</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.monico.2011.151">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Monico</surname>
                    <given-names>CG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Milliner</surname>
                    <given-names>DS</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Genetic determinants of urolithiasis.</article-title>
                <source>Nat Rev Nephrol</source>
                <volume>8</volume>
                <fpage>151</fpage>
                <lpage>62</lpage>
                <pub-id pub-id-type="pmid">22183508</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.monico.2005a.183">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Monico</surname>
                    <given-names>CG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olson</surname>
                    <given-names>JB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Milliner</surname>
                    <given-names>DS</given-names>
                  </name>
                </person-group>
                <year>2005a</year>
                <article-title>Implications of genotype and enzyme phenotype in pyridoxine response of patients with type I primary hyperoxaluria.</article-title>
                <source>Am J Nephrol</source>
                <volume>25</volume>
                <fpage>183</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">15849466</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.monico.2002.392">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Monico</surname>
                    <given-names>CG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Persson</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ford</surname>
                    <given-names>GC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rumsby</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Milliner</surname>
                    <given-names>DS</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Potential mechanisms of marked hyperoxaluria not due to primary hyperoxaluria I or II.</article-title>
                <source>Kidney Int</source>
                <volume>62</volume>
                <fpage>392</fpage>
                <lpage>400</lpage>
                <pub-id pub-id-type="pmid">12110000</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.monico.2005b.1704">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Monico</surname>
                    <given-names>CG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rossetti</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olson</surname>
                    <given-names>JB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Milliner</surname>
                    <given-names>DS</given-names>
                  </name>
                </person-group>
                <year>2005b</year>
                <article-title>Pyridoxine effect in type I primary hyperoxaluria is associated with the most common mutant allele.</article-title>
                <source>Kidney Int</source>
                <volume>67</volume>
                <fpage>1704</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">15840016</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.monico.2007.1905">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Monico</surname>
                    <given-names>CG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rossetti</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwanz</surname>
                    <given-names>HA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olson</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lundquist</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dawson</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harris</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Milliner</surname>
                    <given-names>DS</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Comprehensive mutation screening in 55 probands with type 1 primary hyperoxaluria shows feasibiity of a gene-based diagnosis.</article-title>
                <source>J Am Soc Nephrol</source>
                <volume>18</volume>
                <fpage>1905</fpage>
                <lpage>14</lpage>
                <pub-id pub-id-type="pmid">17460142</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.monico.2011.2289">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Monico</surname>
                    <given-names>CG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rossetti</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Belostotsky</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cogal</surname>
                    <given-names>AG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Herges</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seide</surname>
                    <given-names>BM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olson</surname>
                    <given-names>JB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bergstrahl</surname>
                    <given-names>EJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Williams</surname>
                    <given-names>HJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haley</surname>
                    <given-names>WE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frishberg</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Milliner</surname>
                    <given-names>DS</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Primary hyperoxaluria type III gene <italic toggle="yes">HOGA1</italic> (formerly <italic toggle="yes">DHDPSL</italic>) as a possible risk factor for idiopathic calcium oxalate urolithiasis.</article-title>
                <source>Clin J Am Soc Nephrol</source>
                <volume>6</volume>
                <fpage>2289</fpage>
                <lpage>95</lpage>
                <pub-id pub-id-type="pmid">21896830</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.monk.2000">
              <mixed-citation publication-type="book">Monk RD, Bushinsky DA. Nephrolithiasis and nephrocalcinosis. In: Johnson RJ, Feehally J, eds. <italic toggle="yes">Comprehensive Clinical Nephrology.</italic> London: Mosby; 2000:12731-44.</mixed-citation>
            </ref>
            <ref id="ph1.REF.nagara.2013.316">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nagara</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tiar</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ben Halim</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ben Rhouma</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Messaoud</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bouyacoub</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kefi</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hassayoun</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ben Ammar</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abdelhak</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chemli</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2013</year>
                <article-title>Mutation spectrum of primary hyperoxaluria type 1 in Tunisia: Implication for diagnosis in North Africa.</article-title>
                <source>Gene</source>
                <volume>527</volume>
                <fpage>316</fpage>
                <lpage>20</lpage>
                <pub-id pub-id-type="pmid">23810941</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.nishiyama.1993.1237">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nishiyama</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Funai</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yokota</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ichiyama</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>1993</year>
                <article-title>ATP-dependent degradation of a mutant serine: pyruvate/alanine:glyoxylate aminotransferase in a primary hyperoxaluria type 1 case.</article-title>
                <source>J Cell Biol</source>
                <volume>123</volume>
                <fpage>1237</fpage>
                <lpage>48</lpage>
                <pub-id pub-id-type="pmid">8245128</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.nogueira.2000.384">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nogueira</surname>
                    <given-names>PK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vuong</surname>
                    <given-names>TS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bouton</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maillard</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marchand</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rolland</surname>
                    <given-names>MO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cochat</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bozon</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Partial deletion of the AGXT gene (EX1_EX7del): a new genotype in hyperoxaluria type 1.</article-title>
                <source>Hum Mutat</source>
                <volume>15</volume>
                <fpage>384</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">10737993</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.norby.2004.277">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Norby</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Milliner</surname>
                    <given-names>DS</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Outcomes and complications of pregnancy in women with primary hyperoxaluria.</article-title>
                <source>Am J Kidney Dis</source>
                <volume>43</volume>
                <fpage>277</fpage>
                <lpage>85</lpage>
                <pub-id pub-id-type="pmid">14750093</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.okombo.2010.169">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Okombo</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liebman</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Probiotic-induced reduction of gastrointestinal oxalate absorption in healthy subjects.</article-title>
                <source>Urol Res.</source>
                <volume>38</volume>
                <fpage>169</fpage>
                <lpage>78</lpage>
                <pub-id pub-id-type="pmid">20224931</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.onaca.2005.421">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Onaca</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sanchez</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Qm Melgon</surname>
                    <given-names>LB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Netto</surname>
                    <given-names>GJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Glastad</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martin</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ueno</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levy</surname>
                    <given-names>MF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goldstein</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klintmalm</surname>
                    <given-names>GB</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Cadaveric orthotopic auxiliary split liver transplantation and kidney transplantation: an alternative for type 1 primary hyperoxaluria.</article-title>
                <source>Transplantation</source>
                <volume>80</volume>
                <fpage>421</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">16082341</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.oppici.2012.132">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Oppici</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Montioli</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lorenzetto</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bianconi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Borri Voltattorni</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cellini</surname>
                    <given-names>B.</given-names>
                  </name>
                </person-group>
                <article-title>Biochemical analyses are instrumental in identifying the impact of mutations on holo and/or apo-forms and on the region(s) of alanine:glyoxylate aminotransferase variants associated with primary hyperoxaluria type I.</article-title>
                <source>Mol Genet Metab.</source>
                <year>2012</year>
                <volume>105</volume>
                <fpage>132</fpage>
                <lpage>40</lpage>
                <pub-id pub-id-type="pmid">22018727</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.orazi.2009.387">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Orazi</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Picca</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schingo</surname>
                    <given-names>PM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fassari</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Canepa</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Oxalosis in primary hyperoxaluria in infancy : Report of a case in a 3-month-old baby. Follow-up for 3 years and review of literature.</article-title>
                <source>Skeletal Radiol.</source>
                <volume>38</volume>
                <fpage>387</fpage>
                <lpage>91</lpage>
                <pub-id pub-id-type="pmid">19132372</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.pace.2000.1905">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pace</surname>
                    <given-names>KT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weir</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tariq</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Honey</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Low success rate of repeat shock wave lithotripsy for ureteral stones after failed initial treatment.</article-title>
                <source>J Urol.</source>
                <volume>164</volume>
                <fpage>1905</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">11061877</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.patwardhan.2005.173">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Patwardhan</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Higgins</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Primary hyperoxaluria type 1: an unprecedented presentation at birth.</article-title>
                <source>Indian Pediatr</source>
                <volume>42</volume>
                <fpage>173</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">15767715</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.pey.2013">
              <mixed-citation publication-type="other">Pey AL, Albert A, Salido E. Protein homeostasis defects of alanine-glyoxylate aminotransferase: new therapeutic strategies in primary hyperoxaluria type I. Biomed Res Int. 2013;2013:687658.</mixed-citation>
            </ref>
            <ref id="ph1.REF.penniston.2009.484">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Penniston</surname>
                    <given-names>KL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakada</surname>
                    <given-names>SY</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Effects of dietary changes on urinary oxalate excretion and calcium oxalate supersaturation in patients with hyperoxaluric stone formation.</article-title>
                <source>Urology</source>
                <volume>73</volume>
                <fpage>484</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">19118878</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.petrarulo.1998.23">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Petrarulo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vitale</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Facchini</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marangella</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Biochemical approach to diagnosis and differentiation of primary hyperoxalurias: an update.</article-title>
                <source>J Nephrol</source>
                <volume>11</volume>
                <fpage>23</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">9604805</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.pirulli.2003.297">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pirulli</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marangella</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Amoroso</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Primary hyperoxaluria: genotype-phenotype correlation.</article-title>
                <source>J Nephrol</source>
                <volume>16</volume>
                <fpage>297</fpage>
                <lpage>309</lpage>
                <pub-id pub-id-type="pmid">12768081</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.pirulli.1999.523">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pirulli</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Puzzer</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferri</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crovella</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Amoroso</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferrettini</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marangella</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mazzola</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Florian</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Molecular analysis of hyperoxaluria type 1 in Italian patients reveals eight new mutations in the alanine: glyoxylate aminotransferase gene.</article-title>
                <source>Hum Genet</source>
                <volume>104</volume>
                <fpage>523</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">10453743</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.pitt.2015.1">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pitt</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Willis</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tzanakos</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Belostotsky</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frishberg</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <article-title>4-hydroxyglutamate is a biomarker for primary hyperoxaluria type 3.</article-title>
                <source>JIMD Rep.</source>
                <year>2015</year>
                <volume>15</volume>
                <fpage>1</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">24563386</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.plumb.2013.1155">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Plumb</surname>
                    <given-names>TJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Swee</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fillaus</surname>
                    <given-names>JA</given-names>
                  </name>
                </person-group>
                <year>2013</year>
                <article-title>Nocturnal home hemodialysis for a patient with type 1 hyperoxaluria.</article-title>
                <source>Am J Kidney Dis</source>
                <volume>62</volume>
                <fpage>1155</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">23830800</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.pruvot.1997.615">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pruvot</surname>
                    <given-names>FR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Noel</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Declerck</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valat-Rigot</surname>
                    <given-names>AS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roumilhac</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hazzan</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Puech</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lelievre</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>1997</year>
                <article-title>Consecutive successful pregnancies in a combined liver and kidney transplant recipient with type 1 primary hyperoxaluria.</article-title>
                <source>Transplantation</source>
                <volume>63</volume>
                <fpage>615</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">9047162</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.puddu.2009.162">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Puddu</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fanos</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Podda</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zaffanello</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>The kidney from prenatal to adult life: perinatal programming and reduction of number of nephrons during development.</article-title>
                <source>Am J Nephrol</source>
                <volume>30</volume>
                <fpage>162</fpage>
                <lpage>70</lpage>
                <pub-id pub-id-type="pmid">19339773</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.purdue.1991.10900">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Purdue</surname>
                    <given-names>PE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Allsop</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Isaya</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosenberg</surname>
                    <given-names>LE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Danpure</surname>
                    <given-names>CJ</given-names>
                  </name>
                </person-group>
                <year>1991</year>
                <article-title>Mistargeting of peroxisomal L-alanine:glyoxylate aminotransferase to mitochondria in primary hyperoxaluria patients depends upon activation of a cryptic mitochondrial targeting sequence by a point mutation.</article-title>
                <source>Proc Natl Acad Sci U S A</source>
                <volume>88</volume>
                <fpage>10900</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">1961759</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.purdue.1990.2341">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Purdue</surname>
                    <given-names>PE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takada</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Danpure</surname>
                    <given-names>CJ</given-names>
                  </name>
                </person-group>
                <year>1990</year>
                <article-title>Identification of mutations associated with peroxisome-to-mitochondrion mistargeting of alanine/glyoxylate aminotransferase in primary hyperoxaluria type 1.</article-title>
                <source>J Cell Biol</source>
                <volume>111</volume>
                <fpage>2341</fpage>
                <lpage>51</lpage>
                <pub-id pub-id-type="pmid">1703535</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.quigley.2012.184">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Quigley</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Developmental changes in renal function.</article-title>
                <source>Curr Opin Pediatr</source>
                <volume>24</volume>
                <fpage>184</fpage>
                <lpage>90</lpage>
                <pub-id pub-id-type="pmid">22426155</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.rao.2014.411">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rao</surname>
                    <given-names>NM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yallapragada</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Winden</surname>
                    <given-names>KD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saver</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liebeskind</surname>
                    <given-names>DS</given-names>
                  </name>
                </person-group>
                <article-title>Stroke in primary hyperoxaluria type I.</article-title>
                <source>J Neuroimaging.</source>
                <year>2014</year>
                <volume>24</volume>
                <fpage>411</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">23551880</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.reich.2004.370">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Reich</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Everding</surname>
                    <given-names>AS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bulla</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brinkmann</surname>
                    <given-names>OA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Aken</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Hepatitis after sevoflurane exposure in an infant suffering from primary hyperoxaluria type 1.</article-title>
                <source>Anesth Analg</source>
                <volume>99</volume>
                <fpage>370</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">15271707</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.remer.2002.561">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Remer</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neubert</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maser-Gluth</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Anthropometry-based reference values for 24-h urinary creatinine excretion during growth and their use in endocrine and nutritional research.</article-title>
                <source>Am J Clin Nutr</source>
                <volume>75</volume>
                <fpage>561</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">11864864</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.riedel.2011.e26021">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Riedel</surname>
                    <given-names>TJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Johnson</surname>
                    <given-names>LC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Knight</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holmes</surname>
                    <given-names>RP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lowther</surname>
                    <given-names>WT</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Structural and biochemical studies of human 4-hydroxy-2-oxoglutarate aldolase: implications for hydroxyproline metabolism in primary hyperoxaluria.</article-title>
                <source>PLoS One</source>
                <volume>6</volume>
                <fpage>e26021</fpage>
                <pub-id pub-id-type="pmid">21998747</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.riedel.2012.1544">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Riedel</surname>
                    <given-names>TJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Knight</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murray</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Milliner</surname>
                    <given-names>DS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holmes</surname>
                    <given-names>RP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lowther</surname>
                    <given-names>WT</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>4-hydroxy-2-oxoglutarate aldolase inactivity in primary hyperoxaluria type 3 and glyoxylate reductase inhibition.</article-title>
                <source>Biochim Biophys Acta</source>
                <volume>1822</volume>
                <fpage>1544</fpage>
                <lpage>52</lpage>
                <pub-id pub-id-type="pmid">22771891</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.rinat.1999.2352">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rinat</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Drukker</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Halle</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frishberg</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Primary hyperoxaluria type I: a model for multiple mutations in a monogenic disease within a distinct ethnic group.</article-title>
                <source>J Am Soc Nephrol</source>
                <volume>10</volume>
                <fpage>2352</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">10541294</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.robbiano.2010.667">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Robbiano</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frecer</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miertus</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zadro</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ulivi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bevilacqua</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mandrile</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Marchi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miertus</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Amoroso</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Modeling the effect of 3 missense <italic toggle="yes">AGXT</italic> mutations on the dimerization of the AGT enzyme in primary hyperoxaluria type 1.</article-title>
                <source>J Nephrol</source>
                <volume>23</volume>
                <fpage>667</fpage>
                <lpage>76</lpage>
                <pub-id pub-id-type="pmid">20564000</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.rumsby.2004.959">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rumsby</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Williams</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coulter-Mackie</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Evaluation of mutation screening as a first line test for the diagnosis of the primary hyperoxalurias.</article-title>
                <source>Kidney Int.</source>
                <volume>66</volume>
                <fpage>959</fpage>
                <lpage>63</lpage>
                <pub-id pub-id-type="pmid">15327387</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.rumsby.2001.1697">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rumsby</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sharma</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cregeen</surname>
                    <given-names>DP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Solomon</surname>
                    <given-names>LR</given-names>
                  </name>
                </person-group>
                <article-title>Primary hyperoxaluria type 2 without L-glycericaciduria: is the disease under-diagnosed?</article-title>
                <source>Nephrol Dial Transplant.</source>
                <year>2001</year>
                <volume>16</volume>
                <fpage>1697</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">11477177</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.rumsby.1997.400">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rumsby</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weir</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Samuell</surname>
                    <given-names>CT</given-names>
                  </name>
                </person-group>
                <year>1997</year>
                <article-title>A semiautomated alanine:glyoxylate aminotransferase assay for the tissue diagnosis of primary hyperoxaluria type 1.</article-title>
                <source>Ann Clin Biochem</source>
                <volume>34</volume>
                <fpage>400</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">9247673</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.salido.2011.870">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Salido</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodriguez-Pena</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santana</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beattie</surname>
                    <given-names>SG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Petry</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Torres</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Phenotypic correction of a mouse model for primary hyperoxaluria with adeno-associated virus gene transfer.</article-title>
                <source>Mol Ther.</source>
                <volume>19</volume>
                <fpage>870</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">21119625</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.santana.2003.7277">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Santana</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salido</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Torres</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shapiro</surname>
                    <given-names>LJ</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Primary hyperoxaluria type 1 in the Canary Islands: a conformational disease due to I244T mutation in the P11L-containing alanine:glyoxylate aminotransferase.</article-title>
                <source>Proc Natl Acad Sci U S A</source>
                <volume>100</volume>
                <fpage>7277</fpage>
                <lpage>82</lpage>
                <pub-id pub-id-type="pmid">12777626</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.scheinman.2005.368">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Scheinman</surname>
                    <given-names>JI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Voziyan</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Belmont</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chetyrkin</surname>
                    <given-names>SV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kim</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hudson</surname>
                    <given-names>BG</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Pyridoxamine lowers oxalate excretion and kidney crystals in experimental hyperoxaluria: a potential therapy for primary hyperoxaluria.</article-title>
                <source>Urol Res</source>
                <volume>33</volume>
                <fpage>368</fpage>
                <lpage>71</lpage>
                <pub-id pub-id-type="pmid">16292584</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.semins.2010.826">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Semins</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Asplin</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steele</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Assimos</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lingeman</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Donahue</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Magnuson</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schweitzer</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matlaga</surname>
                    <given-names>BR</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>The effect of restrictive bariatric surgery on urinary stone risk factors.</article-title>
                <source>Urology</source>
                <volume>76</volume>
                <fpage>826</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">20381135</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.sidhu.2001.1487">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sidhu</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Allison</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chow</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clark</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peck</surname>
                    <given-names>AB</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Rapid reversal of hyperoxaluria in a rat model after probiotic administration of Oxalobacter formigenes.</article-title>
                <source>J Urol</source>
                <volume>166</volume>
                <fpage>1487</fpage>
                <lpage>91</lpage>
                <pub-id pub-id-type="pmid">11547118</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.sikora.2003.2194">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sikora</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roth</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kribs</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Michalk</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hesse</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoppe</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Hypocitraturia is one of the major risk factors for nephrocalcinosis in very low birth weight (VLBW) infants.</article-title>
                <source>Kidney Int</source>
                <volume>63</volume>
                <fpage>2194</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">12753307</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.sikora.2008.1181">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sikora</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Unruh</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beck</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feldkotter</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zajaczkowska</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hesse</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoppe</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>[13C2]oxalate absorption in children with idiopathic calcium oxalate urolithiasis or primary hyperoxaluria.</article-title>
                <source>Kidney Int.</source>
                <volume>73</volume>
                <fpage>1181</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">18337715</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.tammachote.2012.2124">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tammachote</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kingsuwannapong</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tongkobpetch</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Srichomthong</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yeetong</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kingwatanakul</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Monico</surname>
                    <given-names>CG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suphapeetiporn</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shotelersuk</surname>
                    <given-names>V</given-names>
                  </name>
                </person-group>
                <article-title>Primary hyperoxaluria type 1 and brachydactyly mental retardation syndrome caused by a novel mutation in AGXT and a terminal deletion of chromosome 2.</article-title>
                <source>Am J Med Genet A.</source>
                <year>2012</year>
                <volume>158A</volume>
                <fpage>2124</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">22821680</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.tarn.1997.689">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tarn</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>von Schnakenburg</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rumsby</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>1997</year>
                <article-title>Primary hyperoxaluria type 1: diagnostic relevance of mutations and polymorphisms in the alanine:glyoxylate aminotransferase gene (AGXT).</article-title>
                <source>J Inherit Metab Dis</source>
                <volume>20</volume>
                <fpage>689</fpage>
                <lpage>96</lpage>
                <pub-id pub-id-type="pmid">9323564</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.tasca.2011.129">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tasca</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Metabolic syndrome and bariatric surgery in stone disease etiology.</article-title>
                <source>Curr Opin Urol.</source>
                <volume>21</volume>
                <fpage>129</fpage>
                <lpage>33</lpage>
                <pub-id pub-id-type="pmid">21191301</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.thamilselvan.1998.66">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Thamilselvan</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Khan</surname>
                    <given-names>SR</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Oxalate and calcium oxalate crystals are injurious to renal epithelial cells: results of in vivo and in vitro studies.</article-title>
                <source>J Nephrol</source>
                <volume>11</volume>
                <supplement>Suppl 1</supplement>
                <fpage>66</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">9604816</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.toussaint.1998.49">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Toussaint</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Pyridoxine-responsive PH1: treatment.</article-title>
                <source>J Nephrol</source>
                <volume>11</volume>
                <supplement>Suppl 1</supplement>
                <fpage>49</fpage>
                <lpage>50</lpage>
                <pub-id pub-id-type="pmid">9604811</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.trotter.2014.241">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Trotter</surname>
                    <given-names>JF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Milliner</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2014</year>
                <article-title>Auxiliary liver transplant is an ineffective treatment of primary hyperoxaluria.</article-title>
                <source>Am J Transplant</source>
                <volume>14</volume>
                <fpage>241</fpage>
                <pub-id pub-id-type="pmid">24330139</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.van_der_hoeven.2012.3855">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>van der Hoeven</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Woerden</surname>
                    <given-names>CS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Groothoff</surname>
                    <given-names>JW</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Primary hyperoxaluria type 1, a too often missed diagnosis and potentially treatable cause of end-stage renal disease in adults: results of the Dutch cohort.</article-title>
                <source>Nephrol Dial Transplant</source>
                <volume>27</volume>
                <fpage>3855</fpage>
                <lpage>62</lpage>
                <pub-id pub-id-type="pmid">22844106</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.van_woerden.2003.273">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>van Woerden</surname>
                    <given-names>CS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Groothoff</surname>
                    <given-names>JW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Davin</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wijburg</surname>
                    <given-names>FA</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Primary hyperoxaluria type 1 in The Netherlands: prevalence and outcome.</article-title>
                <source>Nephrol Dial Transplant</source>
                <volume>18</volume>
                <fpage>273</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">12543880</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.van_woerden.2004.746">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>van Woerden</surname>
                    <given-names>CS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Groothoff</surname>
                    <given-names>JW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wijburg</surname>
                    <given-names>FA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Annink</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waterham</surname>
                    <given-names>HR</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Clinical implications of mutation analysis in primary hyperoxaluria type 1.</article-title>
                <source>Kidney Int</source>
                <volume>66</volume>
                <fpage>746</fpage>
                <lpage>52</lpage>
                <pub-id pub-id-type="pmid">15253729</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.van_woerden.2006.346">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>van Woerden</surname>
                    <given-names>CS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Groothoff</surname>
                    <given-names>JW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wijburg</surname>
                    <given-names>FA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duran</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barth</surname>
                    <given-names>PG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poll-The</surname>
                    <given-names>BT</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>High incidence of hyperoxaluria in generalized peroxisomal disorders.</article-title>
                <source>Mol Genet Metab</source>
                <volume>88</volume>
                <fpage>346</fpage>
                <lpage>50</lpage>
                <pub-id pub-id-type="pmid">16621644</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.von_schnakenburg.1997.489">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>von Schnakenburg</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rumsby</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>1997</year>
                <article-title>Primary hyperoxaluria type 1: a cluster of new mutations in exon 7 of the AGXT gene</article-title>
                <source>J Med Genet</source>
                <volume>34</volume>
                <fpage>489</fpage>
                <lpage>92</lpage>
                <pub-id pub-id-type="pmid">9192270</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.von_schnakenburg.1994.27">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>von Schnakenburg</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Byrd</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Latta</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reusz</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Graf</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brodehl</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>1994</year>
                <article-title>Determination of oxalate excretion in spot urines of healthy children by ion chromatography.</article-title>
                <source>Eur J Clin Chem Clin Biochem</source>
                <volume>32</volume>
                <fpage>27</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">8167190</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.waters.2001.57">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Waters</surname>
                    <given-names>PJ</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Degradation of mutant proteins, underlying "loss of function" phenotypes, plays a major role in genetic disease.</article-title>
                <source>Curr Issues Mol Biol</source>
                <volume>3</volume>
                <fpage>57</fpage>
                <lpage>65</lpage>
                <pub-id pub-id-type="pmid">11488412</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.watts.1985.87">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Watts</surname>
                    <given-names>RW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Veall</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Purkiss</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mansell</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haywood</surname>
                    <given-names>EF</given-names>
                  </name>
                </person-group>
                <year>1985</year>
                <article-title>The effect of pyridoxine on oxalate dynamics in three cases of primary hyperoxaluria (with glycollic aciduria).</article-title>
                <source>Clin Sci (Lond)</source>
                <volume>69</volume>
                <fpage>87</fpage>
                <lpage>90</lpage>
                <pub-id pub-id-type="pmid">4064559</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.watts.1998.4">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Watts</surname>
                    <given-names>RW</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>The clinical spectrum of the primary hyperoxalurias and their treatment.</article-title>
                <source>J Nephrol</source>
                <volume>11</volume>
                <fpage>4</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">9604800</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.williams.2009.910">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Williams</surname>
                    <given-names>EL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Acquaviva</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chevalier</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coulter-Mackie</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Monico</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giachino</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robbiano</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salido</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waterham</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rumsby</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Primary hyperoxaluria type 1: Update and additional mutation analysis of the AGXT gene.</article-title>
                <source>Hum Mut</source>
                <volume>30</volume>
                <fpage>910</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">19479957</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.williams.2007.1216">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Williams</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rumsby</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Selected exonic sequencing of the AGXT gene provides a genetic diagnosis in 50% of patients with primary hyperoxaluria type 1.</article-title>
                <source>Clin Chem</source>
                <volume>53</volume>
                <fpage>1216</fpage>
                <lpage>21</lpage>
                <pub-id pub-id-type="pmid">17495019</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.williams.2012.3191">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Williams</surname>
                    <given-names>EL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bockenhauer</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van&#x02019;t Hoff</surname>
                    <given-names>WG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Johri</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laing</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sinha</surname>
                    <given-names>MD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Unwin</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Viljoen</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rumsby</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>The enzyme 4-hydroxy-2-oxoglutarate aldolase is deficient in primary hyperoxaluria type 3.</article-title>
                <source>Nephrol Dial Transplant</source>
                <volume>27</volume>
                <fpage>3191</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">22391140</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.williams.2003.1092">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Williams</surname>
                    <given-names>JC</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Saw</surname>
                    <given-names>KC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paterson</surname>
                    <given-names>RF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hatt</surname>
                    <given-names>EK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McAteer</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lingeman</surname>
                    <given-names>JE</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Variability of renal stone fragility in shock wave lithotripsy.</article-title>
                <source>Urology.</source>
                <volume>61</volume>
                <fpage>1092</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">12809867</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.ye.2007.521">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ye</surname>
                    <given-names>ZQ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kong</surname>
                    <given-names>DB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>ZQ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yao</surname>
                    <given-names>LF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guo</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yu</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liu</surname>
                    <given-names>GL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>WM</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Stable expression of the oxc and frc genes from Oxalobacter formigenes in human embryo kidney 293 cells: implications for gene therapy of hyperoxaluria.</article-title>
                <source>Int J Mol Med</source>
                <volume>20</volume>
                <fpage>521</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">17786282</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.zhang.2003.643">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roe</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hou</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bartlam</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rao</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pearl</surname>
                    <given-names>LH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Danpure</surname>
                    <given-names>CJ</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Crystal structure of alanine:glyoxylate aminotransferase and the relationship between genotype and enzymatic phenotype in primary hyperoxaluria type 1.</article-title>
                <source>J Mol Biol</source>
                <volume>331</volume>
                <fpage>643</fpage>
                <lpage>52</lpage>
                <pub-id pub-id-type="pmid">12899834</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="ph1.Suggested_Reading">
          <title>Suggested Reading</title>
          <ref-list id="ph1.Suggested_Reading.reflist0">
            <ref id="ph1.REF.knight.2007.111">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Knight</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holmes</surname>
                    <given-names>RP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Assimos</surname>
                    <given-names>DG</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Intestinal and renal handling of oxalate loads in normal individuals and stone formers.</article-title>
                <source>Urol Res.</source>
                <volume>35</volume>
                <fpage>111</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">17431604</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.kumar.2004.1403">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kumar</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ghoshal</surname>
                    <given-names>UC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Singh</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mittal</surname>
                    <given-names>RD</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Infrequency of colonization with Oxalobacter formigenes in inflammatory bowel disease: possible role in renal stone formation.</article-title>
                <source>J Gastroenterol Hepatol</source>
                <volume>19</volume>
                <fpage>1403</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">15610315</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.leumann.2005.555">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Leumann</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoppe</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Primary hyperoxaluria type 1: is genotyping clinically helpful?</article-title>
                <source>Pediatr Nephrol</source>
                <volume>20</volume>
                <fpage>555</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">15772831</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.nouvenne.2009.725">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nouvenne</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meschi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guerra</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Allegri</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prati</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fiaccadori</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maggiore</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Borghi</surname>
                    <given-names>L</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Diet to reduce mild hyperoxaluria in patients with idiopathic calcium oxalate stone formation: a pilot study.</article-title>
                <source>Urology.</source>
                <volume>73</volume>
                <fpage>725</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">19193409</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.perera.2011.354">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Perera</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sharif</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lloyd</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Foster</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hulton</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mirza</surname>
                    <given-names>DF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McKiernan</surname>
                    <given-names>PJ</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Pre-emptive liver transplantation for primary hyperoxaluria (PH-I) arrests long-term renal function deterioration.</article-title>
                <source>Nephrol Dial Transplant.</source>
                <volume>26</volume>
                <fpage>354</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">20573805</pub-id>
              </element-citation>
            </ref>
            <ref id="ph1.REF.trinchieri.2002.61">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Trinchieri</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lizzano</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Castelnuovo</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zanetti</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pisani</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Urinary patterns of patients with renal stones associated with chronic inflammatory bowel disease.</article-title>
                <source>Arch Ital Urol Androl.</source>
                <volume>74</volume>
                <fpage>61</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">12161938</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="ph1.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="ph1.Author_History">
          <title>Author History</title>
          <p>Ben H Chew, MD, MSc, FRCSC (2009-present)Marion B Coulter-Mackie, PhD (2002-present)R Morrison Hurley, MD, MSc, FRCPC; BC Children&#x02019;s Hospital (2002-2014)Dirk Lange, PhD (2009-present)Colin T White, MD (2002-present)</p>
        </sec>
        <sec id="ph1.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>17 July 2014 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>17 November 2011 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>11 August 2009 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>21 December 2006 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>25 June 2004 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>19 June 2002 (me) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>4 January 2002 (rmh) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
      <sec sec-type="figs-and-tables">
        <title/>
        <fig position="float" id="ph1.F1" orientation="portrait">
          <label>Figure 1. </label>
          <caption>
            <p>Proposed algorithm for the diagnosis and conservative treatment of primary hyperoxaluriasPH = primary hyperoxaluriaGFR = glomerular filtration rateUox = urinary oxalatePox = plasma oxalateCaOx = calcium oxaluateAGT = alanine:glyoxylate aminotransferaseAGXT = AGT geneGR/HPR = glyoxylate reductase/hydroxypyruvate reductase[<xref ref-type="bibr" rid="ph1.REF.harambat.2011">Harambat et al 2011</xref>]</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ph1-Image001" position="anchor" orientation="portrait"/>
        </fig>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
